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Mammographic density (MD), created predominantly by increased stromal tissue, is a 
major breast cancer risk factor, though little is known about the biological mechanisms 
mediating it.  
Tamoxifen prevents breast cancer in a subset of high risk women via mechanisms that 
appear dependent on reduction of MD. Animal models suggest tamoxifen remodels the 
mammary stroma to a tumour-inhibitory phenotype. This study aims to analyse the 
effect of tamoxifen on human breast fibroblast function and identify pro-tumourigenic 
pathways contributing to density-associated risk.  
 
Methods 
Primary human breast fibroblasts from normal, high risk or breast cancer patients were 
treated with hydroxytamoxifen (100nM-5µM). Fibroblast function was analysed by 
measuring: proliferation, expression of stromal proteins fibronectin and collagen 1; 
effects on TGF-β signalling and up-regulation of myofibroblast marker SMA. Genome 
wide analysis was performed using RNA-Seq. Significantly deregulated pathways were 
validated by PCR, western blotting and mass spectrometry. 
 
Results 
Fibroblasts from 23 patients were treated with hydroxytamoxifen. All patients showed 
reduced proliferation with treatment. 62% of patients showed reduced fibronectin 
expression. TGF- β-mediated up-regulation of SMA and fibronectin were consistently 
inhibited by tamoxifen.  
RNA-Seq analysis revealed down-regulation of Wnt signalling, an established pro-
fibrogenic and pro-tumourigenic pathway. In addition, there was significant modulation 
of many metabolic pathways, including components of the microsomal anti-oestrogen 
binding site (AEBS).  
Binding of tamoxifen to the AEBS inhibits cholesterol epoxide hydrolase (ChEH) 
enzyme activity, promoting an anti-tumourigenic phenotype. The effects of tamoxifen 
on fibroblasts could be partly replicated using tesmilifene, a commercially available 
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inhibitor of ChEH. Mass spectrometry analysis confirmed an altered cholesterol 
metabolite profile in tamoxifen treated fibroblasts. 
 
Conclusion 
These data indicate that tamoxifen can directly remodel the mammary stromal 
microenvironment, generating a less ‘reactive’ stroma. Thus, tamoxifen impacts on 
multiple pathways, many independent of the oestrogen receptor, to create a tumour-
inhibitory microenvironment. This offers exciting potential for patient monitoring and 





















































































































































































































































































































































































































































List of Abbreviations 
4-OHTam 4-hydroxytamoxifen 
8DHC  8-dehydrocholesterol 
7DHC  7-dehydrocholesterol 
ABC  ATP-binding cassette 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 
ADH  Atypical ductal hyperplasia 
AEBS  Anti-oestrogen binding site 
AI   Aromatase inhibitor 
AKT  Active protein kinase B 
AMH  Anti-Müllerian hormone 
ANOVA Analysis of variance 
AU  Arbitrary Unit 
bFGF  Basic fibroblast growth factor 
BCN  Breast Cancer Now 
BCI  Barts Cancer Institute 
BMI  Body mass index 
BMP  Bone morphogenic proteins 
BSA  Bovine serum albumin 
BRCA1/2 Breast cancer 1/2 gene 
CAF  Cancer associated fibroblast   
CAV-1  Caveolin 1 
CB1/2  Cannabinoid receptor 1/2   
CCL  c-c motif chemokine ligand  
CDH1  E Cadherin 
ChEH  Cholesterol epoxide hydrolase 
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COX  Cyclo-oxygenase 
CRP  C-reactive protein 
CT  Cholestane triol 
CYP19  Aromatase 
CYP2D6 Cytochrome P450 2D6 
CYP3A4/5 Cytochrome P450 3A4/5 
dH20  distilled water 
D8D71  3β-hydroxysteroid-Δ8Δ7-isomerase 
DCIS  Ductal carcinoma in situ 
DCSS  Double charcoal stripped foetal bovine serum 
DDA  Dendrogenin A 
DHCR7 7-dehydrocholesterol reductase 
DHCR24 24-dehydrocholesterol reductase 
DMSO  Dimethyl sulphoxide 
DPPE  Tesmilifene 
E2  17-β oestradiol 
EC  Cholesterol epoxide/epoxy-cholesterol 
ECM  Extra-cellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
EMT  Epithelial to mesenchymal transition 
ER  Oestrogen receptor 
ERK  Extracellular signal-regulated kinase 
FAK  Focal adhesion kinase 
FAP   Fibroblast activation protein 
FBS  Foetal bovine serum 
FC  Fold change 
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FCM  Fibrobast conditioned media 
FDM  Fibroblast derived matrix 
FDR  False discovery rate 
FGF  Fibroblast growth factor  
FN  Fibronectin 
FSP1  Fibroblast specific protein 1 
GC  Gas chromatography 
GDF  Growth and differentiation factors 
GSEA  Gene set enrichment analysis 
H+E  Haematoxylin and Eosin 
Her2  Human epidermal growth factor receptor 2 
HGF  Hepatocyte growth factor 
HRP  Horse radish peroxidase 
HRT  Hormone replacement therapy 
HOXA9 Homeobox A9 
IBIS  International breast cancer intervention study 
IgG  Immunoglobulin 
IGF  Insulin-like growth factor 
IKKβ  IκB-kinase-β 
IL-6  Interleukin six 
LI  Lobular involution 
LDL  Low density lipoprotein 
LXR  Liver X receptor 
JNK-1  c-Jun N-terminal kinase 1 
LDH  Lactate dehydrogenase 
LOX  Lysyl oxidase 
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LOXL  Lysyl oxidase-like 
miR  Micro RNA 
MD  Mammographic density 
MDS  Multidimensional scaling 
MLB  Multilamellar bodies 
MMP  Matrix metalloproteinase 
MRI  Magnetic resonance imaging 
NBF  Neutral buffered formalin 
NGAL  Neutrophil gelatinase-associated lipocalin 
NHSBCSP National Health Service Breast Cancer Screening Programme 
NICE  National Institute for Clinical Excellence 
p21  Cyclin-dependent kinase inhibitor 1 
p53  Tumour protein p53 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline and tween 20   
PCA  Principle component analysis 
PDGFRα/β  Platelet derived growth factor receptor alpha/beta 
PHD2  Prolyl hydroxylase domain protein 2 
PI3K  Phosphoinositide 3-kinase 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PIP3  Phosphatidylinositol (3,4,5)-trisphosphate 
PPAR  Peroxisome proliferator-activated receptor 
PR  Progesterone receptor 
PTEN  Phosphatase and tensin homologue 




Rho  Rho GTPase 
RIPA  Radioimmunoprecipitation assay 
ROCK  Rho-associated coiled-coil-containing protein kinase  
ROS  Reactive oxygen species 
RT   Room temperature 
SARA  SMAD anchor for receptor activation 
SDF-1  Stromal derived factor 1 
SDS  Sodium dodecyl sulphate 
SDS-PAGE SDS-Polyacrylamide gel electrophoresis 
SEER  Surveillance, Epidemiology and End Results 
SERM  Selective oestrogen receptor modulator 
siRNA  Small interfering RNA 
SMA  Alpha smooth muscle actin 
SNP   Single nucleotide polymorphism 
SREBP Steroid response element binding proteins 
STK11  Serine/threonine kinase 11 
TACS  Tumour associated collagen signatures 
TDLU  Terminal duct lobular unit 
TEM  Transmission electron microscopy 
TGF-β  Transforming growth factor beta 
TIMP  Tissue inhibitor of metalloproteinase 
TP53  Tumour protein p53 
TNF  Tumour necrosis factor 
VEGF  Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
24	
	




I have many people to thank for their support, without which this work would not have 
been possible. 
Firstly, my supervisor Professor Louise Jones has been an incredible source of support 
and guidance throughout my PhD. Her enthusiasm and passion for science initially 
inspired me to undertake a PhD and continues to inspire me to undertake academic 
research in my future career. Undertaking this PhD has allowed to participate in a 
wealth of other academic activities outside of the lab and I am extremely grateful for 
these opportunities. It has been an immense privilege to work with someone with such 
fantastic vision and whose leadership inspires such dedication and commitment 
amongst her team. Thank you so much for everything.  
My second supervisor, Professor Claude Chelala and Dr Jun Wang have been an 
enormous help in analysing the sequencing data from this project. The results from 
their analysis have been critical in directing the entire focus of this project. I have also 
benefited immensely from the exposure to publically available resources for mining 
data and basic bioinformatics analysis. 
Our colleagues in Toulouse, Dr Marc Poirot and Dr Sandrine Silvente-Poirot have been 
fantastic collaborators and provided invaluable expertise on the role of cholesterol 
metabolism in breast cancer biology. The sterol quantification analysis and electron 
microscopy work they completed in conjunction with Dr Antonin Lamaziere have been 
crucial to allowing me to complete this work. 
I also owe a huge debt of gratitude to the other members of the Breast Group. Firstly 
thank you to my wonderful mentors in primary cell culture, Dr Jenny Gomm and Dr 
Linda Haywood, for such excellent training, keeping me continually stocked up with a 
supply of primary fibroblasts and making the tiny Cat 2 room such an enjoyable, if 
space limited, place to work. Many thanks also to Mr Iain Goulding for also helping to 
supply fibroblasts and his patience with the multiple requests for retrieving clinical data 
for my samples.  
A big thank you to Dr Mike Allen for his advice with planning experiments, 
troubleshooting problems in the lab, unique analysis of current affairs and sci-fi/gaming 
related discussions. Many thanks to Dr Sally Dreger for her tuition in various laboratory 
techniques, inspirational fancy dress ideas, limitless supply of cake and impressive 
demonstrations on how to keep 200 first year undergraduate students under control. 
26	
	
Thanks to Dr Sally Smith for helping to identify suitable cases for the project, allowing 
me to maintain my cut up skills during my research time and for her London theatre, 
restaurant and holiday recommendations. 
Many thanks to Miss Rachel Nelan the RNA ‘guru’ for her advice on RNA extraction, 
preparation of samples for sequencing, daily coffee shop visits and in depth insider 
knowledge of the UK and European festival and clubbing scenes. Thanks very much to 
my fellow PhD students Miss Mary Kate Hayward, Miss Natalie Allen and Dr Kathryn 
Hawkesford for their support following experimental failures, fashion advice, lessons in 
social media etiquette and wedding planning tips.  
A big thanks also to Dr Reema Paudel for her assistance with cutting sections, 
reacquainting me with Nepalese and Tibetan momos and invaluable support with the 
tissue study which has allowed me to have the time to write up this thesis. Finally a big 
thank you to Dr Adrienne Morgan for her tuition in immunocytochemistry, introducing 
me to the value of patient and public involvement in research, advice on political 
activism and the local eating and drinking establishments of Clerkenwell. 
I would also like to thank various other members of the Tumour Biology laboratory 
including Dr George Elia for his tuition in immunohistochemistry and support with 
paraffin embedding and cutting tissue sections. Many thanks to Dr Linda Hammond for 
training me to use the confocal and Axiophot microscopes. Thanks also to Dr Ed Carter 
and Miss Zareen Khan for their help with preparing collagen gels for 3D cell culture and 
performing the gel contraction assay.  
Many thanks to Professor John Marshall and Dr John Connelly for their input 
discussing the project progress at my 9 and 18 month assessments. Thanks also to 
Professor Valerie Speirs who kindly supplied the normal HB2 cells and the HB2 cells 
overexpressing Her2.  
 
 
Finally, a huge thank you to John for your continual support, understanding and 
tolerance of weekends and evenings spent in the lab over the past three years and to 






1.1 Biology of the normal breast 
 
The adult breast is a tear shaped gland which sits anteriorly on the chest wall on top of 
the pectoralis major muscle. It extends horizontally from the edge of the sternum to the 
mid axillary line. A small portion of breast tissue extends into the axilla itself as the tail 
of Spence [1]. The breast shows considerable variation in size and shape between 
individuals. 
The structure of the breast is adapted to the production of milk (lactation) following 
pregnancy and childbirth. The epithelial component consists of a branching network of 
ducts ending in a terminal duct lobular unit (TDLU) [1].  The terminal duct branches into 
clusters of small, highly specialised acini to form a lobule (Figure 1). 
 
Figure 1: Terminal duct lobular unit (TDLU) of the breast. Multiple specialised lobules branch 





The ducts and lobules are lined by two types of epithelial cells; an inner luminal 
epithelial cell layer which secretes the milk proteins, and an outer myoepithelial cell 
layer with associated basement membrane [2]. The myoepithelial cells have contractile 
properties to facilitate milk protein secretion and synthesise the basement membrane 
components [2] (Figure 2).  
	
	
Figure 2: (i) Structure of a normal breast duct. The duct has a bilayered structure comprising an 
inner layer of luminal epithelial cells surrounded by an outer myoepithelial cell layer and 
basement membrane.  (ii) High power (x20 objective) view of a normal breast duct, H+E stained 
section. 
	
The ducts and lobules are embedded throughout the breast in a stroma which forms 
the principle tissue mass of the breast. The specialised intralobular stroma is myxoid 
and highly vascularised whereas the interlobular stroma comprises more collagenous 
fibrous tissue, adipose tissue, scattered blood vessels and mixed inflammatory cells 
[2]. Approximately 12-20 large ducts converge at the nipple where the milk is secreted 




Figure 3: Anatomy of the breast. The ducts and lobules are embedded in a stroma which forms 
the principle tissue mass of the breast. Approximately 12-20 large ducts converge at the nipple. 
Adapted from www.cancerresearchuk.org  
	
The breast undergoes dynamic changes in response to alterations in systemic 
hormone levels associated with the menstrual cycle. After ovulation, there is a rise in 
oestrogen and progesterone levels and this is accompanied by an increase in epithelial 
cell proliferation and an increase in the number of acini per lobule [1]. The intralobular 
stroma also becomes oedematous. Following menstruation, hormone levels fall, the 
lobules regress and the oedema resolves [1].  
The onset of pregnancy results in full maturation of the breast with a marked increase 
in the number and size of lobules [1]. Following childbirth the lobules produce milk until 
the cessation of lactation when the epithelial cells undergo programmed cell death and 




With increasing age, there is a gradual involution of the lobules and the specialised 
intralobular stroma. The lobular involution is particularly pronounced after the 
menopause [1]. The interlobular stroma is also remodelled and this process is 
characterised by a reduction in the proportion of radiodense fibrous tissue and an 




1.2 Pathogenesis of breast cancer 
 
The vast majority of breast cancer (>95%) is adenocarcinoma arising in the 
ductal/lobular system of the breast, initially as ductal carcinoma in situ (DCIS) [2]. DCIS 
refers to a clonal proliferation of neoplastic cells that is confined to the ducts and 
lobules by the basement membrane (Figure 4) [2]. Myoepithelial cells are preserved in 
involved ducts and lobules.   
	
Figure 4: Comparison of a normal breast duct versus DCIS. Most breast cancer arises initially 
as DCIS, a clonal proliferation of neoplastic cells confined to the ducts and lobules by the 
basement membrane. The myoepithelial cell layer is preserved. 
	
Invasive carcinoma is defined as the moment when the neoplastic epithelial cells in 
DCIS have penetrated the basement membrane and infiltrated into the surrounding 
stroma (Figure 5) [2]. The transition from DCIS to invasive disease is accompanied by 




Figure 5: The progression of DCIS to invasive carcinoma. The definition of invasive carcinoma 
is when the neoplastic epithelial cell population in DCIS has breached the basement membrane 
and infiltrated the surrounding stroma. There is loss of the intact myoepithelial cell layer. 
	
The biological and molecular events governing the initiation of DCIS, and those 
governing the transition from DCIS to invasive breast cancer are presently unknown.  
Invasive breast carcinoma is traditionally classified based on the morphological 
appearance of the tumour. The advent of high throughput sequencing technologies has 
enhanced our understanding of the diversity of genetic mutations present in invasive 
breast cancer and facilitated the classification of this heterogenous disease at the 
molecular level. 
Four distinct molecular sub groups have been identified: Luminal A, luminal B, Her2 
over-expressing and basal like.  
Charles Perou and colleagues first defined four breast cancer ‘intrinsic’ subtypes with 
similar gene expression patterns (Her2 over-expressing, basal like, luminal and normal 
breast like), based on hierarchical clustering analysis of microarray data [4]. 
Subsequent studies by the Sorlie group further sub-classified the luminal group into 
luminal A and luminal B tumours, and demonstrated that the classification of breast 




Clinically the four molecular categories (luminal A, luminal B, Her2 over-expressing and 
basal like) reflect three therapeutic groups [2, 7]. Immunohistochemistry and 
fluorescent in-situ hybridization (FISH) are used in routine clinical practice to classify 
tumours into one of these three groups based on tumour cell expression of oestrogen 
receptor (ER), and Her2.  
Firstly, the ER positive group, which may also be progesterone receptor (PR) positive, 
includes the luminal A and luminal B subtypes (approximately 50-65% of cases). 
Secondly, the Her2 overexpressing tumours (20%) and finally the triple negative 
(ER/PR/Her2 negative) tumours (15%) which represent the basal like subtype [2, 7]. 
These three therapeutic groups represent the major genetic pathways of breast cancer 
tumourigenesis [7].  
Despite the fact that basal like breast cancer is associated with negative 
immunohistochemical expression of ER, PR and Her2 [6], a number of studies have 
demonstrated that triple negative tumours are in fact a heterogeneous group of 
tumours encompassing a variety of molecular subtypes [8, 9]. Bertucci and colleagues 
examined the gene expression profile of 172 triple negative tumours and found that 
only 123 (71%) clustered with basal like breast cancer, suggesting not all triple 
negative tumours are of the basal like subtype [8]. Furthermore, of 160 tumours defined 
as showing a basal like pattern of gene expression, just 123 (77%) were found to be 
triple negative by immunohistochemistry [8].  
In addition, Rakha and colleagues performed a large immunohistochemical analysis on 
two well defined breast cancer cohorts with clinical follow up [9]. They found that triple 
negative tumours were a particularly heterogeneous group of breast cancers and 
advocate the use of specific basal immunohistochemical markers (cytokeratin 5/6, 
cytokeratin 14, cytokeratin 17 and epidermal growth factor receptor) to define basal like 
breast cancer within triple negative tumours [9].  
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1.3 Breast cancer incidence and mortality 
 
Breast cancer is a major public health burden globally, in 2008 more than 1.4 million 
women were diagnosed with the disease and there were 459,000 deaths [10]. The 
Surveillance, Epidemiology and End Results (SEER) database estimates that 246,660 
American women will be diagnosed with breast cancer in 2016, with 40,450 dying of 
the disease [11]. It is also estimated that 12.4% of American women will be diagnosed 
with breast cancer at some point in their lifetime [11].  
Breast cancer is the most common cancer in the UK with 50,285 new diagnoses in 
2014 and 11,762 deaths in 2012. The lifetime risk for being diagnosed with breast 
cancer for women in the UK is 1 in 8 [12]. Breast Cancer incidence in the UK has 
increased significantly over the past 4 decades (Figure 6) [12]. 
	
Figure 6: UK female invasive breast cancer age-standardised incidence rates per 100,000 




This increase is partly attributed to the introduction of the National Health Service 
Breast Cancer Screening Programme (NHSBCSP) in 1988. Currently the NHSBCSP 
invites women aged between 50 and 70 years for mammographic screening every 
three years. The value of increasing the age limits for screen in currently being 
evaluated in England with women aged 47-73 being offered screening mammograms 
[12]. 
Mortality from breast cancer has overall progressively decreased since the early 1970s 
(Figure 7), this has been attributed to a variety of factors including earlier detection due 
to the advent of NHSBCSP and improvements in treatment with better surgical 
techniques, radiotherapy and adjuvant treatments including tamoxifen [13, 14]. 
	
Figure 7: UK female age-standardised breast cancer mortality rates per 100,000 population 
1971-2012. Taken from www.cancerresearchuk.org [12] 
	
Earlier detection of breast cancer substantially improves survival, as demonstrated by 
the notable fall in 5 year survival with increasing stage of disease (Figure 8). Thus 
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there is considerable interest, not only in increasing detection at an earlier stage, but 





Figure 8: UK female breast cancer relative survival by stage 2002-2006. Taken from 
www.cancerresearchuk.org [12] 
	
There is considerable geographic variation in the incidence of breast cancer globally 
with the highest rates seen in economically developed countries [15]. These 
differences in incidence may be partly explained by variation in exposure to the 
different risk factors for breast cancer. Gaining an improved understanding of these risk 




1.4 Breast cancer risk factors 
	
Many factors have been identified as being influential in a woman’s likelihood of 
developing breast cancer.  
1.4.1 Age and family history 
	
Increasing age is associated with the strongest relative risk of all the breast cancer risk 
factors [16] with the majority of tumours occurring over age 50. Women with a family 
history are at increased risk of developing breast cancer with an increased lifetime 
incidence of 5.5% for women with one affected first degree relative and 13.3% for 
those with two [16].  
1.4.2 Genetic factors 
	
A small proportion of breast cancers, approximately 5-10%, are due to germline 
mutations in breast cancer susceptibility genes [17]. These mutations can be classified 
as high, moderate risk or low risk based on the strength of the relative breast cancer 




















High	Risk	 	 	 	 	
17q21	 BRCA1	 	 5-45	 	
13q12.3	 BRCA2	 	 9-21	 	
17p13.1	 TP53	 	 2-10	 	
10p23.3	 PTEN	 	 2-10	 	
19p13.3	 STK11	 	 2-10	 	
16q22.1	 CDH1	 	 2-10	 	
16p12.1	 PALB2	 	 2-7	 	
Moderate	Risk	 	 	 	 	
11q22.3	 ATM	 	 2-3	 	
22q12.1	 CHEK2	 	 2-3	 	
17q22-q24	 BRIP1	 	 2-3	 	
Low	Risk	 	 	 	 	
1p36.22	 PEX14	 rs616488	 1.06	 	
1p13.2	 AP4B1	 rs11552449	 1.07	 	
1p11.2	 NOTCH2/FCGR1B		 rs11249433	 1.09	 	
1q32.1	 LGR6	 rs11249433	 1.1	 	
1q32.1	 MDM4	 rs4245739	 1.14	 	
2p24.1	 LINC01376	 rs12710696	 1.1	 	
2q14.2	 INHBB	 rs120487546	 1.1	 	
2q31.1	 CDCA7	 rs1550623	 1.06	 	
2q35	 TNP1/IGFBP5/2/TNS1		 rs13387042	 1.14	 	
2q35	 DIRC3	 rs16857609	 1.08	 	
3p26.1	 ITPR1	 rs6762644	 1.07	 	
3p24	 NEK10/SLC4A7		 rs4973768	 1.1	 *	
3p24.1	 TGFBR2	 rs12493607	 1.06	 	
4q24	 TET2	 rs9790517	 1.05	 	
4q34.1	 ADAM29	 rs6828523	 1.11	 	
5p15.33	 TERT	 rs10069690	 1.06	 	
5p12	 FGF10AS1.MRPS30	 rs4415084	 1.17	 	
5q11	 MAP3K1	 rs889312	 1.12	 	
5q11.2	 RAB3C	 rs10472076	 1.05	 	
5q12.1	 PDE4D	 rs1353747	 1.09	 	
5q14.3	 ARRDC3	 rs10474352	 1.09	 	
5q33.3	 EBF1	 rs1432679	 1.07	 *	
6p25.3	 FOXQ1	 rs11242675	 1.06	 	
6p23	 RANBP9	 rs204247	 1.05	 	
6q14.1	 FAM46A	 rs17529111	 1.05	 	
6q25.1	 TAB2	 rs9485272	 1.11	 *	
6q25.1	 ESR1	 rs2046210	 1.16	 *	
7q35	 ARHGEF5	 rs720475	 1.06	 	
8p12	 RPL17P33	 rs9693444	 1.07	 	
8q21.13	 HNF4G	 rs6472903	 1.1	 	
8q21.13	 HNF4G	 rs2943559	 1.13	 	
8q24.21	 MYC	 rs11780156	 1.07	 	
9p21.3	 CDKN2A/2B	 rs1011970	 1.06	 	
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9q31.2	 KLF4	 rs10759243	 1.06	 	
9q31.2	 KLF4	 rs865686	 1.12	 	
10p21.31	 MLLT10	 rs7072776	 1.07	 	
10q21.2	 ZNF365	 rs10822013	 1.12	 *	
10q22.3	 ZMIZ1	 rs704010	 1.08	 	
10q25.2	 TCF7L2	 rs7904519	 1.06	 	
10q26	 FGFR2	 rs2981579	 1.27	 	
11p15	 LSP1	 rs3817198	 1.07	 *	
11q13.3	 CCND1	 rs554219	 1.27	 	
11q24.3	 BARX2	 rs11820646	 1.05	 	
12p13.1	 ATF7IP	 rs12422552	 1.05	 	
12p11.22	 PTHLH	 rs10771399	 1.16	 	
12q22	 NTN4	 rs17356907	 1.1	 *	
12q24.21	 MED13L	 rs1292011	 1.09	 	
14q13.3	 PAX9	 rs2236007	 1.08	 	
14q24.1	 RAD51L1	 rs999737	 1.09	 *	
14q32.12	 CCDC88C	 rs941764	 1.06	 	
15q26.1	 PRC1	 rs2290203	 1.08	 	
16q12.1	 TOX3	 rs3803662	 1.24	 *	
16q12.2	 FTO	 rs17817449	 1.08	 *	
17q22	 STXBP4	 rs6504950	 1.06	 	
18q11.2	 AQP4	 rs527616	 1.05	 	
18q11.2	 CHST9	 rs1436904	 1.04	 	
19p13.11	 BABAM1	 rs8170	 1.15	 	
19p13.11	 ELL	 rs4808801	 1.08	 	
19q13.31	 KCNN4	 rs3760982	 1.06	 	
20q11.22	 RALY	 rs2284378	 1.1	 	
21q21.1	 NRIP1	 rs2823093	 1.09	 	
22q12.2	 EMID1	 rs132390	 1.12	 	
22q13.2	 MKL1	 rs6001930	 1.12	 *	
 
Table 1: Known cancer susceptibility gene variants and their relative breast cancer risk 
compared to individuals who do not possesses the variant. Taken from Mavaddat et al [17], Ziv 
et al [18] and Couch et al [19]. The variants also associated with MD are highlighted (*). 
	
High risk genes such as BRCA1 and BRCA2 have been extensively studied with 
regard to their contribution to breast cancer risk and the tumour types they predispose 
to [17, 20]. The contribution of the lower risk genetic variants and the biological 
mechanisms behind the risk they impart is less well understood.  
1.4.3 Reproductive and hormonal factors 
 
Cumulative lifetime exposure to oestrogen is associated with an increased risk of 
breast cancer; early age of menarche and late menopause both independently 
increase risk [21]. Conversely, term pregnancy and, in particular, early age of first birth 
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reduce risk. Pregnancies which end in spontaneous or induced abortion do not appear 
to increase breast cancer risk [22]. Breastfeeding demonstrates a protective effect 
against breast cancer in addition to the effect of parity [23]. Despite the long term 
protective effect of parity on breast cancer risk, it has been suggested by Schedin and 
colleagues that there is a transient increase in risk immediately following pregnancy 
[24]. This increased risk falls to normal levels within a few years in younger women but 
may remain elevated for substantially longer in older women [24].   
Combined oral contraceptive use imparts a small increase in breast cancer risk [25]; 
however, tumours diagnosed in women who had used oral contraceptives were found 
to be less advanced clinically than those who had never taken these medications [25].  
Hormone replacement therapy increases the risk of breast cancer in current users and 
the risk increases with the duration of treatment [26]. However, the increased risk 
reduces after stopping treatment and largely disappears after five years following 
treatment cessation [26].  
1.4.4 Mammographic density 
	
Women with high mammographic density (MD) have a risk of developing breast cancer 
4-6 times higher than those with very little density [27].  MD is discussed in detail in 
section 1.5.  
1.4.5 Proliferative breast disease 
	
Clinical studies have indicated that intraductal proliferative breast lesions are 
associated with varying degrees of risk for the development of invasive breast cancer 
based on their morphological classification [28]. This risk ranges from 1.5 times that of 
the background population for usual type ductal hyperplasia, to 4-5 fold for atypical 
ductal hyperplasia (ADH) and 8-10 fold for ductal carcinoma insitu (DCIS) [28-30]. The 
associated risk of ADH may be further increased in premenopausal women and in 





Women from different ethnic groups have varying risks of breast cancer. This is 
demonstrated by data from the SEER database which shows that in the USA the 
highest incidence of breast cancer is in white women with an age-adjusted incidence of 
127.9 per 100,000. This is higher than black women (124.4 per 100,000) and 
substantially higher than American Indian/Alaskan native women (82.0 per 100,000) 
[11]. Despite having a lower incidence of breast cancer, black women have a 
significantly higher mortality (30.2 per 100,000) compared to white women (21.3 per 
100,000) [11].  
Ethnic variation in breast cancer incidence and mortality has also been noted in the UK 
where black women have been observed to have a higher rate of mortality from early 
stage tumours and present at an earlier age [31].  
The underlying causes of ethnic variation in breast cancer incidence and mortality 
appear to be multifactorial with factors such as access to treatment, socioeconomic 
status and tumour biology influencing outcome [32]. 
1.4.7 Obesity and diet 
	
Studies have demonstrated that obesity is a significant risk factor for breast cancer in 
post-menopausal women not taking exogenous hormones [33, 34].  Conversely, 
reduction in weight is thought to have a protective effect [35]. 
An Italian study observed an association with a high glycaemic load diet and breast 
cancer risk [36]. Diets high in fruit and vegetables and high in fibre have both been 




1.5 Mammographic density 
 
1.5.1 Mammographic density and breast cancer risk 
	
Mammographic density (MD) refers to the proportion of a mammogram occupied by 
radiologically dense fibroglandular tissue and is a major, highly heritable, independent 
risk factor for breast cancer (Figure 9). 
 
Figure 9: Series of mammogram images of increasing density from 0 – 75% density, taken from 
Boyd [39]	
	
The association of dense breast tissue with increased breast cancer risk was first noted 
by Wolfe in 1976 [40]. Since then, there have been numerous studies that have 
examined this association further. A comprehensive meta-analysis of 14,000 cases 
observed that women with >75% breast density had 4-6 times the risk of developing 
breast cancer compared to women with breasts of the lowest 25% density [41]. This 
study also demonstrated that the increased breast cancer risk imparted by high MD 
was largely consistent across different types of study, encompassing different 
geographical populations and employing a variety of methods of MD measurement 
[41].  
The relative risk imparted by high MD is greater than family history or menstrual and 
reproductive risk factors, only age and BRCA mutation status are associated with a 






























Table 2: Comparison of relative risk imparted by high mammographic density to relative risk of 
other breast cancer risk factors. Adapted from Mavaddat et al [42], Boyd et al [43] and Veronesi 
et al [16] 
	
Such is the strength of the association of MD with breast cancer risk that a recent study 
by Brentnall and colleagues found that MD alone was a slightly stronger risk factor than 
both the Tyler-Cuzick and Gail models of risk prediction in their univariate analysis [44]. 
In addition, a recent Canadian study found that MD at screening outperformed clinical 
risk factors (age, number of births, HRT use, first-degree family history of breast cancer 
and menopausal status) in predicting future cancer risk [45]. 
Furthermore, given the high frequency of breast density in the general population, the 
attributable risk is substantial and it is estimated that approximately one third of breast 
cancers could be explained by density in more than 50% of the breast [43]. This is a 
much greater attributable risk than other strong relative risks for breast cancer such as 
BRCA gene mutation, which accounts for just 5% of all breast cancer [43]. High MD is 
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also associated with increased local recurrence and risk of second primary breast 
cancer [46, 47].  
1.5.2 Pathological correlate of dense breast tissue 
 
MD reflects variations in the tissue composition of the breast and is positively 
associated with collagen, epithelial and stromal cells and negatively associated with fat 
[48]. Despite this, MD is not reflected by a specific histological abnormality. However, 
MD is associated with histological lesions associated with a significant increased risk of 
breast cancer such as atypical hyperplasia, columnar cell lesions and ductal carcinoma 
in-situ [49, 50].  
 
MD has also been associated with reduced lobular involution (LI) - the increase in the 
proportion of fat and reduction in glandular tissue and collagen noted in the breasts of 
post-menopausal women (age related atrophy) [3]. A recent study by Gierach and 
colleagues found three measures of reduced LI were associated with greater area and 
volumetric MD in premenopausal women [51].  A study from the Mayo clinic also 
reported the correlation between MD and reduced LI. In addition, they found that when 
controlling for MD, women with reduced LI still had an increased risk of breast cancer, 
suggesting the two variables are independent risk factors [52].  
 
Given that MD and reduced LI are correlated but independently associated with breast 
cancer risk, Gierach and colleagues investigated whether a common pathological 
feature linked the two variables [53]. They found serum insulin-like growth factor 1 
(IGF-1) levels were elevated in women with higher TDLU counts (a marker of reduced 
LI) and that this association was strongest in women with high MD [53]. They propose 
that elevated IGF-1 levels may identify a subgroup of high risk women with both high 
MD and reduced LI [53]. 
Stroma is the major tissue component of the breast and is composed of stromal cells 
(fibroblasts, endothelial cells, immune cells and adipocytes) and ECM proteins, the 
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most abundant of which is collagen I.  A number of studies have indicated that 
mammographic density corresponds more to alterations in stromal composition rather 
than epithelial changes [54-58]. Corroborative of these findings, one study has recently 
investigated the association of leukocyte telomere length, a surrogate marker for 
epithelial cell replication, with MD and found no significant association [59].  
A comprehensive study by Li and colleagues examined histological features of breast 
tissue obtained at forensic autopsy [48]. They found that the area of stromal collagen 
was most strongly associated with percentage density and accounted for 29% of the 
variation in percentage density whereas nuclear area and glandular area accounted for 
between 4 and 7% of the variation [48]. Similarly, Pang et al have recently reported a 
significant association of increasing MD with increased proportion of fibrous stroma 
[60]. Representative histological images of high and low density breast tissue are 
displayed in Figure 10 below. 
 
Figure 10: Representative H+E stained sections of low and high density breast tissue (x10 
objective) 
 
A recent proteomics study by McConnell and colleagues found high MD breast tissue 
was associated with aligned periductal collagen fibrils rather than total quantity of 
amorphous stromal collagen [61]. Their analysis also highlighted mediators of collagen 
fibril organisation (periostin and collagen XVI) as showing significantly up-regulated 
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expression in high MD breast tissue [61]. In addition, Huo and colleagues have 
reported more organised stromal collagen present in high MD breast tissue compared 
to low MD tissue [62]. These findings highlight the contribution of both quantitative and 
qualitative factors to the composition of high MD breast tissue.  
MD has also been hypothesised to represent the influence of local oestrogen 
production on the breast [63]. However, systemic levels of oestrogen have so far only 
shown an inverse or no association with MD [64].  One study has reported an inverse 
association of serum levels of leptin, C-reactive protein (CRP) and other adipose-
derived factors with MD [65]. 
Serum levels of prolactin and IGF-1 have been associated with MD in a number of 
studies [53, 66, 67]. In addition, dense breast tissue has been associated with higher 
immunohistochemical expression of IGF-1, IGF-1 receptor and higher levels of tissue 
inhibitor of metalloproteinases 3 (TIMP 3) within both the epithelium and stroma [68, 
69]. Furthermore, genetic polymorphisms in several components of the insulin-like 
growth factor (IGF) pathway also show an association with increased MD [70]. These 
findings suggest that the IGF-1 pathway may have a contributory role in determining 
MD.   
Stromal expression of cyclo-oxygenase 2 (COX-2) has been associated with MD in 
human tissue samples [71] and an animal model of MD [72], suggesting high MD tissue 
may facilitate a more pro-inflammatory microenvironment.   
Stromal proteoglycans have been proposed as major contributors to MD and potentially 
to density-associated risk [73]. Studies investigating the association of proteoglycans 
and MD have been limited with inconclusive results [73]. To date, increased expression 
of the proteoglycans lumican, decorin, perlecan and syndecan-4 have been reported in 
high MD versus low MD tissues [54, 73].  
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Despite the association of stromal components and high MD breast tissue, there is no 
standardised approach to measuring MD in histological sections. This, combined with 
the fact that MD is often heterogenous in nature throughout the breast, poses a 
significant challenge to the planning to translational studies using human tissue. 
1.5.3 Measurement of mammographic density 
 
A variety of methods have been employed to assess MD and, to date, no ideal method 
has been developed.  Initial classification systems incorporated both qualitative and 
quantitative measures. Wolfe described four mammographic parenchymal patterns: 
N1, predominantly fat, P1, ductal prominence in <25% of the breast, P2, ductal 
prominence in >25% of the breast and DY, extensive dysplasia [40] . These were 
stratified into two categories reflecting high and low risk for the subsequent 
development of cancer.  Another example is the Tabar classification, consisting of 5 
patterns (I-V) based on anatomic-mammographic correlation [74]. Four of the five 
Tabar patterns (II-V) largely correspond to the four patterns described by Wolfe. 
The American College of Radiology has developed a qualitative and quantitative 
classification system for clinical purposes, known as BI-RADS, which has largely 
replaced the Wolfe and Tabar classifications and is categorised accordingly: (1) almost 
entirely fatty (<25% dense), (2) scattered fibroglandular densities (26-50%), (3) 
heterogeneously dense (51-74%) and (4) extremely dense (>75%). This visual 
assessment method is relatively quick and easy to perform however, there is a degree 
of both intra and inter observer variability [75].  
Cumulus is a computer-assisted technique allowing purely quantitative assessment of 
breast density. The software allows the total breast area, absolute dense area, 
absolute non-dense area and percentage density to be calculated. Quantitative 
methods of density assessment have been observed to give a better risk prediction [76, 
77]. However, there are some important limitations with Cumulus. It requires digitised 
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analogue films and is not yet compatible with digital images. Since many units are 
converting to digital images, this may prove a problem for conducting future studies. 
The digitisation of analogue images is also time consuming and therefore the 
development of high throughput, fully automated methods is a priority. Assessment 
methods that measure volumetric density are also being developed which will hopefully 
provide a more accurate estimation of the amount of fibroglandular tissue within the 
breast. However, surprisingly, initial results suggest that the volumetric methods do not 
give better risk estimations than 2D area-based measurements [78]. 
Most studies assessing MD in quantitative terms use the relative measure of density - 
percentage density. However, this does not convey any information about the absolute 
amounts of dense and non-dense tissues. The amount of non-dense tissue may be 
important, since the fatty tissue is an important source of local oestrogens, which may 
influence the dense tissue. The evidence to date is inconclusive as to whether relative 
or absolute density is a better predictor of breast cancer risk.  One study by Vachon 
demonstrated a comparable prediction potential for both [79], whereas  Stone and 
colleagues have suggested that, as a single parameter, the absolute dense area 
provides more information than percentage density on breast cancer risk [80]. 
Conversely, a study in an Asian population by Wong et al [81], and a recent large 
meta-analysis by Pettersson and colleagues, have suggested that percentage density 
is a better risk predictor than absolute dense area [82]. 
1.5.4 Modifiers of MD 
 
A key feature of MD compared to other established risk factors for breast cancer is that 
it is dynamic and modifiable. This modifiability offers significant therapeutic potential in 
the form of cancer prevention strategies targeted to reduce breast density. 
MD typically decreases with advancing age, whereas breast cancer incidence 
conversely increases with advancing age [43, 83]. The Pike model (Figure 11) can be 
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used to resolve this apparent paradox. This a theoretical model which suggests that 
cumulative lifetime exposure of the breast to dense tissue and associated growth 
factors and hormones, also referred to as ‘breast tissue ageing’, results in increased 
cell division and accumulation of genetic damage, conferring the age-related risk of 
developing breast cancer (equivalent to the area under the curve in Figure 11) [84]. 
The breast tissue ageing rate is an estimate of the number of breast cell divisions 
occurring during a given time period.	 
  
Figure 11: The Pike Model of breast tissue ageing. The red line represents the rate of breast 
tissue ageing (an estimate of the number of breast cell divisions occurring during a given time 
period) and reflects changes in breast density with age. Breast density is at its highest following 
the menarche, falls with each successive pregnancy and then falls sharply during the 
perimenopausal period. The model helps to explain the discrepancy observed when there is a 
high risk of breast cancer at advanced age, but breast density is at its lowest. The model 
suggests that the cumulative lifetime exposure to dense breast tissue, and the associated 
growth factors and hormones, imparts the risk (equivalent to the area under the red line) by 
increasing cell division and accumulation of genetic damage. Thus, at a higher age, there is a 
greater area under the curve and there is a higher risk of breast cancer. Adapted from Pike et al 
[84]. (A.U. = Arbitrary Units)	
	
According to the model, the rate of breast tissue ageing is greatest during menarche, 
falls with each successive pregnancy and then falls rapidly at the onset of the 
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perimenopausal period [84]. The underlying assumptions of this model are that breast 
tissue 'ages' at a constant rate, starting at menarche and continuing to first birth. The 
model also assumes that cell division is proportional to the age of the individual, and 
that reproductive factors modify the rate of cell division after first birth and again after 
menopause. 
This is reflected in the apparent hormonally responsive nature of MD; women with risk 
factors for breast cancer related to prolonged oestrogen exposure, such as late first 
pregnancy and early menarche, show a higher degree of MD [27]. In addition, the use 
of combined hormone replacement therapy (HRT) also increases MD [85, 86]. 
Conversely parous women have a lower degree of MD (approximately a 10% reduction 
per live birth [87]) and there is a significant reduction in MD following the menopause 
[27, 88]. Bone mineral density is a putative marker of lifetime exposure to oestrogen 
and has been associated with MD in obese premenopausal and postmenpausal 
women [89].  
An important confounding factor is that MD is also negatively associated with body 
mass index (BMI), an independent risk factor for breast cancer [87, 90]. High BMI 
reduces percentage density by increasing the non-dense portion of the breast and has 
also been associated with reduced absolute density in some studies [91, 92], however 
this is not a consistent finding [93, 94]. Failure to correct for BMI may lead to a 
significant underestimation of risk [90]. 
Interestingly, a recent prospective analysis of BMI during childhood showed a 
significant inverse association with premenopausal MD at age 25-29 years [95]. These 
results suggest childhood body fatness may have a role in determining premenopausal 
breast density, independently of adult BMI [95]. 
Rather surprisingly, given the trend for inverse association of BMI with MD, a Korean 
study has reported components of the metabolic syndrome, a condition often 
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accompanied by obesity, to be associated with increased MD in premenopausal 
women and that blood glucose and insulin resistance were associated with MD in 
postmenopausal women [96]. MD has also been associated with increased birth weight 
in postmenopausal women in a Swedish population [97].  
The influence of diet and lifestyle factors on MD have been investigated by a number of 
studies with mixed findings. A recent Spanish study found a lower degree of MD in 
postmenopausal and non-smokers adhering to the World Cancer Research Fund 
dietary and exercise recommendations for cancer prevention [98].  A randomised 
controlled trial of dietary soy supplementation was found to have no effect of MD [99], 
whereas a weak association with dietary animal fat and red meat intake in adolescence 
with MD has also been reported [100]. A Danish study has recently reported an inverse 
association with smoking and MD [101]. In addition, no association with long term 
exposure to air pollution and MD was observed within the same cohort [102]. 
The association of alcohol consumption and MD has also been examined by a number 
of studies with inconsistent findings. A positive association has recently been 
demonstrated in a multi-ethnic urban cohort [103] and in premenopausal women [104]. 
However no association was found with alcohol consumption in early adulthood and 
midlife with MD in two US cohorts [105].  
Given the inconsistencies in many of the studies investigating determinants of MD, it is 
clear that further research is needed to clarify these complex associations. An 
International Consortium on Mammographic Density has recently been established 
[106] with the aim of precisely characterising the determinants of MD and analysing 
how these vary across different global populations [106]. The results of these analyses 




1.5.5 Pharmacological modulation of MD 
As previously mentioned, combined hormone replacement therapy has been 
associated with increased MD and breast cancer risk [85, 86, 107], particularly among 
current users [108]. To date, no consistent association with MD and oral contraceptive 
use has been demonstrated [107].  
Tamoxifen is a selective oestrogen receptor modulator (SERM), demonstrated in the 
first International Breast Cancer Intervention Study (IBIS I) to reduce MD and breast 
cancer risk [109]. A further nested case control study within the IBIS I cohort revealed 
that, in those women taking tamoxifen, those who showed a >10% reduction in MD had 
a 63% lower risk of developing breast cancer [110]. Furthermore, those women who 
showed a poor response to tamoxifen treatment (<10% reduction in MD) showed no 
associated risk reduction. Thus the protective effect of tamoxifen appears associated 
with a reduction in MD. 
This has been further highlighted in a recent retrospective study of breast cancer 
patients who received adjuvant tamoxifen for 15 years [111]. A 20% relative reduction 
in MD was reported for women who took tamoxifen, and this reduction was associated 
with a 50% risk reduction in breast cancer mortality [111]. In addition, Czene and 
colleagues found that women who experienced a >10% reduction in MD in the 
contralateral breast following adjuvant therapy for breast cancer had a 55% less 
likelihood of contralateral recurrence [112]. 
 
Intriguingly, on-going follow up from the IBIS I study has shown that the 5 years of 
tamoxifen treatment given as per the trial protocol have long lasting benefits, with a 
protective effect still evident at 15 years [113].  
 
Presently the mechanisms conferring susceptibility to the protective effect of tamoxifen 
treatment remain unknown, however, an association of cytochrome P450 2D6 
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(CYP2D6) metaboliser status with MD change in response to tamoxifen has recently 
been reported [114]. 
  
In an animal model of breast cancer, tamoxifen treatment initiated remodelling of the 
mammary stroma to a tumour inhibitory phenotype with lower levels of fibronectin and 
reduced extra-cellular matrix (ECM) turnover [115]. Furthermore, a recent study 
utilising a xenograft model of high MD human tissue maintained in murine biochambers 
showed that tamoxifen treatment resulted in a reduction in radiographic tissue density 
characterised histopathologically by a decrease in stromal tissue and increase in 
adipose tissue [116]. The evidence from these studies suggest that tamoxifen may 
modulate density and breast cancer risk by modifying the stromal microenvironment of 
the breast. 
 
Raloxifene, another SERM found to be effective at preventing breast cancer (to a 
lesser degree than tamoxifen, but with an improved side effect profile [117]) has also 
been investigated in two small studies for ability to modulate MD, however no 
significant change in density with treatment was observed [118, 119]. 
 
Overall there have been nine randomised controlled trials of SERMs for the prevention 
of breast cancer. A recent meta-analysis incorporating data from over 83,000 
participants found a 38% reduction in breast cancer incidence with tamoxifen [120]. On 
the basis of these findings, the National Institute for Clinical Excellence (NICE) 
approved tamoxifen and raloxifene for breast cancer prevention in high risk individuals 
in 2013 [121].  
 
Aromatase inhibitors (AI) are another class of drug which have demonstrated superior 
efficacy to SERMs in breast cancer prevention in two randomised clinical trials [122, 
123]. The IBIS II trial of anostrazole versus placebo in 3,864 post-menopausal women 




A limited number of small studies have examined the effect of the AIs letrozole and 
examestane on MD and have yielded inconsistent results [124-128]. One study has 
reported a decrease in MD in 11 out of 16 postmenopausal women treated for one year 
with letrozole [126] and a recent phase II trial of examestane for high risk women 
showed a reduction in MD at one year [128]. Conversely, other studies have 
demonstrated no change in MD with AI treatment [127] [124, 125]. The inconsistencies 
in these findings may be explained by the small study sizes and variation in methods 
for assessing MD.  
 
A gonadotrophin-releasing hormone agonist has also been reported to reduce MD after 
one year’s treatment in a single, small study of premenopausal women [129]. Statins 
are another group of drugs that have been extensively investigated for their influence 
on breast cancer risk and prognosis [130]. One study has investigated the influence of 
statin use on MD and found no significant association [131]. 
 
1.5.6 Genetic contribution to MD 
 
MD appears to be highly heritable; studies of twins have attributed up to 65% of the 
variation in MD to genetic factors [132, 133] with the remaining 35% being modifiable.  
The majority of studies investigating the genetic contribution to MD have focused on 
investigating the single nucleotide polymorphisms (SNPs) associated with increased 
breast cancer risk and their relationship with MD. So far SNPs in the region of ESR1, 
CCDC170, EBF1, LSP1, MIR1972-2:FTO, RAD51L1, ZNF365, MKL1, TNRC9/TOX 3, 
NTN4, NEK10, TAB2 and loci at 2p24.1 and 12q24 [134-140] have all been identified 
as having a significant association with MD. Most of these studies were conducted in 
women of European descent. Recently Mariapun et al compared the association of 
these previously described SNPs with MD in an Asian population and found a similar 
association of SNPs in the 6q25.1 region near to ESR1 with MD [141]. The findings 
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suggest there is a shared heritability of MD and breast cancer risk across different 
global populations with varying levels of breast cancer incidence [141]. 
One study has investigated SNPs that can modify the increase in MD seen with current 
use of HRT, however no significant interactions were identified after adjustment for 
multiple testing [142].  
In addition, a recent meta-analysis of 10,727 women found that 18% of breast cancer 
susceptibility variants were associated with at least one MD measure [140].  Despite 
this, these SNPS are thought to account for only a small percentage of the variance in 
breast density with the remainder attributed to genes that are currently unknown [135].  
Vachon and colleagues have investigated the association of germline copy number 
variations and MD across two patient cohorts [143]. In one cohort they found five 
chromosomal regions (3q26.1 (2 regions), 8q24.22, 11p15.3 and 17q22) that were 
significantly associated with MD [143]. The locus at 3q26 demonstrated the strongest 
association and interestingly there are no known SNPs in this region. Despite 
demonstrating these significant associations with MD, the findings were unable to be 
replicated in the second patient cohort [143].  
Studies investigating more established genetic mutations known to confer a strong risk 
for breast cancer have focused on BRCA1 and BRCA2, and have demonstrated no 
significant association with MD [144-146]. To date, no studies have investigated other 
established genetic risk factors such as phosphastase and tensin homolog (PTEN), 
tumour protein 53 (TP53), E-Cadherin (CDH1) or serine/threonine kinase 11 (STK11) 
for association with MD. 
Studies investigating candidate genes involved in oestrogen metabolism, oestrogen 
receptors, COMT enzyme and the insulin like growth factor (IGF) pathway have shown 
a positive association with MD [147, 148]. In addition, variants of the prolactin gene 
were associated with MD in a Norwegian population currently taking HRT [149]. 
56	
	
However, not all findings are consistent; a recent study investigating SNPs in hormone 
metabolism genes in an Asian population found no association with MD [150]. A 
comprehensive study of over 2000 SNPs in genes involved in the regulation of mitosis 
also found no association with MD [151].   
Given the strong heritability of MD, the inconsistencies reported between candidate 
gene studies, and the small proportion of the variation in MD that can be attributed to 




1.5.7 Mammographic density and breast tumour characteristics  
	
It is uncertain whether high MD predisposes to the development of a particular tumour 
type, for example, a more aggressive tumour phenotype than those found in non-dense 
breasts. Therefore, a number of studies have investigated the association of 
percentage density and breast cancer sub-type. Overall these studies report largely 
inconsistent findings which are most likely a reflection of the wide variation present in 
study design, size, method of MD measurement, and whether other confounding 
factors were controlled for.  
Given that MD appears to be a hormonally responsive trait, one might expect high MD 
to predispose to the development of tumours that are ER positive. Of those studies 
which made adjustments in their analysis to control for confounding factors, two groups 
have found an increased risk for the development of ER positive tumours only [152, 
153]. However, several studies have found an increased risk for the development of 
both ER positive and ER negative tumours [154-157].  
A recent Swedish study, controlling for possible confounding factors, found no 
association of MD with hormone receptor status, histological tumour type or lymph 
node status [158]. A significant association was seen with tumour size; however this 
may be due, in part, to the masking effect of high density breast tissue. More recently, 
a Norwegian study has also reported an association of tumour size and lymph node 
involvement with MD [159] and a North American study has reported association of MD 
with larger tumour size and higher tumour grade [157].  
A North American case-control study has reported an increased risk for the 
development of Her2 negative, luminal A and triple negative tumours [155]. However, 
another larger North American study has reported no association with Her2 status 
[157].   
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Given the degree of inconsistency in the findings of studies which have investigated the 
association of MD with tumour subtype, McCormack and dos Santos Silva have 
recently performed a systematic meta-analysis incorporating over 24,000 cases. Their 
extensive analysis  found a similar magnitude of association with ER+ and ER- 
tumours and no difference in the association with Her2 status [160]. This 
comprehensive analysis suggests that MD increases the risk of all breast tumour types. 	
1.5.8 High MD breast tissue fosters a tumour-promoting stromal 
microenvironment 
	
Whilst there is a strong clinical correlation, MD has not yet been causally linked to 
tumour formation and there have been a limited number of studies investigating the 
biological pathways mediating MD. Given that the stroma forms the major constituent 
component of dense breast tissue, the pathways contributing to the density-associated 
breast cancer risk are likely to involve the stromal cells, ECM proteins, and their 
interaction with the epithelial component. 
There has been much more focus on the role of the stromal microenvironment in 
established breast cancer than the role of stroma in the regulation of normal breast 
function, and clues as to the function of the stroma may be gleaned from this body of 
work, which is briefly summarised below. 
1.5.8.1 Cancer associated fibroblasts 
	
Cancer associated fibroblasts (CAFs) display an activated phenotype and share many 
similarities with activated myofibroblasts found at sites of wound healing and 
inflammation [161]. CAFs have been shown to contribute to the progression and 
outcome of many other solid tumours, in addition to breast cancer [162] through both 
common and distinct pathways depending on the tumour type [163]. 
At present, there is no single universal marker capable of reliably identifying all CAFs. 
Instead, a variety of different markers have been employed, often in combination. The 
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most commonly used are: high expression of alpha smooth muscle actin (SMA), 
fibroblast specific protein 1 (FSP1), fibroblast activation protein (FAP), platelet derived 
growth factor alpha receptor (PDGFRα) and beta receptor (PDGFRβ) [164]. The lack of 
a single marker for CAFs reflects the heterogeneity that exists between CAFs located 
within the same tumour microenvironment.  
1.5.8.2 Activation of CAFs 
	
The molecular events mediating the activation of CAFs are not fully understood. 
Tumour-cell derived TGF-β and SDF-1 are thought to be the principal activators of 
fibroblasts in the local tumour microenvironment via an autocrine signalling loop [165]. 
Other tumour derived factors which have been demonstrated to induce activation of 
fibroblasts include PDGFα/β [166], basic fibroblast growth factor (bFGF) [167] and 
interleukin 6 (IL-6) [168].  
Recently Clare Isacke and colleagues have identified Wnt7a as a key factor secreted 
by aggressive breast tumour cells capable of inducing the CAF phenotype and 
triggering ECM remodelling to facilitate tumour cell invasion [169]. The authors propose 
Wnt7a acts to potentiate TGF-β signalling rather than activating the canonical Wnt 
signalling pathway [169].  
Another crucial molecular event in the activation of CAFs appears to be down-
regulation of tumour suppressor genes such as PTEN, p53, p21 and CAV-1. Levels of 
CAV-1 protein have been found to be lower in CAFs compared to normal fibroblasts 
[170] and this has been proposed to be a consequence of oxidative stress signalling / 
autophagy [171]. In addition, the absence of stromal CAV-1 expression has been 
repeatedly correlated with poor prognostic factors, resistance to therapy and reduced 
survival in breast cancer patients [172-174].  
Gene expression profiling studies comparing CAFs to normal fibroblasts have 
attempted to further dissect the mechanisms involved in fibroblast activation and 
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crosstalk with the epithelial cells. Bauer et al found up-regulation of Wnt1 inducing 
signalling pathway protein 1 (WISP1), Collagen X and TGF-β isoforms in CAFs [175]. 
They proposed that WISP1 expression in CAFS could activate Wnt signalling in tumour 
cells in a paracrine manner [175].  
Whether fibroblast activation can occur at an early stage in tumourigenesis, even 
before epithelial transformation, remains unclear.  
1.5.8.3 CAFs and breast cancer initiation and progression 
	
The ability of CAFs to facilitate tumourigenesis has been demonstrated in animal 
models where normal fibroblasts within the host animal were pre-irradiated before 
implanting premalignant epithelium. The irradiated hosts developed tumours much 
faster and displayed a more aggressive phenotype [176]. TGF-β was implicated as a 
key signalling pathway affecting the tumour latency [176]. 
CAFs are also reported to enhance tumour growth via the production of growth factors 
such as hepatocyte growth factor (HGF), bFGF, and insulin-like growth factor (IGF) 
[177, 178]. It has been reported by one group that the tumour cells act in a paracrine 
manner to stimulate HGF production by CAFs [179], resulting in a positive feedback 
loop promoting tumour growth. CAFs have also been suggested to fuel tumour growth 
by increasing local oestrogen production via amplified stromal aromatase activity [180].  
Recent evidence also suggests a key role for CAFs in breast cancer cell invasion and 
metastasis. CAFs from the tumour/stroma interface have been proposed to be potent 
inducers of EMT [181] -  the process by which tumour cells lose polarity and epithelial 
markers such as E-cadherin and gain a more invasive mesenchymal phenotype.  In 
addition, CAFs are known to produce a number of MMPs [182], which not only facilitate 
invasion by degrading ECM, but have also been proposed to have a role in enhancing 
EMT [183]. CAFs have also been proposed to promote the transition of DCIS to 
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invasive carcinoma [184] via a mechanism involving COX-2,  vascular endothelial 
growth factor (VEGF) and MMP9 [185]. 
1.5.8.4 CAFs and ECM remodelling 
The proteases secreted by CAFs degrade and facilitate remodelling and reorganisation 
of the ECM, a process which is associated with cancer progression [186]. This process 
may be facilitated by high expression of syndecan-1 in CAFs, which has been reported 
to have a role in mediating collagen fibre alignment [187]. In addition, CAFs may 
aberrantly secrete proteins such as collagen, fibronectin and tenascin C, which could 
contribute to an altered ECM composition [178].  
1.5.8.5 CAFs and inflammation 
	
Infiltration of immune cells into the tumour microenvironment is observed in many solid 
tumours including breast cancer and is associated with tumour progression [188]. 
Cytokines and chemokines secreted by CAFs are potent recruiters of inflammatory 
cells to the tumour microenvironment [188]. The chemokine c-c motif chemokine ligand 
2 (CCL2) has been reported to promote the infiltration of monocytes/macrophages into 
both the primary tumour and metastatic site in a mouse model [189]. Other 
inflammatory mediators secreted by CAFs include IL-6, tumour necrosis factor (TNF) 
and SDF-1, which are capable of recruiting a diverse array of inflammatory cells to the 
tumour microenvironment [190]. 
1.5.8.6 CAFs and epigenetic changes 
	
Data regarding the role of epigenetic changes within the breast cancer 
microenvironment to breast cancer progression is limited. CAFs have been 
demonstrated to have different methylation patterns when compared to normal 
fibroblasts [191]. The CYP19 gene encoding aromatase has been found to be 
hypomethylated in stromal fibroblasts with enhanced aromatase activity [192]. Histone 
H3K27 has also been found to be hypomethylated in CAFs, resulting in increased 
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ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS1), which 
correlated with a more invasive phenotype [193].  
1.5.8.7 CAFs and tumour metabolism 
	
Recently, the contribution of CAFs to the metabolic reprogramming of the breast 
cancer microenvironment has been elucidated. Tumour cells display a complex, altered 
glucose metabolism where they utilise aerobic glycolysis to form lactate from glucose, 
a process known as the ‘Warburg Effect’ [194]. In addition, intra-tumoural hypoxia is 
also common, resulting in the activation of hypoxia inducible factor 1 alpha (HIF1α) 
signalling and the production of lactate and pyruvate via anaerobic glycolysis. 
Furthermore, tumour cells can also generate energy via oxidative phosphorylation 
[194].  
The influence of CAFs on the tumour cell metabolism is known as the ‘Reverse 
Warburg effect’. In this recently described model, CAFs undergo aerobic glycolysis and 
‘feed’ the tumour cells with high energy metabolites pyruvate and lactate [195]. This 
altered fibroblast metabolism is proposed to be due to oxidative stress induced by 
reactive oxygen species (ROS), such as hydrogen peroxide, generated by intra-
tumoural hypoxia [195, 196]. Oxidative stress results in reduction of CAV-1 and 
lysosomal activation and autophagy/mitophagy, inducing a shift to glycolytic 
metabolism [195]. Activated CAFs themselves produce ROS, which further activates 
more fibroblasts in the local environment.  
The generation of ROS by CAFs is proposed to contribute to genomic instability and 
aneuploidy in the cancer cells, driving co-evolution of the tumour and stroma [171]. 
Eventually the tumour cells switch to metabolism predominantly via oxidative 
phosphorylation and ROS continue to be generated only by the stroma [171].  
A recent study by Janine Erler and colleagues has suggested that the activated CAF 
phenotype may be reversible [197]. Chronic hypoxia resulted in CAF deactivation, less 
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contractile force and reduced ECM remodelling [197]. The authors propose a 
mechanism involving inhibition of prolyl hydroxylase domain protein 2 (PHD2), leading 
to HIF1α stabilisation and gradually reduced expression of SMA [197]. This study 
challenges the accepted notion of hypoxia being a tumour promoting factor within the 
microenvironment and suggests that there may be variations in response to hypoxia 
depending on the cell type involved [197].  
A summary of the various mechanisms by which CAFs promote breast cancer 
progression is displayed in Figure 12.  
	
Figure 12: Summary of the multiple mechanisms by which CAFs contribute to breast tumour 
progression 
	
In addition to CAFs, the tumour microenvironment consists of a diverse array of cell 
types including inflammatory cells, endothelial cells, adipocytes and ECM proteins 
which have been investigated for their potential contribution to the progression of 
breast cancer. These will not be covered in detail here.  
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1.5.9 Biological mechanisms contributing to density-associated risk 
 
As discussed above, the stromal microenvironment is known to have an important role 
in the progression of established invasive breast cancer [198], acting via multiple 
diverse mechanisms including the influence of growth factors secreted by cancer 
associated fibroblasts and remodelling of the ECM [198, 199].  In addition, ECM gene 
expression levels are also associated with breast cancer prognosis [200], response to 
neo-adjuvant chemotherapy [201] and endocrine therapy [202]. Similar stromal 
mechanisms may also have a role in promoting tumourigenesis in breast tissue of high 
MD; the evidence for this is reviewed below.  
1.5.9.1 Paracrine factors 
	
It has been hypothesised that in areas of high MD, abundant stromal fibroblasts may 
aberrantly secrete growth factors and hormones/cytokines that stimulate epithelial cell 
proliferation [68, 203]. One study has suggested that local oestrogen production in the 
breast may be responsible for determining density [63]. Local oestrogen is synthesised 
from androgens in the breast by aromatase enzyme activity. Studies from Vachon et al 
and Huo et al have both reported increased aromatase immunoreactivity in the stromal 
cells of mammographically dense regions of the breast compared to non-dense regions 
[62, 63].  
Increased stromal aromatase activity could result in sufficient local oestrogen 
production to stimulate epithelial cell proliferation and drive tumourigenesis. These 
findings are supported by in-vitro work from another group who have observed that cell 
density, shape and ECM proteins are capable of inducing stromal aromatase 
expression [204], thus providing a potential mechanistic link. This study also 
highlighted a role for IκB-kinase-β (IKKβ) as a key messenger in mediating this 
response. Figure 13 summarises the potential contribution of paracrine and mechanical 




Figure 13: Local paracrine and mechanical signals may contribute to increased stromal 
aromatase expression, leading to increased oestrogen production and epithelial cell 
proliferation.	
	
1.5.9.2 Collagen density, force and ECM stiffness 
	
It has been suggested that increased collagen production by stromal fibroblasts 
contributes to a stiffer ECM. The inability of normal breast epithelium to contract stiff 
matrix causes a tensional imbalance, reflected by altered signalling pathways that have 
the potential to induce epithelial cell proliferation [205]. 
Patricia Keely and colleagues developed a bi-transgenic mouse to model high breast 
density, utilising the Col1a1tmJae transgene which reduces collagen proteolysis, and 
examined the propensity for tumour formation with increased mammary collagen. They 
observed that higher stromal collagen density in mouse mammary tissue resulted in a 
threefold increase in tumour number and that the tumours which developed displayed a 
more invasive phenotype with greater local invasion and metastasis. The authors 
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propose a functional link between increased stromal collagen density and breast 
cancer initiation and progression [206].  
Two possible mechanisms are suggested by which increased collagen density might 
promote tumour development. The first is a direct effect of increased matrix stiffness, 
resulting in a higher mechanical force and resistance to contractility on the epithelial 
cells. These forces might alter focal adhesion and Rho GTPase (Rho) signalling, 
resulting in increased proliferation [206]. The second proposed mechanism is more 
indirect and suggests that collagen density modulates the behaviour of mammary 
fibroblasts, resulting in altered secretion of soluble growth factors and chemokines 
such as TGF-β, epidermal growth factor (EGF) and IGF, which in turn influence 
epithelial cell behaviour [206], as summarised in Figure 14. 
Figure 14: Increased collagen density may influence mammary epithelial cell behaviour directly 




Further work by this group examined whether collagen density alone, in the absence of 
fibroblasts, could alter mammary epithelial cell behaviour in 3D culture models. 
Supporting this hypothesis, greater collagen density alone increased matrix stiffness 
and promoted epithelial cell proliferation and invasion [207]. They showed that 
mammary epithelial cells formed clustered 3D matrix-adhesions containing activated 
focal adhesion kinase (FAK) in response to matrices of high stiffness. FAK, Rho and 
ERK were all found to be necessary for successful mechanotransduction of mammary 
epithelial cells, and inhibition of ERK or the Rho/Rho-associated protein kinase (ROCK) 
pathway reverted the invasive phenotype promoted by high density matrices [207].  
The authors propose that continued mechanical stimulation from a dense stromal 
matrix results in sustained activation of FAK-Rho signalling which, in turn, up-regulates 
other pathways such as Ras- MAPK. ERK acts as a crucial bottleneck, regulating the 
response and inducing transcription of proliferation associated genes.  
The significance of the Rho/ROCK pathway in mediating mechanotransduction has 
been further highlighted in a mouse model of tissue stiffness with sustained ROCK 
activation. ROCK increased tissue stiffness by increasing collagen deposition in mouse 
skin and stabilised epithelial nuclear beta catenin expression, leading to transcriptional 
activation of pro-proliferative pathways and epidermal thickening [208]. Inhibition of 
ROCK or actomyosin contraction inhibited these responses [208].  
Soon et al examined the effect of high density collagen matrices on mammary epithelial 
cell behaviour. They found that high density matrices up-regulated the expression and 
activity of Rho-associated coiled-coil-containing protein kinase 1 (ROCK 1) via 
inhibition of notch homolog 1 (NOTCH1) [209]. ROCK- 1 is proposed to have a key role 
in cell contractility and facilitating epithelial cell migration in conjunction with MMP 




As well as collagen density, the significance of collagen fibre alignment within the ECM 
in facilitating mammary tumour cell invasion has also been investigated by the Keeley 
group [210]. Collagen changes at the tumour/stroma boundary termed ‘Tumour 
associated collagen signatures’ (TACS) have been classified and used as markers of 
malignant progression. TACS-3, where the collagen fibres are orientated perpendicular 
to the tumour boundary, has been shown to correspond to sites of focal invasion in 
mouse models [206, 210] and in an analysis of human tissue samples is also 
associated with poor disease-specific and disease-free survival [211].  
The precise biological mechanisms mediating alignment of the ECM remain unclear 
though it has been suggested that syndecan signalling, cyclooxygenase-2 (COX-2) 
signalling, stromal immune cells and other glycoproteins such as neutrophil gelatinase-
associated lipocalin (NGAL) may play a role [205].   
The Schedin group has also recently examined the contribution of collagen fibre 
architecture within the ECM to mammary tumourigenesis [212]. They found that ECM 
from parous rats decreased tumour growth compared to ECM from nulliparous rats. 
Proteomic analyses revealed that, surprisingly, the parous matrix contained a greater 
quantity of collagen I than the nulliparous matrix [212]. Crucially, second-harmonic 
generation imaging revealed the collagen fibres in the parous matrix were significantly 
less linearised and aligned than those in the nulliparous ECM. Furthermore, using 3D 
cell culture models, they demonstrated that linearised collagen 1 induced cell 
phenotypes associated with invasive behaviour compared to non-linearised collagen 
[212].  
These data once again emphasise the importance of assessing both qualitative and 





1.5.9.3 Collagen cross-linking, integrin signalling and ECM stiffness 
	
Weaver and colleagues have investigated how collagen cross-linking mediated by lysyl 
oxidase (LOX), a family of ECM cross-linking enzymes, can influence mammary 
epithelial cell behaviour. They used the MMTV-Neu mouse model of breast cancer to 
show that fibroblasts overexpressing LOX form a stiffer mammary fat pad and promote 
the growth and invasion of premalignant mammary epithelial cells. Similarly, inhibition 
of LOX resulted in a less stiff matrix and reduction in tumourigenesis [213].  LOX-
mediated collagen cross-linking resulted in a stiff matrix characterised by increased 
focal adhesions, integrin clustering and subsequent increase in integrin signalling, 
increased FAK activity and enhanced PI3-K signalling. PI3-K signalling has been 
suggested to promote invasion of mammary epithelial cells in-vitro and tumourigenesis 
in-vivo [214]. Thus it is proposed that LOX may have a pivotal role in modulating breast 
tumour progression by stiffening the ECM and initiating integrin-mediated 
mechanotransduction of mammary epithelial cells.  In keeping with these findings, LOX 
expression is also elevated in many cancers [215], has been associated with prognosis 
[216] and is proposed to have a key role in facilitating tumour metastasis [217].  
The Weaver group has also conducted a biophysical study of human breast tissue 
stiffness at the epithelial-stromal border in adjacent normal, in-situ and invasive 
disease [218]. They found the histological progression from normal to in-situ to invasive 
disease was accompanied by progressive tissue stiffening characterised by increased 
collagen fibre deposition, linearisation and fibre thickening [218]. TGF-β signalling and 
immune cell infiltration also correlated with tissue stiffness, which was greatest in the 
more aggressive molecular tumour subtypes (basal-like and Her2 over-expressing) 
[218]. This study further demonstrates the association of breast tissue stiffening and 
cancer initiation and progression.  
The same group have also studied the molecular determinants of mammary epithelial 
cell mechanotransduction, and have highlighted a crucial role for the focal adhesion 
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component vinculin in translating the mechanical cues from a stiff ECM into tumour 
promoting intracellular signalling pathways [219]. 
It is suggested that a stiff ECM drives integrin binding and activation, forming focal 
adhesions. At the focal adhesion, vinculin is activated and binds talin and actin forming 
a stable talin-vinculin-actin complex. The stabilisation of this complex facilitates PI3-K 
conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), phosphorylation of FAK and AKT, and up-regulation of 
pro-tumourigenic signalling pathways [219]. Thus, common mechanisms for 
mammographic density signalling, centering around focal adhesions and the 
cytoskeleton, are becoming apparent, as summarised in Figure 15. 
	
Figure 15: The focal adhesion component vinculin is activated in response to stiff ECM, forming 
a stable talin-vinculin-actin complex which promotes pro-oncogenic signalling pathways. 
	
The Weaver group have also reported that changes in ECM stiffness can modulate 
micro RNA expression [220].  They demonstrated that increased matrix stiffness in 
both human and mouse mammary tissue induces expression of micro RNA-18a (miR-
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18a) via integrin-dependent activation of beta catenin and MYC. miR-18a subsequently 
interacts and inhibits expression of the tumour suppressor gene PTEN, which itself is a 
negative regulator of PI3-K activity – previously demonstrated as a key pathway 
promoting mammary epithelial cell malignant progression [213].  
miR-18a was also noted to indirectly inhibit PTEN expression via decreasing levels of 
homeobox A9 (HOXA9) (Figure 16). Interestingly, loss of PTEN expression in breast 
CAFs has also been implicated in mammary tumourigenesis [221], acting via a 
mechanism involving down-regulation of micro RNA 320 [222]. Whether this response 
can be modulated by tissue/ECM stiffness is unknown.  
Figure 16: Dense ECM induces expression of micro RNA 18a via activation of MYC and beta 
catenin. miR-18a inhibits PTEN both directly and indirectly via HOXA9, resulting in up-regulation 
of PI3-K signalling.	
	
In the Weaver study, miR-18a levels were able to distinguish luminal A from luminal B 
tumours and high miR-18a expression was predictive of poor outcome in tissue 
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biopsies of patients with luminal breast cancers, suggesting that this pathway could be 
utilised clinically.  Whether this could be used to monitor patient response to 
chemopreventive measures remains to be determined.  
1.5.9.4 Reduced expression of CD36  
	
One of the key features of high mammographic density is the change in balance of 
adipose tissue to fibrous stroma, and it might be anticipated that factors determining 
adipose differentiation may be altered. A recent study from Tlsty and colleagues has 
suggested a critical role for the transmembrane receptor CD36 in mediating MD by 
controlling two key density-determining factors: stromal adipocyte content and ECM 
accumulation [223].  
Gene expression profiling was used to determine differentially expressed genes in 
fibroblasts from high and low density disease-free breast tissue and cancer associated 
fibroblasts. CD36 expression was repressed in a range of stromal cell types 
(fibroblasts, adipoytes, endothelial cells) in both tissues of high MD and in tumour 
stroma. Loss of stromal CD36 expression in-vitro and in-vivo resulted in less fat 
accumulation and greater ECM accumulation, a phenotype shared by tissues of high 
MD and desmoplastic tumour stroma [223].  
The authors suggest that reduced CD36 expression across multiple stromal cell types 
results in a complex, co-ordinated set of signalling pathways which increases the risk of 
tumour development via a variety of mechanisms including adipocyte differentiation, 
angiogenesis, cell-ECM interaction and immune signalling.  In addition, clinically more 
aggressive tumours were associated with a greater degree of CD36 repression [223]. 
These findings highlight the potential importance of CD36 as a targetable stromal 
biomarker of MD-associated risk in the cancer prevention setting.  
Further work by this group has demonstrated that epithelial cells in high MD tissue 
show more DNA damage signalling, shorter telomeres and increased activin A 
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secretion compared to low density tissue [224]. In addition, epithelial expression of 
activin A and telomere dysfunction were capable of reducing CD36 expression in the 
surrounding stromal fibroblasts, suggesting a potential pathway by which high MD 
tissue might arise. Whether the initiating DNA damage event occurs in the epithelial or 
stromal compartment of the breast remains to be elucidated, but these studies highlight 
the dynamic interaction between stromal and epithelial compartments.  
1.5.9.5 JNK-1 stress signalling and the myofibroblast phenotype 
 
Further interrogating gene expression array data from low and high density fibroblasts, 
Lisanti et al focused on genes that were transcriptionally up-regulated by at least 1.5 
fold in high compared to low density fibroblasts [225]. They performed gene-set 
enrichment analysis and found that high density fibroblasts demonstrated up-regulation 
of several cellular processes including stress signalling, stemness, angiogenesis, 
inflammation and fibrosis. These processes are similar to those observed in the wound 
healing response and could potentially mediate a pro-inflammatory and pro-fibrotic 
microenvironment, with high density fibroblasts sharing similar characteristics to 
activated myofibroblasts.  
In addition, when the high density fibroblast gene signature was compared to the profile 
of tumour stroma, c-Jun N-terminal kinase 1 (JNK-1) stress signalling emerged as the 
most significant biological process shared between the two data sets [225].  The 
authors postulate that the stromal JNK-1 activation occurs via stressors in the 
microenvironment such as reactive oxygen species, TGF-β and fibroblast growth factor 
(FGF) signalling. The activated JNK-1 stress signalling mediates the onset of a 
‘myofibroblast’ phenotype characterised by ongoing inflammation and fibrosis, resulting 





Figure 17: Microenvironment stressors induce activation of JNK-1 signalling in breast stromal 
cells. JNK-1 signalling confers a pro-inflammatory, pro-fibrotic ‘myofibroblast’ phenotype, 
leading to increased breast density and cancer risk. Adapted from Lisanti et al [225] 
	
The authors also highlight a potential role for JNK-1 inhibitors as a cancer prevention 
strategy by inhibiting the development of the high density fibroblast phenotype.  
Whether such markers of an activated stroma could be used to measure patient risk 
and as indicators of response to treatment strategies is an intriguing possibility.  
1.5.9.6 Mitogenesis, mutagenesis and the ‘inactive’ stromal microenvironment 
gene signature 
	
Martin and Boyd have proposed that the combined effects of cell proliferation 
(mitogenesis) and genetic damage to proliferating cells by mutagens (mutagenesis) 
may account for the increased risk of breast cancer with high MD [226]; a hypothesis 
similar to the concept of ‘breast tissue ageing’ proposed by Pike [84].  
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The Martin and Boyd model has been further adapted by Sun and colleagues, who 
examined stromal gene expression signatures from non-neoplastic breast tissue 
adjacent to invasive carcinoma in a series of breast cancer patients. They found that 
high MD was particularly associated with an ‘Inactive’ stromal microenvironment 
signature [57]. This inactive subtype was associated with increased stromal 
composition, higher expression of cellular adhesion genes, increased oestrogen 
response gene expression and reduced TGF-β signalling. Interestingly, the observation 
of reduced TGF-β signalling in high MD stroma is somewhat contradictory to the model 
proposed by Lisanti et al, discussed in the previous section. A possible explanation for 
this discrepancy is that the morphologically normal tissue adjacent to invasive 
carcinoma sampled in the study by Sun et al may be displaying aberrant gene 
expression, due to the proximity to the tumour. Therefore, it may not be representative 
of truly non-neoplastic breast tissue.  
 
These data further emphasise the importance of stromal biology in mediating MD. The 
revised Martin and Boyd model incorporates and highlights the role of the stromal 
microenvironment in breast tumourigenesis. 
 
Reduced TGF-β signalling in dense breast tissue has also been observed by Yang and 
colleagues who compared gene expression in high and low density non-tumour breast 
tissue taken 5cm away from invasive carcinoma [71]. A number of genes implicated in 
TGF-β signalling showed decreased expression in dense tissue (TGFBR2, SOS, 
SMAD3, CD44 and TNFRSF11B). Immunohistochemical analysis of the same tissues 
showed higher stromal expression of COX-2 and proliferation marker Ki67 [71].  
Inhibition of TGF-β by COX has previously been reported in other organ systems [227] 
and loss of TGF-β ligand-mediated inhibition of mammary epithelial cell proliferation is 




The authors also suggest a potential role for COX-2 inhibitors as a breast cancer 
prevention strategy for high risk individuals. This is somewhat counter-intuitive, given 
the established pro-fibrogenic role of TGF-β. Furthermore, of note, the increased 
stromal Ki67 expression observed in this study is inconsistent with data from other 
groups who have reported no association of Ki67 with MD [62, 228, 229]. 
 
Chew and colleagues have also reported increased COX-2 expression in the stromal 
and (to a lower degree of significance) epithelial cells of high MD breast tissue in both 
human samples and a xenograft model of MD [72]. Furthermore, tumours developing in 
a mouse model of high collagen density breast tissue were found to express more 
COX-2 than those developing in wild type mammary stroma [230]. When the transgenic 
mice were treated with COX-2 inhibitors, the tumours which developed were smaller 
and displayed a less aggressive phenotype [230]. Furthermore, the stromal 
microenvironment of these tumours showed reduced recruitment of neutrophils and 
macrophages and fewer SMA expressing activated fibroblasts [230].  
 
The contribution of neutrophils to tumour initiation in high density stroma was further 
explored by the same group [231]. They found enhanced neutrophil cytokine signalling 
in tumours developing in high collagen density stroma compared to wild type stroma 
[231]. In addition, when neutrophils were depleted, the number of tumours developing 
in high density stroma was significantly reduced [231]. No effect of neutrophil depletion 
was observed in tumours developing in wild type stroma [231]. 
 
This study further highlights the potential significance of COX-2 in mammary 
tumourigenesis within a high collagen density microenvironment and once again 
highlights a potential therapeutic role for COX-2 inhibitors. Furthermore, the findings 
once again allude to the pro-inflammatory nature of high MD stroma with a key 




A summary of our current understanding of the complex stromal biological pathways 
conferring MD-associated breast cancer risk is displayed in Figure 18 below.  
	
Figure 18: Potential stromal molecular pathways mediating the density-associated cancer risk 
conferred by high MD breast tissue. 
	
Despite the progress made in these preclinical studies towards identifying potential 
stromal markers and signalling pathways contributing to breast density, this has not 
readily translated into clinically relevant markers or targets. Further clinically applicable 
approaches are needed to identify the key stromal molecules driving density-






1.6 Clinical implications 
	
The influence of MD on breast cancer risk has a number of important clinical 
implications, particularly with regard to identification of high risk individuals, screening 
and prevention. Currently MD is not routinely measured as part of the NHS Breast 
Cancer Screening Programme in the UK.  
 
A number of studies have investigated whether including a measure of MD improves 
risk estimation compared to standard risk models [232-235], with some additionally 
incorporating SNPs associated with breast cancer risk into their prediction models 
[236]. All of these studies found a small but consistent improvement in risk estimation 
with the addition of MD measures. Furthermore, a recent prospective study of over 
50,000 women in the UK found that MD alone was a stronger univariate risk factor for 
breast cancer than both the Tyrer-Cuzick and Gail models [44], and in their full analysis 
added accuracy to both models [44]. These findings serve to emphasise the potential 
clinical power of MD to accurately identify populations at increased risk of breast 
cancer.  
 
Screening at more frequent intervals with more than one imaging modality may be 
appropriate for women with dense breasts due to their increased risk of developing 
cancer and their increased risk of tumour ‘masking’. A recent analysis of personalised 
mammographic screening according to MD, age, family history and history of breast 
biopsy was found to be cost effective [237].  
 
The investigators of the Predicting Risk at Screening (PROCAS) study in the UK have 
proposed that the first mammographic screening appointment as an ideal opportunity 
to assess an individual’s future breast cancer risk using a model which incorporates 
MD and educate them regarding relevant lifestyle modifications and, if appropriate, 
chemoprevention [238]. The same group also report that the majority of study 
participants wished to receive risk information and that this had no detrimental effect on 
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their attendance for screening [239].  Introduction of risk assessment to the initial 
screening appointment could facilitate the development of risk-stratified screening to 
closely monitor those at higher risk whilst those at low risk may not need to attend as 
frequently. Currently the NHSBCSP only provides additional screening with magnetic 
resonance imaging (MRI) for those at very high risk of breast cancer with BRCA1/2 or 
TP53 gene mutations.  
 
In order for chemopreventive strategies for high risk individuals to have an impact on 
breast cancer incidence, there would need to be a substantial increase from the uptake 
of tamoxifen reported in the IBIS I trial of just 10% [240]. Barriers to increased uptake 
include concern regarding the potential risks of thromboembolic events and 
endometrial cancer and, in particular, the anti-oestrogenic side effects of tamoxifen 
including debilitating hot flushes and sexual dysfunction [241, 242]. It has been 
estimated that up to 50% of breast cancers could be prevented in the subgroups of 
women at high and moderate risk if there was maximal uptake of current 
chemoprevention [243].   
 
It has been postulated that change in MD could be used as a marker of response in 
clinical trials evaluating breast cancer prevention strategies [244]. This could reduce 
the need for long observation periods currently required to evaluate the likelihood of 
developing breast cancer following an intervention. Interestingly, a number of studies 
have suggested that reduction in MD can be used as a prognostic marker of response 
to tamoxifen in the adjuvant setting [111, 245]. Li and colleagues reported that 
postmenopausal women taking adjuvant tamoxifen showing a greater than 20% 
reduction in MD had a 50% reduced risk of death from breast cancer [111]. In addition, 
Ko et al found reduction in MD with adjuvant tamoxifen was associated with a reduced 
risk of recurrence in ER positive breast cancer patients [245]. Furthermore, Nyante et 
al found a reduced risk of breast cancer with a substantial reduction in MD following 
adjuvant tamoxifen in both pre- and postmenopausal women, though the protective 
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effect was only seen in those women with a moderate to high baseline level of MD 
[246].  
 
Subsequent work from this group found that the majority of MD reduction with adjuvant 
tamoxifen occurs after the first year of treatment with very little further reduction after 
the fifth year [247]. A further subset analysis, limited by statistical power, demonstrated 
that patients who showed a ≥10% reduction in MD at one year had a non-significant 
improvement in disease free survival [248]. These data suggest that a single 
measurement of MD after one year of treatment may be sufficient to identify those 
individuals likely to respond well to treatment in both the preventive and adjuvant 
settings. Importantly, non-responders can also be identified and potentially switched to 
an alternative treatment regime.  
 
Brentnall and colleagues recently investigated whether SNPs in the regions of ZNF423 
and CTSO could predict response to tamoxifen in the preventive setting. However, no 
significant predictive value for SNPs in either gene region was identified [249]. 
 
MD is more strongly associated with breast cancer risk than other variables such as 
family history and reproductive factors. Therefore, understanding the biology of MD 
may allow individual risk prediction for breast cancer. MD also offers the advantage 
over other breast cancer risk factors of being modifiable, which provides exciting 
potential for targeted therapeutic intervention to reduce both MD and breast cancer 
risk.  
 
Targeting components of the microenvironment is already an established strategy in 
the adjuvant treatment setting for a number of different tumour types [250, 251]. The 
most advanced of these strategies are agents targeting VEGF signalling in the tumour 
vasculature with a number agents now licenced for use in several metastatic cancers in 
combination with cytotoxic therapies [251, 252]. Beyond VEGF there are several other 
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anti-angiogenic agents in preclinical trials targeted against PDGF and FGF signalling 
pathways [253, 254]. 
Components of tumour-associated inflammation are also a focus of new agents 
targeted against the microenvironment. An IL-6 neutralising antibody is currently 
undergoing evaluation in clinical trials [255], and neutralising antibodies against human 
chemokines have shown promising results in preclinical models of prostate and breast 
cancer [256]. Disrupting tumour-stroma crosstalk via integrin inhibition is also the 
subject of clinical trials with agents showing limited anti-tumour efficacy at present [257, 
258]. Specifically targeting cancer associated fibroblasts, utilising their expression of 
fibroblast activation protein α, remains at the preclinical stage of development. Such 
strategies involve; the development of anti-FAP antibodies conjugated to cytotoxic 
drugs [259], utilising the enzymatic activity of FAP to activate pro-drugs in the vicinity of 
the tumour [260], and vaccines targeted against FAP [261].  
 
Harnessing similar approaches in the preventive setting to target the stromal molecules 
and pathways mediating MD could provide an effective cancer prevention strategy. 
Thus, further work to dissect the complex biological pathways mediating MD is urgently 






1.7 Exploiting the modifiability of MD by tamoxifen 
 
The drug tamoxifen has been demonstrated to reduce both MD and breast cancer risk 
in a proportion of high risk women. Thus, the ability to exploit the modifiability of MD 
with tamoxifen could prove of significant clinical value.  
1.7.1 Pharmacology of tamoxifen 
 
Tamoxifen is a member of the selective oestrogen receptor modulator (SERM) family of 
drugs. It is described as a SERM due to its complex pharmacology, displaying a variety 
of tissue-specific actions at the oestrogen receptor (ER) [262, 263].  This family of 
drugs contain a hydrophobic core that mimics the steroid backbone of oestrogens, 
grafted to a dialkylaminoalkyl side chain [264].  
In mammary epithelial cells the classical mechanism of action of tamoxifen is as a 
competitive antagonist at oestrogen receptor alpha (ERα). Binding of tamoxifen to ERα 
blocks the pro-proliferative effects of oestrogen (17-β oestradiol) on neoplastic ERα-
positive mammary epithelial cells [265, 266].  
The binding of 17-β oestradiol to ERα up-regulates the expression of c-MYC and cyclin 
D1 and promotes cell cycle progression from G1 to S phase in mammary epithelial 
cells [267].  Hence the binding of oestrogen to ER and subsequent target gene 
stimulation is considered the predominant mechanism responsible for oestrogen-driven 
mammary tumour initiation and progression [268]. 
The diverse functions of oestrogens are mediated via specific oestrogen receptors 
(ER). Currently there are two identified ER isoforms – ERα and ERβ which share a 
common structural architecture and function as ligand-dependent transcription factors 
that stimulate target gene expression [269].  
Expression of both ERα and ERβ has been demonstrated in mouse skin fibroblasts 
[270]. The expression of ER in human breast fibroblasts remains uncertain.   
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1.7.2 Tamoxifen metabolism 
 
Tamoxifen itself has weak affinity for ER [265] however, undergoes extensive first pass 
metabolism in the liver to two active metabolites: N-dimethyltamoxifen (subsequently 
metabolised to α-hydroxytamoxifen, N-didesmethyl-tamoxifen and 4-hydroxy-N-
desmethyl-tamoxifen (endoxifen)) and 4-hydroxy-tamoxifen (4-OHTam) [271], a small 
proportion of which also undergoes further metabolism to endoxifen. These active 
metabolites have substantially higher affinity for ER (30-100 fold) than tamoxifen [265].  
 
Several enzymes are known to regulate the metabolism of tamoxifen [272] (Figure 19). 
The conversion of tamoxifen to N-dimethyltamoxifen, and of 4-OHTam to endoxifen is 
predominantly regulated by the activity of hepatic cytochrome P450 3A4/5 (CYP3A4/5) 
[272]. Whereas, the conversion of tamoxifen to 4-OHTam, and of N-dimethyltamoxifen 
to endoxifen is predominantly regulated by activity of hepatic cytochrome P450 2D6 
(CYP2D6) [272].  
 
Figure 19: Metabolism of tamoxifen. Tamoxifen undergoes first pass metabolism in the liver to 
N-dimethyltamoxifen and 4-Hydroxytamoxifen which both can be further metabolised to 
endoxifen. The cytochrome P450 enzymes CYP2D6 and CYP3A4/5 have important roles in 
regulating the metabolism of tamoxifen.  
	
Recent attention has focused on genetic variants (polymorphisms) in CYP2D6, which 
have been proposed to alter the activity of the enzyme, and potentially influence how 
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patients respond to tamoxifen treatment [273].  The potential therapeutic significance of 
CYP2D6 genotype is unclear and a recent meta-analysis of 25 studies failed to find an 
association between CYP2D6 genotype and tamoxifen response for all-cause mortality 
or overall survival in breast cancer patients [274]. However, an association of CYP2D6 
genotype with change in MD with tamoxifen treatment has been reported in the 
preventive setting [114]. 
 
The concentration of tamoxifen and its metabolites within breast tissue is hugely 
variable due to the variation in individuals’ ability to metabolise the drug [275] and the 
fact that the drug accumulates in tissue with treatment [276, 277]. One study has 
investigated the concentration of tamoxifen, endoxifen and 4-OHTam after 28 days 
treatment and found that all three showed substantial tissue accumulation, with 4-
OHTam showing the greatest accumulation (up to 1411 fold the serum concentration, 
equivalent of up to 10µM) in cancer tissue [278]. In addition, there was significant 
variation in the tissue concentrations of all metabolites between individuals, 
emphasising the complex nature of tamoxifen metabolism. 
 
This substantial variability in tissue concentration may contribute towards the 
differences seen in patient response to tamoxifen in the preventive and adjuvant 
settings.  
1.7.3 Clinical use of tamoxifen 
	
Tamoxifen has been used as a treatment for established breast cancer since the 
1970s. A meta-analysis of 20 randomised clinical trials demonstrated that five years 
adjuvant tamoxifen for ERα positive breast cancer reduced both recurrence (RR 0.53, 
95% CI: 0.47-0.59) and mortality (RR 0.71, 95% CI: (0.61-0.81) [279]. Furthermore, the 




In clinical practice, the level of expression of the ERα isoform is the principle marker 
used to predict response to tamoxifen. Tumours which are designated ER-negative 
may not be completely devoid of ER and may still express very low levels of ERα. 
 
Despite the reported benefits of tamoxifen, a proportion of ERα positive breast cancer 
patients develop resistance to treatment [280, 281]. The mechanisms governing 
tamoxifen resistance are presently unknown. As discussed previously, tamoxifen has 
also shown efficacy in the prevention of breast cancer in high risk individuals [282] 
(which appears to be related to a corresponding decrease in breast density, as 
mentioned above) and as a treatment for DCIS [283]. 
 
The long term safety of tamoxifen is a subject of controversy due to significant 
treatment-related toxicities including increased risk of endometrial cancer and thrombo-
embolic events [284]. Furthermore, patient adherence to medication is also a 
significant challenge due to the debilitating anti-oestrogen side effects [241, 242]. Thus, 
there is significant interest in dissecting the mechanisms by which tamoxifen exerts its 
cancer protective effect, so that these pathways might be specifically targeted and 
undesirable toxicities and side effects avoided. 
 
Interestingly, 5-10% of ERα negative breast tumours have been reported to show a 
degree of sensitivity to tamoxifen therapy [285, 286]. A number of studies have 
suggested that expression of the oestrogen receptor beta (ERβ) isoform may explain 
sensitivity to treatment in patients with ERα negative tumours [287-289], however there 
are inconsistencies in findings between studies. Saal and colleagues found that ERβ 
protein levels were predictive of response to tamoxifen treatment with a strong positive 
correlation reported for patients with ERβ +/ ERα – tumours and disease free survival 
[287]. Conversely, a recent study from the Mayo clinic found that expression of ERβ1 
was associated with improved outcome following tamoxifen treatment in patients with 
co-expression of ERα [288].  
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1.7.4 ER-Independent mechanisms of action 
	
In addition, there is emerging evidence of alternative mechanisms of action, 
independent of the ER [290, 291].  Tamoxifen has been found to have a variety of non-
genomic effects at therapeutic doses [292].  
1.7.4.1 Effect on cholesterol and sphingolipid metabolism 
 
After the ER, tamoxifen has another high affinity binding site in the endoplasmic 
reticulum known as the microsomal anti-oestrogen binding site (AEBS) [293]. Recent 
work by Poriot and colleagues has suggested that the binding of tamoxifen and other 
SERMs to the AEBS inhibits cholesterol epoxide hydrolase (ChEH) enzyme activity, 
resulting the in the accumulation of cholesterol precursors [294, 295]. This mechanism 
has been proposed to contribute to the anti-cancer effects of tamoxifen in breast 
tumour cells [296].  
 
In addition, tamoxifen and its metabolites have been found to influence sphingolipid 
metabolism [297]. This mechanism has been proposed to have clinical significance by 
enhancing the pro-apoptotic properties of ceramide-based chemotherapy regimens. In 
addition, a direct effect on neutrophil behaviour by tamoxifen has been observed and 
attributed to modulation of intracellular ceramide [298].  
Reddel and colleagues reported in 1985 that tamoxifen was capable of inhibiting 
proliferation and inducing apoptosis in a number of ER negative breast cancer cell lines 
[299]. Since then there have been significant interest in trying to delineate the ER-
independent, pro-apoptotic, mechanisms of action of tamoxifen. 
1.7.4.2 Rises in intracellular calcium 
 
A number of studies have reported that tamoxifen significantly increases intracellular 
calcium levels in a variety of ER negative tumour cell lines, and this is associated with 
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increased apoptosis [300-302]. However, the precise mechanism leading to enhanced 
intracellular calcium has yet to be determined.  
 
Recently, it has been reported that tamoxifen has low micromolar affinity for 
cannabinoid 1 and 2 (CB1 and CB2) receptors and demonstrates an inverse agonist 
effect upon binding [303]. Normally agonists of CB1 and CB2 induce the inhibition of 
intracellular calcium influx [304], suggesting that the inverse agonist of tamoxifen at 
these receptors may explain the observed rise in intracellular calcium levels.   
 
The induction of oxidative stress by tamoxifen has also been proposed to modulate 
JNK-1 signalling [305], a pathway proposed to initiate apoptosis via increasing the 
activity of caspase 8 [305] and up-regulating the expression of Fas-ligand [306]. 
Tamoxifen has also been reported to induce apoptosis in the triple negative breast 
cancer cell line MDA-MB-231 by reducing AKT phosphorylation when used in 
combination with the phosphoinositide-dependent kinase-1 (PDK1) inhibitor OSU-
03012, however suppression of AKT phosphorylation was also noted with PDK1 
inhibitor treatment alone [307]. Thus it is not clear whether the reported induction of 
apoptosis can truly be attributed to the effect of tamoxifen treatment.  
 
1.7.4.3 Effect of tamoxifen on the stromal microenvironment  
 
The ability of tamoxifen to directly modulate the stromal microenvironment is a novel 
concept, contrary to the classical rationale for tamoxifen prescription as a targeted 
therapy against ER expressed in neoplastic breast epithelial cells.  Nevertheless, there 
is emerging data to support a direct effect on the mammary stroma. 
Much of this work has focused on the ability of tamoxifen to modulate TGF-β signalling. 
TGF-β is a pro-fibrotic cytokine up-regulated in the wound healing response and is the 
most potent known inducer of fibroblast activation to the myofibroblast phenotype [308].  
As discussed in the earlier section, gene expression studies have highlighted up-
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regulation of TGF-β signalling in high density mammary stroma [225]. Thus it is 
plausible that tamoxifen may modulate density by inhibiting the pro-fibrotic actions of 
TGF-β.  
 
TGF-β signalling is mediated either via the canonical pathway involving 
phosphorylation of SMAD proteins or via a variety of non-canonical routes [309]. The 
canonical signalling pathway involves one of the TGF-β superfamily of ligands 
(including TGF-βs, bone morphogenic proteins (BMPs), growth and differentiation 
factors (GDFs), Anti-Müllerian hormone (AMH) and activins) binding to a TGF-β type II 
receptor dimer (Figure 20A) [310]. The type II receptor is a serine/threonine receptor 
which recruits a type I receptor dimer forming a hetero-tetrameric complex (Figure 
20B). The type II receptor phosphorylates serine residues on the type I receptor, 
activating it (Figure 20B) [310].  
	
Figure 20: The canonical TGF-β signalling pathway. TGF-β ligands bind to a type II receptor (A) 
which recruits a type I receptor to form a hetero-tetrameric complex (B). The type II receptor 
phosphorylates serine residues on the type I receptor and activates it (B). One of five R-SMAD 
proteins binds to the activated type I receptor via interaction with the SARA protein (C). The 
type 1 receptor phosphorylates the R-SMAD, inducing a conformational change and 
subsequent dissociation of the R-SMAD from the receptor and SARA (D). The phosphorylated 
R-SMAD associates with a CO-SMAD (E) and translocates to the nucleus, binds to transcription 




One of five receptor regulated SMAD proteins (R-SMAD) binds the type I receptor via 
an interaction with the SMAD anchor for receptor activation (SARA) protein (Figure 
20C) [311]. In the case of the TGF-β ligands, intracellular signalling is mediated via 
SMAD 2 and SMAD3 [311]. The type I receptor subsequently phosphorylates the R-
SMAD, inducing a conformational change resulting in the dissociation of the R-SMAD 
from the receptor complex and SARA (Figure 20D) [311]. The phosphorylated R-SMAD 
then associates with a CO-SMAD such as SMAD 4 (Figure 20E). The R-SMAD/CO-
SMAD complex translocates to the nucleus, binds transcription factors resulting in the 
transcription of target genes (Figure 20F) [311].  
TGF-β can also signal through a variety of non-canonical (non-SMAD) pathways to 
mediate changes in gene transcription and cellular function [312]. These pathways 
include branches of the MAP kinase pathways, Rho-like GTPase pathways and PI3-
K/AKT pathways [312].  
 
A recent study from Carthy and colleagues found that tamoxifen inhibited TGF-β-
mediated activation of primary skin and breast fibroblasts. They reported no effect on 
canonical TGF-β signalling but reported inhibition of non-SMAD signalling via ERK1/2 
and transcription factor FRA2 [313]. Conversely, Kim and colleagues found that 
tamoxifen inhibited canonical TGF-β signalling in a mouse renal fibroblast cell line and 
inhibited renal fibrosis in a mouse model [314]. Thus, whilst a consistent inhibitory 
effect on TGF-β signalling has been observed in both of these studies, the precise 
mechanism of action remains to be elucidated and it is possible that differing tissue-
specific mechanisms of action may exist.  
 
The antifibrotic properties of tamoxifen have also been utilised clinically as a treatment 
for disorders of fibrosis such as chronic renal disease [315], dupytrens contracture 
[316], desmoid tumours [317] and idiopathic retroperitoneal fibrosis [318]. These 
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antifibrotic properties may contribute to remodelling of the mammary stroma and the 
observed reduction in MD with tamoxifen treatment [110].   
 
A recent study by Shim and colleagues reports an anti-angiogenic effect of tamoxifen 
and other SERMs on endothelial cells by disrupting cholesterol trafficking, leading to an 
abnormal distribution of  vascular endothelial growth factor receptor 2 (VEGFR2) [319]. 
In addition, an anti-angiogenic effect of tamoxifen has been reported in ER negative in-
vitro and animal models of angiogenesis [320]. Therefore, tamoxifen may be able to 




2 Introduction and aims of the study 
 
There is now robust epidemiological data demonstrating the protective effect of 
tamoxifen for women at high risk of breast cancer [113]. Furthermore, this protection is 
associated with a reduction in MD [110].  
Recent studies consistently report that high density breast tissue corresponds 
predominantly to increased stromal tissue [54, 55]. This suggests that tamoxifen may 
be acting directly on the mammary stroma to reduce density and breast cancer risk. In 
addition, there is evidence from a variety of models that tamoxifen can directly modify 
stromal cell behaviour [115, 321]. 
These observations form the hypothesis for this study:  
 
Tamoxifen protects the breast through a direct effect on stromal fibroblast function, 
modifying key biological pathways, reflected as a decrease in MD. 
 
The biological mechanisms mediating density-associated breast cancer risk are poorly 
understood. Thus, the aim is to exploit the effects of tamoxifen on MD to elucidate the 
pathways involved in determining stromal density. 
Knowledge of such pathways could be utilised clinically in the form of risk prediction 
and personalised screening regimens, prediction of response to chemopreventive 
agents such as tamoxifen, and the in development of novel targeted cancer prevention 
strategies.  
To investigate this hypothesis, the aims are: 
(i) To use in-vitro models of primary human breast fibroblasts to dissect the 
effect of tamoxifen on stromal cell function. 
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Initially, a cohort of patients’ fibroblasts will be screened for response to tamoxifen. 
Data from Cuzick and colleagues suggest that 46% of high risk women show a 
significant reduction in MD (>10%) with tamoxifen [110], therefore it is anticipated that 
not all patients will respond. Target genes will be those implicated in generating stromal 
density and assays will be performed to measure fibroblast proliferation, migration, 
markers of activation and effect on TGF-β signalling. 
(ii) To use RNA Seq to carry out a whole transcriptome analysis on the effect of 
tamoxifen on fibroblast gene expression. 
The genome wide analysis will be undertaken to compare the transcriptome of 
tamoxifen treated vs vehicle control treated fibroblasts. The samples selected for this 
part of the analysis will be those demonstrating a significant response to tamoxifen in 
part (i).  
(iii) Validation of selected pathways modulated by tamoxifen and investigation 
of the role of the ER in these pathways. 
Significant changes in gene expression will be validated by quantitative real-time 
polymerase chain reaction (qRT-PCR) or western blotting. 
Several of the ‘top hit’ genes modulated by tamoxifen are involved in cholesterol and 
lipid metabolism, therefore analysis of fibroblast phenotype and differentiation will also 
be undertaken. 
(iv) To explore the impact of tamoxifen-modified fibroblasts on epithelial cell 
behaviour. 
Data from in-vitro and in-vivo models suggests that a dense stroma promotes epithelial 
cell proliferation and, in pre-malignant cells, can promote tumorigenic behaviour, 
including invasion [213]. 
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Fibroblasts pre-treated with tamoxifen or vehicle control will be cultured in 3D with 
epithelial cells. The effect on epithelial cell behaviour will be analysed by measuring 
proliferation (Ki67), colony size and morphology. The effect of fibroblast-derived matrix 
and conditioned media from fibroblasts pre-treated with tamoxifen and vehicle control, 





3 Methods and Materials  
	
3.1 Fresh breast tissue acquisition 
	
Fresh human breast tissue was obtained from samples donated to the Breast Cancer 
Now Breast (BCN)/ Barts Cancer Institute (BCI) tissue bank (Ethical Approval 
Reference	10/H0308/49,	Cambridgeshire Ethics Committee October 2010). Following 
surgery, the tissue was examined by a pathologist and samples of fresh and snap 
frozen tissue were taken which would not compromise the diagnostic work up of the 
specimen.  
3.2 Tissue definitions and abbreviations 
	

































3.3 Cell Culture 
	
3.3.1 Isolation of primary human breast fibroblasts from breast tissue 
	
Primary breast fibroblasts were isolated using an adapted protocol from Gomm et al 
[322] (summarised in Figure 21). The fresh breast tissue was briefly washed in 70% 
ethanol, then three successive washes in RPMI (Sigma, R5886) supplemented with 
gentamycin (10µg/ml) (Sigma, G1397). The tissue was then chopped and digested 
overnight at 37oC with collagenase (1mg/ml, Sigma, C2674) and hyaluronidase 
(1mg/ml, Sigma, H3506) on a roller mixer. This process separates the tissue into three 
components: fat, organoids and stromal cells/fibroblasts. The following day the fat layer 
was separated by decanting and the organoids and stromal cells/fibroblasts were 
washed three times in RPMI followed by three sedimentation steps at room 
temperature (RT) to isolate the stromal/fibroblast component. After 30 minutes of 
sedimentation, the supernatant (stromal/fibroblast) component was removed and 
placed into culture or frozen for later use. The organoid component underwent further 
processing to isolate single epithelial and myoepithelial cells, which did not form part of 





Figure 21: Summary of the steps to isolate purified cell types from primary human breast 
tissue, adapted from Gomm et al [322]. 
	
3.3.2 Cell types and media requirements 
	
Primary human breast fibroblasts were cultured for a limited number of passages in 
Dulbecco’s Modified Eagles Medium with HAM F-12 (DMEM F12, Sigma, D8437) 
supplemented with 10% foetal bovine serum (FBS, Invitrogen, 10500), 
penicillin/streptomycin (100µg/ml, Sigma, P4333) and amphotericin B (2.5µg/ml, 
Sigma, A2942).  
 
The ERα positive cell line (MCF 7) utilised in this study was previously available in the 
laboratory. Cells were cultured in Dulbecco’s Modified Eagles’s Medium (DMEM, 
Sigma, D6429) supplemented with 10% FBS and penicillin/streptomycin (100µg/ml).  
 
The normal mammary epithelial cell line HB2 and Her2 overexpressing HB2 cells were 
a gift from Professor Valerie Speirs, University of Leeds. These cells were originally 
obtained from Dr Fedor Berditchevski, University of Birmingham. The cells were 
97	
	
cultured in DMEM supplemented with 10% FBS, hydrocortisone (5µg/ml, Sigma, 
H0888) and human insulin (2µg/ml, Sigma, I9278).  
3.3.3 Cell culture in experiments using tamoxifen, 4-OHTam, 17-β 
oestradiol, fulvestrant and tesmilifene 
	
Tissue culture media supplemented with phenol red has been shown to have 
oestrogenic properties [323, 324] and FBS is known to harbour small quantities of 
endogenous hormones [325, 326]. 
In order to ensure the cells under investigation were completely deprived of any 
hormonal stimulation prior to treatment with Tamoxifen (Sigma, T5648) 4-OHTam 
(Sigma, H7094), 17-β oestradiol (E2, Sigma, E2257), Fulvestrant (Sigma 14409) and 
Tesmilifene (DPPE, Sigma, D2571) cells were cultured in phenol red free DMEM F12 
(Sigma, D64134) supplemented with 5% double charcoal stripped  foetal bovine serum 
(DCSS, First Link, 02-46-850) and L-glutamine (2mM, Sigma, G7513) for at least 24 
hours before drug treatment.  
3.3.4 Propagation and subculture 
	
Cells were grown in T175 flasks (Fisher Scientific) and incubated at 37oC in 5% CO2. 
The cells were monitored using an inverted phase contrast microscope. Culture media 
was changed every 3-4 days. 
Once cells had reached confluence, the cells were passaged by removing and 
discarding the media and washing with phosphate buffered saline (PBS). 5ml of 
Trypsin/Ethylenediaminetetraacetic acid (EDTA) solution (Hyclone, SV30031.01) was 
added at a concentration of 0.05% trypsin and 0.02% EDTA. The flask was placed at 
37oC for 3 minutes until they started to detach. The cells were then washed with media, 
scraped and spun down in a centrifuge for 3 minutes at 1500 rpm. The supernatant 
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was discarded and the pellet re-suspended in fresh media before being seeded into a 
new flask.  
 
HB2 cells and HB2 cells overexpressing Her2 were passaged by washing with PBS 
then adding 10ml of 0.1% EDTA (Fisher Chemical, D065053) for 5 minutes at 37oC. 
The EDTA was then removed and 5ml of trypsin/EDTA solution at a concentration of 
0.25% trypsin and 0.1% EDTA was added for a further 3 minutes at 37oC until the cells 
started to detach. The cells were then washed with media, scraped and spun down in a 
centrifuge for 3 minutes at 1500 rpm. The supernatant was discarded and the pellet re-
suspended in fresh media before being seeded into a new flask.  
3.3.5 Preservation and de-frosting 
	
Cells were preserved in liquid nitrogen in freezing media comprising 54% DMEM F12, 
40% FBS and 6% dimethyl sulphoxide (DMSO, Sigma, D2650).  Cells were re-
suspended in 1ml of freezing medium per cryovial. For reconstitution, frozen cells were 
rapidly thawed until semi-solid and then added to 5ml DMEM F12 in a 15ml tube. The 
DMSO was removed by centrifuging at 1500 rpm for 3 minutes, removing the 




3.4 Western blotting 
3.4.1 Cell lysis 
	
When harvesting cells for protein analysis, culture medium was removed and the flask 
rinsed with cold PBS, before adding cold radioimmunoprecipitation assay (RIPA) buffer 
(50mM Tris-HCl pH 8.0, 150mM NaCl (Fisher, 358-1), 1mM EDTA (Fisher, BP 118-
500), 1% Igepal CA-630 (NP-40; Calbiochem, 490216), 0.1% sodium dodecyl sulphate 
(SDS)) mixed with a cocktail of protease inhibitors (Calbiochem, 539131) at 1:100, 
activated sodium orthovanadate at 1:100 and sodium fluoride at 1: 20. The plate was 
scraped and the suspension was placed in an eppendorf tube and incubated on ice for 
15 minutes. The eppendorf was then centrifuged at 10000 rpm at 4oC for 5 minutes. 
The pellet was discarded and the supernatant transferred to a new eppendorf.  
3.4.2 Protein quantification 
	
Protein concentration was estimated with a Bio-Rad DC protein Assay (Bio Rad 
Laboratories, 500-0114, 114, 115). Cell lysates and BSA (bovine serum albumin, 
Sigma, A9418) standards (diluted in distilled water) were added at 5µl volumes to a 96 
well plate in triplicate, before adding 25µl of solution A/S (1000µl reagent A and 20µl 
reagent S) per well followed by 200µl of reagent B per well. The reagents were left to 
incubate for 10 minutes at room temperature before reading on a 96 well plate reader 
at 620nm. An absorbance versus concentration curve was plotted using the BSA 
standards and this was used to estimate the sample protein concentration. Samples 
were frozen at -20oC until required.  
3.4.3 SDS gel electrophoresis 
	
An SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) gel was prepared with 
component volumes adjusted depending on the molecular weight of the protein of 
interest. The resolving gel solution (4.6ml distilled water (dH2O), 2.7ml 30% acrylamide 
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mix (National Diagnostics, EC 890), 2.5ml 1.5M Tris (pH 8.8), 100µl 10% SDS 
(National Diagnostics EC 874), 100µL 10% ammonium persulphate (APS, National 
Diagnostics, EC 504) and 8µl TEMED (Flowgen, H17459)) was dispensed into a 1mm 
thick gel cassette (Invitrogen, NC2010) and 1ml of dH20 was overlaid to allow sample 
diffusion. After the gel was set (approximately 10 minutes), the dH20 was poured off.  A 
5% SDS-PAGE stacking gel solution (2.1ml dH20, 500µl 30% acrylamide, 380µl 1M 
Tris (pH6.8), 30µl 10% SDS, 30µl 10% APS and 3µl TEMED) was added to the 
cassette, a 1mm 10 well comb was inserted and the gel left to set for about 10 minutes. 
The comb was removed and the cassette placed in a gel tank containing 500ml of 
running buffer (50ml tris-glycine/SDS (Amresco, 0307) in 450ml dH20).  
 
Once the stacking gel had set, 10-30µg of each protein sample was added to 4X 
sample loading buffer (5% SDS, 20% buffer (0.5M tris, 0.2M NaH2PO4, pH 7.8), 5% β-
mercaptoethanol (Sigma, M7522), 50% glycerol (Fisher, G/0600/17), 0.01% 
bromophenol blue (Sigma, B8026) and 20% dH20) to give a final concentration of 1X.  
Samples were then boiled for 5 minutes at 95oC before being loaded into the gel along 
with 5µl of PageRuler pre-stained protein ladder (Generon, SM0671) and run for 80 
minutes at 150V, RT.  
 
A non-reducing protocol was utilized when blotting for collagen I. This involved omitting 
β-mercaptoethanol from the x4 sample loading buffer and not boiling the samples prior 
to loading into the gel. 
 
Transfer buffer (50ml tris-glycine buffer (Severn Biotech, 20-6400-10) in 450ml 80% 
dH20/ 20% MeOH) was prepared. Transfer sponges and a 0.45µM nitrocellulose 
membrane (Amersham, RPN2030) were soaked in transfer buffer while the cassette 
was removed from the gel tank and the stacking gel separated. A sandwich was 
created within the transfer apparatus, containing wet sponges, filter paper, the gel and 
presoaked nitrocellulose membrane with the membrane immediately adjacent to the 
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gel. Any air bubbles were removed by gently rolling a glass tube along the sandwich, 
prior to sealing the lid and placing the apparatus into the inner chamber of the gel tank. 
Transfer buffer was added to the top of the inner chamber and dH2O added to the outer 
chamber. The whole tank was then placed in ice and run at 30V for 90 minutes at 4oC. 
	
After transfer, the membrane was blocked in 5% skimmed milk powder (Sigma, 70166)/ 
PBST (0.1% Tween 20 (Applichem, A4974) in PBS) for 1 hour with gentle rocking. The 
membrane was inserted into a 50ml tube containing 5ml of primary antibody diluted 
1:1-2000 in 5% milk/PBST (depending on primary antibody used (Table 4)) and 
incubated overnight at 4oC on a roller mixer. The membrane was then washed in PBST 
three times for 5 minutes each time, after which the membrane was placed in 5ml of 
horse radish peroxidase (HRP)-conjugated secondary antibody (anti-mouse/rabbit IgG 
HRP, 1: 2000, Dako, P0488, P0260) and incubated for 1 hour RT on a roller mixer. The 
membrane was washed three times in PBST (5 minutes each) and the protein was 
visualised by developing in ECL detection (Amersham, RPN 2106) reagent.   
Antibody	 Dilution	 Species	 Manufacturer	
FN-IST	4	 1:	2000	 Mouse	monoclonal	 Sigma	(F0196)	
pSMAD	2	 1:	1000	 Rabbit	polyclonal	 Cell	Signalling	(3101S)	
SMAD	2	 1:	1000	 Rabbit	polyclonal	 Cell	Signalling	(8657)	
pSMAD	3	 1:	1000	 Rabbit	polyclonal	 Cell	Signalling	(9520S)	
SMAD	3	 1:	1000	 Rabbit	polyclonal	 Cell	Signalling	(9523S)	
pERK	1/2	 1:1000	 Rabbit	polyclonal	 Cell	Signalling	(9101S)	
Total	ERK	 1:1000	 Rabbit	polyclonal	 Cell	Signalling	(9102)	
LOX	 1:1000	 Rabbit	polyclonal	 Novus	Biologicals	(NB100-2527)	
Collagen	1	 1:1000	 Rabbit	polyclonal	 AbCam	(ab34710)	
SMA	 1:	5000	 Mouse	monoclonal	 Sigma	(M0581)	
ER-Beta	 1:	1000	 Rabbit	polyclonal	 AbCam	(ab3576)	
DHCR7	 1:	500	 Rabbit	polyclonal		 AbCam	(ab103296)	
ER-Alpha	 1:	1000	 Rabbit	polyclonal	 Cell	Signalling	(8644S)	
Her-2/ErbB2	 1:	1000	 Rabbit	monoclonal	 Cell	Signalling	(2165S)	
HSC70	 1:	5000	 Mouse	monoclonal	 Santa	Cruz	(sc-7298)	
 





3.5  Immunocytochemistry 
	
Cells were fixed in 10% neutral buffered formalin (NBF, Cell Path Ltd, BAF-0010-25A) 
for 10 minutes at RT and washed twice with PBS. Cells were then permeabilised by 
incubating with 0.1% Triton for 15 minutes at RT, washed with PBS and blocked with 
5% normal horse serum (NHS, Sigma, 12449C)/ 3% BSA for 15 minutes at RT. Cells 
were then incubated overnight at 4oC with the appropriate primary antibody diluted in 
5% NHS/ 3% BSA (Table 5). Cells were then washed three times in PBS, incubated 
with biotinylated secondary anti-mouse or anti-rabbit secondary antibody (Vector 
Laboratories, 1:200 in 1% BSA) for 40 minutes at RT, washed in PBS a further three 
times before incubating with avidin-biotinylated peroxidase complex (Vectastain ABC 
kit, Vector Laboratories, PK 6101, 6102) for 30 minutes at RT. Cells were washed with 
PBS three more times before developing using a DAB kit (Vectastain, Vector 
Laboratories, SK 4100). Cells were then washed twice with PBS and counterstained 
with Haematoxylin for 2 minutes, rinsed in tap water and then stored in PBS at 4oC.   
Antibody	 Species	 Dilution	 Manufacturer	





ER-Beta	 Rabbit	polyclonal	 1:100	 Abcam	(ab3576)	
	
Table 5: Primary antibodies used for immunocytochemical staining 
	
3.5.1 Ki67 quantification 
	
10 randomly selected fields were examined at x10 objective and the number of positive 
cells were counted and expressed as a percentage of the total number of cells present 





3.6 Statistical analysis 
	
Statistical significance was determined by two tailed Student’s t-test using Prism 









Epidemiological data suggest that tamoxifen can reduce MD in a proportion of women 
at high risk for breast cancer [109].  A significant (>10%) reduction in MD following 
treatment appears crucial to receive the protective effect of the drug [110]. Numerous 
studies have observed that high density breast tissue is characterised by increased 
stromal content [54, 55]. Thus tamoxifen may act directly on stroma to reduce density.   
 
Studies investigating a direct effect of tamoxifen on stromal cells are limited, however 
there is emerging evidence of significant ER-independent mechanisms of tamoxifen 
action at therapeutic doses [298, 313, 315, 319]. 
The effect of tamoxifen on the proliferation of primary breast fibroblasts was examined 




4.2 Methods and materials 
	
4.2.1 MTS and Alamar Blue cell proliferation assays 
	
Cell proliferation was measured using CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (MTS, Promega, G350) and CellTiter-Blue Cell Viability Assay 
(Alamar Blue, Promega, G8081). Both assays use the metabolic activity of cells as a 
surrogate measure for cell viability. The indicator dye reagents act as intermediate 
electron acceptors and are reduced by viable cells, resulting in a colour change. The 
MTS assay reagent is a tetrazolium salt (yellow colour) which is reduced to coloured 
formazan (brown/red colour). The Alamar Blue reagent is resazurin (blue colour) which 
is reduced to resofurin (pink colour). 
 
Indicator dye reagent (70µl) was added to one well of cultured cells with 350µl fresh 
media (5:1 media: reagent v/v ratio). After incubation for 2 hours at 37oC, 100µl 
aliquots were removed in triplicate and dispensed into a 96 well plate. Absorbance at 
492nm (MTS) or 550nm and 600nm (Alamar Blue) was determined using a 96 well 
plate reader.   
4.2.1.1  Fibroblast proliferation assay 
	
Individual patient’s fibroblasts were optimised for seeding in 24 well plate format. Cells 
were treated with 4-OHTam (100nM-25µM), E2 (100pM – 100nM), or 4-OHTam and E2 
in combination for 10 days with fresh drug and media changes every 2-3 days. The 
cells were cultured in phenol red free medium and charcoal stripped serum (as 
described in section 3.3.3). Proliferation was measured immediately prior to treatment 





4.2.1.2  MCF7 proliferation assay 
	
Cells were seeded at 5x 104 cells per well in 24 well plate format and serum starved for 
24 hours. Cells were treated with E2 (100pM-100nM), 4-OHTam (5µM) and Fulvestrant 
(5µM) for up to 10 days with fresh drug and media changes every 2-3 days. The cells 
were cultured in phenol red free medium and charcoal stripped serum (as described in 
section 3.3.3). Proliferation was measured as described above. 
	
4.2.2 LDH cytotoxicity assay 
	
Cell toxicity was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay 
(Promega, G1780). Lysed cells release lactate dehydrogenase (LDH), a stable 
cytosolic enzyme. LDH in conditioned media is measured using a coupled enzymatic 
assay resulting in the conversion of a tetrazolium salt to a red formazan product. The 
amount of colour formed is proportional to the number of lysed cells.  
 
50µl aliquots of conditioned media from fibroblasts treated with vehicle control or 4-
OHTam for three days were removed in triplicate and dispensed into a 96 well plate. 
50µl of substrate mix was added to each well and incubated at room temperature for 
30 minutes in the dark. 50µl of stop solution was then added to each well and 
absorbance at 492nm determined using a 96 well plate reader. To calculate 
percentage cytotoxicity, lysis solution was added to triplicate wells of vehicle control 
treated fibroblasts to give a measurement of the maximum possible cell lysis per well. 
The absorbance values obtained in the remaining experimental wells were normalised 







4.3.1 Fibroblast patient cohort 
	
4.3.1.1 Cohort characteristics 
	
Fibroblasts from 24 patients were isolated and cultured successfully from a variety of 
different tissue types.  The patient characteristics of the cohort with regard to age and 




1004	 Normal	reducing	mammoplasty	 27	 Pre-menopausal	
1024	 Dense	surround	 51	 Peri-menopausal	
1203	 Dense	surround	 43	 n/a	
1247	 Dense	surround	 51	 n/a	
1299	 Dense	surround	 77	 Post-menopausal	
1299	 Non	dense	surround	 77	 Post-menopausal	
1513	 Normal	reducing	mammoplasty	 21	 Pre-menopausal	
1567	 Prophylactic	mastectomy	 44	 Pre-menopausal	
1621	 Prophylactic	mastectomy	 21	 Pre-menopausal	
1681	 Dense	Surround	 44	 Pre-menopausal	
1890	 Non	dense	surround	 60	 Post-menopausal	
1923	 Prophylactic	mastectomy	 45	 Pre-menopausal	
1989	 Normal	reducing	mammoplasty	 33	 Pre-menopausal	
1991	 Prophylactic	mastectomy	 41	 Pre-menopausal	
2090	 Dense	surround	 48	 Pre-menopausal	
2093	 Contralateral	prophylactic	 53	 Post-menopausal	
2124	 Prophylactic	mastectomy	 41	 Pre-menopausal	
2182	 Normal	reducing	mammoplasty	 25	 Pre-menopausal	
2204	 Prophylactic	mastectomy	 46	 Pre-menopausal	
2266	 Contralateral	prophylactic	 48	 Peri-menopausal	
2585	 Normal	reducing	mammoplasty	 24	 Pre-menopausal	
3078	 Normal	reducing	mammoplasty	 58	 Post-menopausal	
3137	 Normal	reducing	mammoplasty	 49	 Pre-menopausal	
3353	 Normal	reducing	mammoplasty	 25	 Pre-menopausal	
	
Table 6: Characteristics of patient fibroblast cohort 
	
The total number of patient samples from each tissue type and the mean age of these 











Table 7: Mean patient age by tissue type 
	
Patients in the normal reducing mammoplasty and prophylactic mastectomy groups 
have a lower mean age than those in the other groups. 
4.3.1.2 Fibroblast morphology 
	
Significant variation in the morphology of fibroblasts between patient samples was 
noted. Some patients’ cells showed a prominent spindled morphology whereas other 
cells were more plump and flattened. Examples of these are displayed in Figure 22 
below.  
	
Figure 22 Variation in primary breast fibroblast morphology. The morphology of fibroblasts from 
different patients varied significantly. Representative examples (A) Prophylactic mastectomy 
with prominent spindled morphology (B) Normal reducing mammoplasty. 
 
4.3.2 Effect of 4-OHTam on fibroblast proliferation 
	
The ranges of 4-OHTam concentration assessed in these experiments were 
determined from previous studies [278, 313, 314]. Primary fibroblasts from all patients 
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in the cohort consistently showed a dose dependent response to 4-OHTam; increasing 
4-OHTam concentration had a negative effect on proliferation. A toxic effect was seen 
at concentrations greater than 6µM. These observations were consistently 
demonstrated using both the MTS and Alamar Blue assays, displayed in Figures 23 + 
24 below. 
	
Figure 23: Effect of increasing 4-OHTam concentration (1-25µM) on fibroblast proliferation 
using MTS assay. Fibroblasts show a dose dependent response of reduced proliferation with 
increasing 4-OHTam concentration. Absorbance values are normalised to Day 0. This is an 
example of patient 1004. Data points represent the mean of three assays. 
	
Figure 24: Effect of increasing 4-OHTam concentration (1-25µM) on fibroblast proliferation 
using Alamar Blue assay. Fibroblasts show a dose dependent response of reduced proliferation 
with increasing 4-OHTam concentration. Absorbance values are normalised to Day 0. This is an 
example of patient 1004. Data points represent the mean of three assays. 
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The negative effect of 4-OHTam on fibroblast proliferation was consistently observed in 
the presence of 17-β oestradiol (E2, Figure 26). E2 alone had no effect on fibroblast 
proliferation (Figure 25).  
 
Figure 25: Effect of increasing 17-β oestradiol (E2) concentration (100pM-100nM) on fibroblast 
proliferation using Alamar Blue assay. No significant effect on proliferation is seen with 
increasing E2 concentration. Absorbance values are normalised to Day 0. This is an example of 
patient 1004. Data points represent the mean of three assays. 
 
 
Figure 26: Effect of increasing 4-OHTam concentration (1-10µM) on fibroblast proliferation in 
the presence of E2 (10nM) using Alamar Blue assay. A decrease in proliferation is seen with 
increasing 4-OHTam concentration. Absorbance values are normalised to Day 0. This is an 
example of patient 1004. Data points represent the mean of three assays. 
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As a positive control, MCF7 cells were treated in triplicate with E2 (1nM, Figure 27). E2 
substantially increased MCF7 proliferation compared to vehicle and 4-OHTam (5µM) 
treated cells. 
	
Figure 27: Effect of E2 (1nM) and 4-OHTam (5µM) on MCF7 cell proliferation using Alamar 
Blue assay.  E2 markedly increases proliferation whereas 4-OHTam has an overall negative 
effect on proliferation. Absorbance values are normalised to Day 0. Data points represent the 
mean of three assays. 
	
	
4.3.3 Comparison of Alamar Blue and MTS Assay sensitivity 
	
To compare the sensitivities of both MTS and Alamar blue assays, a standard curve 
was prepared for each assay using a range of dilutions (1:1) with known numbers of 























Table 8: Standard curve data for MTS assay. The assay loses sensitivity for accurately 
quantifying cell number at a concentration of around 400 cells per well.  
	
Figure 28: MTS Assay standard curve. The assay has a lower limit of detection at around 400 

























Table 9: Standard curve data for AB assay. The assay continues to have sensitivity for 
detecting cell number to a concentration of less than 100 cells per well.  
	
	
Figure 29: Alamar Blue assay standard curve. The assay has a lower limit of detection of less 
than 100 cells per well.  
	
The MTS assay had a lower limit of detection of around 400 cells per well, whereas the 
Alamar Blue assay had a lower limit of detection of around 100 cells per well. 
 
Given the enhanced sensitivity of the Alamar Blue assay for detecting small changes in 
cell number, this was adopted as the preferred assay. A negative absorbance value is 
seen for lower cell numbers in the Alamar Blue assay since the absorbance ratio is 
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calculated by subtracting the absorbance of the substrate of the reaction from the 
absorbance of the product. Thus, when fewer cells are present, less product is formed 
and the ratio becomes negative in value. 
 
4.3.4 Effect of 4-OHTam on fibroblast proliferation using Ki67 
	
Given that both the MTS and Alamar blue assays use cell metabolism as a surrogate 
measure for proliferation, Ki67 immunocytochemistry was performed on primary 
fibroblasts from two patients treated with vehicle control and 4-OHTam (5µM) for one 










	 	 	 	
	
Figure 30: (i) Representative images of Ki67 immunocytochemistry staining (X10 magnification) 
of (A) vehicle control treated fibroblasts (B) 4-OHTam (5µM) treated fibroblasts. (C) MCF7 cells 
(positive control). (D) MCF 7 cells (negative control with mouse immunoglobulin, Haematoxylin 
staining of nuclei only). (ii) Graph showing % positive staining cells per total number of cells per 
x10 objective field (n = 10).  
 
Significantly more cells in the cell cycle (Ki67 positive) were present in the vehicle 





4.3.5 Effect of 4-OHTam on fibroblast proliferation by direct cell counts 
	
To further evaluate the effect of 4-OHTam on fibroblast proliferation, T175 flasks were 
seeded with 4 x105 cells from three patients, hormone deprived for 24 hours and 
treated with vehicle control, 4-OHTam (5µM), 4-OHTam and E2 (10nM), or  E2 for 7 
days. Viable cells were counted using trypan blue (Sigma, T8154). Fibroblasts treated 
with 4-OHTam (+/- E2) were significantly reduced in number after 7 days compared to 
those treated with vehicle control or E2 alone (p <0.001, Figure 31). 
	
Figure 31: Number of viable cells present after one week treatment with vehicle control, 4-
OHTam (5µM), 4-OHTam + E2 (10nM) or E2. Cells treated with 4-OHTam or 4-OHTam + E2 










4.3.6 Effect of 4-OHTam on fibroblast toxicity 
	
To confirm the observed effect on proliferation was not simply due to a toxic effect 
causing cell death, the LDH assay was performed using three patients’ primary 
fibroblasts treated with increasing concentrations of 4-OHTam (1-25µM). Significant 
toxicity was only seen in concentrations of 4-OHTam >6µM, suggesting the effect on 
proliferation noted at lower concentrations is not merely a toxic effect (Figure 32). 
	
 
Figure 32: (i) and (ii): Effect on increasing 4-OHTam concentration on cell toxicity using the 
LDH assay. Significant toxicity is only seen at concentrations of 6µM and above. (i) Overall 













4.3.7 Effect of 4-OHTam on fibroblast phenotype 
	
Fibroblasts treated with concentrations of 4-OHTam of 200nM and above displayed a 
consistent phenotype characterised by the accumulation of small perinuclear 
cytoplasmic vesicles (Figure 33). This was observed in fibroblasts from all patients in 




Figure 33: Phase contrast image of primary fibroblast phenotype following one week treatment 












4.3.8 Reversibility of 4-OHTam treated fibroblast phenotype 
	
Primary fibroblast proliferation was measured following 4-OHTam treatment for 5 days 
and then again after switching back to control media, to determine if the observed 
negative proliferative effect of 4-OHTam was retained after removal of the drug from 
the culture media (Figures 34 + 35). 
 
The negative effect of 4-OHTam on fibroblast proliferation showed a degree of 
recovery after switching back to control media following 5 days of 4-OHTam (Figure 
34). In addition, a partial reversal of the morphological 4-OHTam phenotype (reduced 
numbers of perinuclear cytoplasmic vesicles) was seen once the culture media was 
changed to vehicle control (Figure 35).  
	
	
Figure 34. Reversibility of 4-OHTam (5µM) effect on cell proliferation using Alamar Blue assay. 
The negative effect of 4-OHTam on cell proliferation shows a degree of recovery once 4-
OHTam is removed from the culture media after day 5. Example of patient 2182. Datapoints 






Figure 35: Reversibility of 4-OHTam fibroblast phenotype. Fibroblasts treated with 4-OHTam 
(5µM) for 5 days showed some reversibility of the 4-OHTam treatment phenotype, with gradual 
loss of perinuclear cytoplasmic vesicles when the culture media was switched to vehicle control. 
(A) Vehicle control treated fibroblasts (B) 4-OHTam treated fibroblasts displaying characteristic 
phenotype (C) 4-OHTam treated fibroblasts 2 days after switching to vehicle control media, 
showing some loss of perinuclear cytoplasmic vesicles. (D) 4-OHTam treated fibroblasts 5 days 










4.4.1 Fibroblast patient cohort 
	
The cohort of primary fibroblasts were isolated from patients with a wide age range (21-
77 years) and a range of non-tumour breast tissue type (Table 6). The fibroblasts 
isolated from reduction mammoplasty and prophylactic ‘risk reducing’ mastectomy 
tissue were from younger patients (mean 32.8 years and 39.6 years respectively), in 
keeping with the clinical need for intervention at an earlier age (Table 7). Cells isolated 
from surround tissue were from older patients (mean 50.6 years) who have a higher 
incidence of breast cancer. The inter-patient variation in the cohort was reflected by 
variation in the morphology of the cultured fibroblasts (Figure 22). Capturing the 
heterogeneity that exists between individual patients by using primary cell cultures is a 
strength of this study. Unfortunately, due to constraints of time, radiological data 
regarding the MD of these patients was not available. 
4.4.2 Effect of 4-OHTAM on fibroblast proliferation 
	
A consistent negative, dose dependent, effect on fibroblast proliferation was observed 
with 4-OHTam treatment in fibroblasts from the entire patient cohort (Figures 23 +24). 
This effect on proliferation was accompanied by a characteristic phenotype where the 
4-OHTam treated fibroblasts accumulated small perinuclear cytoplasmic vesicles 
(Figure 33). At present it is unclear what these vesicles represent.  
 
The negative effect on proliferation was observed at 4-OHTam concentrations of 
100nM and above, within the range detected in the breast tissue of breast cancer 
patients treated with tamoxifen for one month [278]. Reduced proliferation was 
measured using two independent cell viability assays utilising cell metabolism as an 
indirect measure of proliferation (MTS and Alamar Blue, Figures 23 + 24). Alamar Blue 
was found to have greater sensitivity (Figures 28 + 29) and thus was adopted as the 
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preferred assay for the remainder of the experimental work. Direct cell counting 
confirmed reduced fibroblast proliferation following 4-OHTam treatment, as significantly 
fewer cells were present after treatment for 7 days with 4-OHTam compared to vehicle 
control (p<0.001, Figure 31).  
 
In order to ensure these observations were physiologically relevant, co-treatment with 
E2 was also performed. Reduced proliferation with 4-OHTam was still observed in the 
presence of E2 both by direct cell counting (Figure 31) and the indirect metabolic 
based assays (Figure 26). Treatment with E2 alone had no significant effect on 
proliferation assessed via direct counting or the indirect assays (Figures 25 +31). The 
fact that E2 did not increase proliferation suggests the mechanisms underlying the 
observed effects on fibroblast proliferation may not be mediated via the 
agonist/antagonist functions of 4-OHTam and E2 at ER.  
 
To further investigate the negative effect of 4-OHTam on fibroblast proliferation using 
an indirect assay not related to cell metabolism, Ki67 immunocytochemistry was 
performed. Positive Ki67 staining highlights cells actively entering the cell cycle. 4-
OHTam treated fibroblasts showed significantly less Ki67 positivity than those treated 
with vehicle control (p<0.001, Figure 30), further highlighting the negative effect of 4-
OHTam on fibroblast proliferation. The LDH assay confirmed that significant toxicity 
was only seen at 4-OHTam concentrations greater than 6µM (Figure 32), suggesting 
the reduced proliferation observed was not merely a result of cell toxicity. 
 
In order to investigate whether the negative proliferative effect of 4-OHTam on 
fibroblasts was reversible, cells were treated with the drug for 5 days before switching 
back to control media. A significant recovery of cell proliferation was noted after 5 days 
of treatment with normal media (Figure 34). This suggests that 4-OHTam treatment 
does not result in irreversible changes to fibroblast function, and that regular drug 
dosing is needed to maintain the 4-OHTam- treated phenotype.  
123	
	




Having observed a direct effect of 4-OHTam on the proliferation of primary breast 
fibroblasts, a more detailed analysis of the fibroblast response to 4-OHTam was 
undertaken, focused on key candidate stromal markers. 
 
Data from Hattar and colleagues suggest that, in animal models, tamoxifen can 
remodel the mammary ECM to a tumour inhibitory phenotype, characterised by 
reduced levels of fibronectin (FN) [115]. The same study also reported modulation of 
expression of collagen I, the most abundant mammary ECM protein, by tamoxifen. This 
has also been observed in animal models of renal fibrosis [314].  
 
Lysyl oxidase (LOX) is a collagen cross-linking enzyme implicated in driving tumour 
progression within a stiff ECM via enhanced integrin signalling and FAK activity [213]. 
Currently no data exists on the ability of tamoxifen to modulate LOX expression.  
 
An anti-fibrotic effect of tamoxifen is well recognised [315] and it has been proposed 
that tamoxifen may affect the transformation of fibroblasts to the activated 
myofibroblast phenotype, in response to stimulation from the pro-fibrogenic cytokine 
TGF-β [313, 314]. However, to date, studies are limited and report contrasting findings. 
Expression of ER has been reported in mouse skin fibroblasts [270], however ER 
expression in primary human breast fibroblasts is not known. The pure ER-antagonist 
fulvestrant (ICI 182780) was used to assess if tamoxifen interaction with fibroblast ER 




5.2 Methods and materials 
	
5.2.1 Fibroblast scratch assay 
	
Primary fibroblasts were seeded in 6 well plates at 4 x105 cells per well, allowed to 
adhere to plastic overnight then changed to phenol-red free media and DCSS. Once 
confluent, cells were serum starved for 24hours.  Two perpendicular scratches were 
made across the diameter of the wells with a 200µl pipette tip forming a central cross 
for reference. The media was aspirated and cells washed with PBS three times. Cells 
were then incubated with vehicle control, 10% DCSS (positive control), 4-OHTam 
(2µM), recombinant TGF-β1 (5ng/ml, Peprotech, 100-21B) + vehicle control or TGF-β + 
4-OHTam. Images of the scratch were captured using a phase contrast microscope at 
x4 objective immediately after scratching (Time 0), and after 8 hours. The area of the 
scratch was measured using Image J at Time 0 and 8 hours and the percentage 
decrease in area compared for each treatment condition (Figure 36). 
	
	





5.2.2 Collagen gel contraction assay 
	
An eight part collagen gel mixture (8 parts collagen 1 (rat tail, BD, 354236), 1 part 
phenol red-free DMEM F12, 1 part filtered DCSS, 1 part 10X DMEM (Sigma, D2429) 
was prepared on ice then neutralised with successive additions of 90µl 0.1M NaOH 
until the mixture changed colour from yellow to bright pink. The gel mixture was then 
dispensed in triplicate to a 24 well plate (500µl per well) and allowed to set for 2 hours 
at 37oC. 4 x 104 primary fibroblasts were seeded onto each gel in 500µl phenol red free 
DMEM with 5% DCSS and either vehicle control or 4-OHTam (5µM). Gels were then 
left overnight at 37oC before being carefully removed from the sides of the well using a 
needle. The media was then aspirated and replaced with fresh media containing 
vehicle control, 4-OHTam (5µM), TGF-β (5ng/ml) + vehicle control or TGF-β + 4-
OHTam. Gels were photographed using a dissecting microscope (Carl Zeiss) 
immediately afterwards (Time 0) and then again at 48 hours. The area of the gel at 
Time 0 and 48 hours was measured using Image J and the percentage reduction in gel 
area calculated for each treatment condition (Figure 37). 
	







5.2.3 Fibroblast derived matrices (FDM) 
	
5.2.3.1 Preparation of glass coverslips, chamber slides and culture plates for 
fibroblast derived matrix generation 
	
Culture plates (24 well, 12 well and 6 well) were coated in 0.2% gelatin (Sigma, G1393) 
for 1 hour at 37oC to prepare them for FDM generation. 13mm2 glass coverslips and 8 
well chamber slides (Lab-Tek Fisher Scientific, TKY-210-916Y) were coated in sterile 
0.2% gelatin for 1 hour at 37oC then washed with PBS and incubated with sterile 1% 
glutaraldehyde (Sigma, G6257) for 25 minutes at RT, washed again with PBS and 
incubated with sterile 1M glycine (Fisher Scientific, BP381-1) for 20 minutes at RT.  
Coverslips, chamber slides and culture plates were then washed with PBS and 
incubated with DMEM F12 for 30 minutes at 37oC.		
5.2.3.2 Generation of fibroblast derived matrices 
	
Primary fibroblasts from three patients were seeded at high density in DMEM F12, 
switching to phenol-red free media after 12 hours. Once confluent, the media was 
changed and replaced with fresh media supplemented with L-ascorbic acid (50µg/ml, 
Sigma, A4403) and either vehicle control or 4-OHTam (5µM). Ascorbic acid increases 
collagen production and helps to stabilise the matrix. The matrix generating media was 
replenished every other day for one week.  
5.2.3.3 Decellurising the FDM 
	
After one week the media was removed and the cells washed gently in sterile PBS 
containing 1mM CaCl2 and 0.5mM MgCl2 (Sigma, D8662). Cells were then lysed using 
warm extraction buffer (10mM Ammonium hydroxide (Sigma, 221228) and 0.1% Triton 
X-100 (Alfa Aesar, A16046)) and incubated at 37oC for 5 minutes. Following cell lysis, 
FDM were carefully washed in sterile PBS twice then incubated for half an hour with 
DNase 1 (10µg/ml, C10104159001, Boehringer/Roche Diagnostics). FDM were 
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carefully washed in PBS twice, examined under phase contrast to ensure the matrix 




Figure 38: Preparation of fibroblast derived matrix (FDM) 
	
5.2.3.4 Immunofluorescent staining of FDM 
	
FDM on glass coverslips or chamber slides were fixed in 10% NBF for 20 minutes at 
RT, washed in sterile PBS then blocked with 5% bovine serum albumin (BSA, Sigma, 
A8022) overnight at 4oC. The 5% BSA was then removed and replaced with 5% BSA 
with anti-fibronectin IST4 antibody (1:100 dilution, Sigma, F0916) for 1 hour at RT. 
FDM were then washed three times with PBS and incubated for 1 hour with Alexafluor 
anti-mouse 488 secondary antibody (Invitrogen, A11059) in 1% BSA for 1 hour at RT. 
FDM were then washed four times in PBS before mounting in Prolong Gold anti-fade 
mounting medium with DAPI (Invitrogen, P36391).  
5.2.3.5 Imaging of FDM 
	
Images were acquired on confocal microscope LSM510 (Carl Zeiss). 488 dye was 
excited with the argon laser at 488nm (green fluorescence). Images were captured at 
1024 x 1024 resolution. A z-stack series was taken through the thickness of the FDM 
with x20 objective. The serial Z stack images were merged as one maximal intensity 
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image for analysis. 4 measurements of FDM thickness were taken in each of the 
triplicate samples by subtracting the distance between the top and bottom sections of 
the fluorescently stained fibronectin matrix.  
5.2.4 SirCol soluble collagen assay 
	
The collagen content of fibroblast conditioned media (FCM) and FDM was determined 
using the SirCol soluble collagen assay (Biocolor, S1000) as per manufacturer’s 
instructions. The assay utilises the binding of Sirius Red dye to quantify the amount of 
collagen present in solution – the greater the amount of red colour present, the greater 
the amount of collagen present. 
5.2.4.1 Sample preparation 
	
Fibroblast conditioned media (FCM) was harvested as described in Chapter 8. 1ml was 
transferred to triplicate eppendorf tubes along with 200µl of collagen isolation and 
concentrating reagent (Biocolor, S1000). The tubes were inverted several times before 
incubating overnight at 4oC in a rack filled with ice and water. The following morning the 
tubes were centrifuged at 12000 rpm to pellet the concentrated collagen and the 
supernatant carefully removed.  
FDM were prepared as described above in triplicate format on 12 well plates. The 
collagen within the matrices was solubilised by incubating overnight at 4oC with 2ml 
pepsin (0.1mg/ml, Invitrogen, 00-3009)/ acetic acid (0.5M, Sigma, A6283). The 
extraction solution was then concentrated using the method described above with the 
addition of 100µl acid neutralising agent per sample, prior to the addition of collagen 





5.2.4.2 Collagen detection and quantification 
	
1ml of SirCol dye reagent (Biocolor, S1000) was added to each sample. Each tube was 
inverted several times and then placed on a rotating wheel for 30 minutes. The 
samples were then centrifuged at 12,000 rpm for 10 minutes and the supernatant 
carefully removed. 750µl ice cold acid-salt wash (Biocolor, S1000) was then carefully 
added on to the pellet to remove unbound collagen from the surface. The samples 
were then centrifuged again at 12,000 rpm for 10 minutes and the supernatant 
removed. 250µl alkali reagent (Biocolor, S1000) was then added to each sample and 
the collagen-bound dye solubilised by placing the tubes on a vortex mixer for 5 
minutes.  
100µl per sample was transferred to an individual well of a 96 well plate and 






5.3.1 Effect of 4-OHTam on fibronectin expression 
	
Data from animal models suggests that fibronectin (FN) may contribute to a pro-
tumourigenic mammary stroma [115]. To assess whether tamoxifen can modulate 
expression of total FN in human stromal cells, fibroblasts were treated with 4-OHTam 





Figure 39: Fibronectin (FN) expression in three patients (A-C) treated with 4-OHTam (5µM) for 
one week. Significantly reduced expression of FN was observed in in 4-OHTam treated 
fibroblasts (p = 0.012) (i) Representative western blot image (ii) Densitometry analysis, 
expression normalised to loading control. (1.0 = equal protein expression level as HSC70 in 




Fibroblasts treated with 4-OHTam showed significantly reduced expression of FN (p= 
0.012, Figure 39), in a proportion of the cohort (Table 10). Primary breast fibroblasts 
from three patients (1513, 1004, 2090) also showed reduced expression of FN when 
treated with both 4-OHTam and E2 (p<0.01, Figure 40). No significant effect on FN 
expression was observed with E2 alone (Figure 40).  
 
 
Figure 40: Effect of treatment with 4-OHTam (5µM) +/- E2 (10nM) on fibroblast expression of 
FN. 4-OHTam and combined 4-OHTam and E2 treatment resulted in a significant reduction in 
FN expression (p<0.01). No effect was observed with E2 alone. (i) Representative western blot 
image (ii) Densitometry analysis, example of patient 1513 (n=3), expression normalised to 




In contrast to the consistent effect on fibroblast proliferation, a reduction in fibronectin 
expression was not observed in all patients. 62% of 23 patients showed a reduction in 
FN expression with 4-OHTam. Those patients who did show a change in FN 
expression were classified as ‘responders’ (Table 10). Any reduction in FN expression 
was regarded as a positive response to 4-OHTam. Reduction in FN expression with 4-
OHTam treatment was used as a screening tool to select patient samples for the whole 
transcriptome (RNA-Seq) pilot analysis (Chapter 6). 
Patient	ID	 Tissue	Type	 Age	(Years)	 Reduction	in	FN	(Y/N)	
1004	 Normal	reducing	mammoplasty	 27	 Y	
1024	 Dense	surround	 51	 Y	
1203	 Dense	surround	 43	 N	
1247	 Dense	surround	 51	 Y	
1299	 Dense	surround	 77	 N	
1299	 Non	dense	surround	 77	 N	
1513	 Normal	reducing	mammoplasty	 21	 Y	
1567	 Prophylactic	mastectomy	 44	 N	
1621	 Prophylactic	mastectomy	 21	 N	
1681	 Dense	Surround	 44	 N	
1890	 Non	dense	surround	 60	 Y	
1923	 Prophylactic	mastectomy	 45	 Y	
1989	 Normal	reducing	mammoplasty	 33	 Y	
1991	 Prophylactic	mastectomy	 41	 N	
2090	 Dense	surround	 48	 Y	
2093	 Contralateral	prophylactic	 53	 Y	
2124	 Prophylactic	mastectomy	 41	 Y	
2182	 Normal	reducing	mammoplasty	 25	 Y	
2204	 Prophylactic	mastectomy	 46	 N	
2266	 Contralateral	prophylactic	 48	 Y	
2585	 Normal	reducing	mamoplasty	 24	 Y	
3078	 Normal	reducing	mammoplasty	 58	 Y	
3137	 Normal	reducing	mammoplasty	 49	 N	
3353	 Normal	reducing	mammoplasty	 25	 Y	
	
Table 10: Fibroblast cohort and response to 4-OHTam 
	
Responders and non-responders had a similar mean age (Table 11). The majority 
(75%) of normal reducing mammoplasty patients showed a reduction in FN expression 
with 4-OHTam treatment (Table 12). A smaller proportion of prophylactic mastectomy 
















Table 12: Response to 4-OHTam and tissue type 
 
5.3.2 Effect of 4-OHTam on fibroblast expression of lysyl oxidase (LOX) 
	
The collagen cross-linking enzyme lysyl oxidase (LOX) has been proposed to 
contribute to high density mammary stroma and increased stromal LOX activity is 
associated with tumour progression [213]. LOX expression was assessed in primary 
breast fibroblasts from three patients, who had previously shown a reduction in FN 








Figure 41: LOX expression in three patients’ (A-C) fibroblasts treated for one week with 4-
OHTam (5µm). No significant effect on LOX expression was seen with 4-OHTam treatment. (i) 
Representative western blot image. (ii) Densitometry analysis, representative data from patient 
2090 (n=3). Expression normalised to loading control.  
	
No significant effect on LOX expression was seen with 4-OHTam treatment in any of 
the three patients’ fibroblasts.  
5.3.3 Effect of 4-OHTam on fibroblast expression and secretion of 
collagen 
	
Increased collagen density is associated with mammary tumour progression in-vitro 
and in-vivo [206, 207]. Collagen I expression was assessed in primary breast 
fibroblasts from three patients (1004, 2090, 2585), who had previously shown a 






Figure 42: Collagen I expression in three patients’ (A-C) fibroblasts treated with 4-OHTam 
(5µm) for one week. Patients A and B showed a significant reduction in collagen I expression 
with 4-OHTam treatment, whilst little response was observed in Patient C. (i) Representative 
western blot image (ii) Densitometry analysis, expression normalised to loading control. 
Representative data from patient 2585 (Patient A, n=3).  
	
Two of the three patient fibroblasts examined showed a significant decrease in 
expression (Patients A and B), whereas the third (Patient C) showed minimal response 
(Figure 42), once again demonstrating inter-patient variability.  
The SirCol soluble collagen assay was performed to assess whether 4-OHTam 
treatment influenced the secretion of soluble collagen into conditioned media by three 





Figure 43: Total collagen concentration in conditioned media following one week treatment with 
4-OHTam (5µM). Significantly less (p < 0.01) collagen was present in the conditioned media 
from 4-OHTam treated fibroblasts compared to those treated with vehicle control. 
Representative data from patient 2585 (n=3).  
	
Significantly less (p < 0.01) collagen was present in the conditioned media from 4-
OHTam treated fibroblasts compared to those treated with vehicle control (Figure 43). 
Fibroblast derived matrices (FDM) generated from three patients primary fibroblasts 
(2093, 2182, 2266) in the presence of vehicle control or 4-OHTam (5µM) were 





Figure 44: Collagen concentration of fibroblast derived matrices (FDM) generated from three 
patients primary fibroblasts in the presence of vehicle control or 4-OHTam (5µM). No significant 
difference is seen in the collagen content of FDM generated under the different treatment 
conditions. Representative data from patient 2266 (n=3).  
 
No significant difference was seen in the collagen content of FDM generated by vehicle 
control or 4-OHTam treated fibroblasts (Figure 44).  
 
5.3.4 Effect of 4-OHTam on fibroblast derived matrix thickness  
FDM were generated from three patients primary fibroblasts (2090, 2182, 2266) 
concurrently treated with vehicle control or 4-OHTam (5µM). Immunofluorescent 
staining for FN was performed to assess FDM thickness (Figures 46 + 47). No 
significant difference was observed in the thickness of FDM generated in the presence 




Figure 45: Thickness of FDM generated in the presence of vehicle control or 4-OHTam. No 
difference in FDM thickness was observed between the two treatment conditions. 
Representative data from 2266 (n=12). 
	
Z stack images were taken at regular intervals (approx. 1.2µm) through the FDM 
(Figure 46) 
 
Figure 46: Serial z stack images through FDM stained with FN, generated in the presence of 
vehicle control or 4-OHTam.  
	





























Figure 47: Maximum intensity projection of Z stack images through FDM stained for FN, 
generated in the presence of vehicle control or 4-OHTam (5µM). Representative images from 
patient 2266.  
	
5.3.5 Effect of 4-OHTam on fibroblast activation by TGF-β 
	
Primary breast fibroblasts were treated with 4-OHTam and stimulated with recombinant 
TGF-β1 to determine the effect of tamoxifen on fibroblast activation by TGF-β. Protein 
expression of SMA was used as a marker of fibroblast activation. 
	
5.3.5.1 Effect of 4-OHTam on fibroblast expression of SMA 
	
Primary fibroblasts from all patients in the cohort were treated with 4-OHTam (5µM) for 






Figure 48: Effect of 4-OHTam (5µM) on fibroblast expression of SMA. A significant reduction in 
SMA expression was consistently seen in all three patients (p <0.01). (i) Western blot image (ii) 
Densitometry analysis, expression normalised to loading control. Representative data from 
patient 3078 (n=3). 
 
4-OHTam treatment consistently resulted in a significant reduction (p <0.01) in SMA 
expression across all patients in the cohort (Figure 48).  
5.3.5.2 Effect of 4-OHTam on TGF-β-mediated up-regulation of SMA  
	
Primary breast fibroblasts from three patients (1004, 2090, 3078) stimulated with TGF- 
β (5ng/ml) showed significant up-regulation of SMA expression (p<0.05, Figure 49). 








Figure 49: Effect of 4-OHTam (5µM) on fibroblast reponse to TGF-β1 (5ng/ml).TGF- β 
stimulation resulted in significant up-regulation of SMA expression (p<0.05). In the presence of 
4-OHTam, this response was consistently inhibited in all patients (p<0.05, n=3). (i) 
Representative western blot image (ii) Densitometry analysis, expression normalised to loading 






5.3.5.3 Effect of 4-OHTam on TGF-β stimulated fibroblast contraction of 
collagen gels 
 
Collagen gels were seeded with primary fibroblasts from two patients (1004, 3078) and 
then stimulated with TGF-β1 (5ng/ml) in the presence of either vehicle control or 4-
OHTam (5µM). Reduced contraction was seen in gels stimulated with TGF-β in the 
presence of 4-OHTam compared to TGF-β in the presence of vehicle control (p = 
0.0085, Figure 50). 
 
	
Figure 50: Effect of 4-OHTam (5µM) on TGF-β stimulated fibroblast contraction of collagen 
gels. The enhanced gel contraction demonstrated by stimulation with recombinant TGF-β1 
(5ng/ml) is inhibited by treatment with 4-OHTam (p = 0.0085). (i) Representative images 48 
hours after gel release (ii) Quantification of reduction in gel area for each treatment condition, 






5.3.5.4 Effect of 4-OHTam on TGF-β stimulated fibroblast migration 
	
Scratch assays were used to assess the effect of 4-OHTam (2µM) on TGF-β (5ng/ml) 
stimulated fibroblast migration using cells from two patients (2090, 2266). TGF-β in the 
presence of vehicle control significantly increased fibroblast migration after 8 hours 
compared to vehicle control and 4-OHTam treated cells (p = 0.0135). TGF-β stimulated 
cell migration was reduced in the presence of 4-OHTam although the difference did not 




Figure 51: Effect of 4-OHTam (2µM) and TGF-β (5ng/ml) on fibroblast migration assessed by 
scratch assay. TGF-β in the presence of vehicle control significantly increased migration after 8 
hours compared to vehicle control and 4-OHTam treated cells (p = 0.0135). TGF-β induced 
migration was lower in the presence of 4-OHTam however this did not reach statistical 
significance (p = 0.1789). (i) Graph quantifying percentage reduction in scratch area (ii) 
representative images at time 0 and 8 hours with scratch area outlined for each treatment 




5.3.5.5 Effect of 4-OHTam on SMAD signalling 
	
Having observed a consistent inhibition of TGF-β mediated up-regulation of SMA, 
inhibition of fibroblast-collagen gel contraction and fibroblast migration with 4-OHTam 
treatment (Figures 49 - 51), primary breast fibroblasts from three patients (2090, 2182, 
3353) were stimulated with recombinant TGF- β1 (5ng/ml) and expression of 
phosphorylated SMAD proteins analysed to determine if 4-OHTam modulated 
canonical TGF-β signalling.  
 
A time course stimulation assay was initially performed using one patient’s fibroblasts 
(3353) to determine the optimum time point to assess phosphorylation of SMAD 
proteins following stimulation with recombinant TGF-β1 (5ng/ml, Figure 52) 
	
Figure 52: TGF-β stimulation assay. Primary fibroblasts were stimulated with TGF-β1 (5ng/ml) 
and cells harvested at sequential time points for analysis of SMAD3 protein phosphorylation. 
Phosphorylation of SMAD3 protein peaked after 15 minutes and remained high until 2 hours 
when the signal intensity fell. Representative data from patient 3353.  
	
Based on the stimulation assay findings, a time-point of 20 minutes was selected to 
harvest cells for assessment of SMAD protein phosphorylation. No significant effect on 
the phosphorylation of SMAD 2 or SMAD3 proteins was observed in the presence of 





Figure 53: Effect of 4-OHTam (5µM) and 10nM E2 (10nM) on SMAD2 protein phosphorylation 
following stimulation with recombinant TGF-β1 (5ng/ml). No significant effect on SMAD2 
phosphorylation was observed in the presence of either 4-OHTam or E2. Representative data 
from patient 3353. 
	
	
Figure 54: Effect of 4-OHTam (5µM) and 10nM E2 (10nM) on SMAD3 protein phosphorylation 
following stimulation with recombinant TGF-β1 (5ng/ml). No significant effect on SMAD3 
phosphorylation was observed in the presence of either 4-OHTam or E2. Representative data 





5.3.5.6 Effect of 4-OHTam on non-canonical TGF-β signalling through ERK1/2 
	
Having observed a significant modulation of primary fibroblast response to TGF-β by 4-
OHTam (Figures 49 - 51), yet no apparent effect on canonical (SMAD) signalling 
(Figures 53 + 54), the effect of 4-OHTam on non-canonical TGF-β signalling through 
ERK1/2 was assessed. The TGF-β stimulation assay was repeated as described in 
section 5.3.5.5 using fibroblasts from patient 2585 and demonstrated phosphorylation 
of ERK1/2 after 2 minutes (Figure 55).  
 
Figure 55: TGF-β stimulation assay. Significant phosphorylation of ERK1/2 was evident after 
two minutes and remained high up to one hour. Representative data from patient 2585.  
	
Based on these findings, cells were harvested 5 minutes after TGF-β stimulation to 
assess ERK phosphorylation. Primary fibroblasts from three patients (1923, 2182, 
2585) were stimulated with TGF-β with and without 4-OHTam, and the effect on 





Figure 56: Effect of 4-OHTam (5µM) on non-canonical TGF-β signalling through ERK1/2. TGF-
β stimulation (5mg/ml) alone resulted in significant up-regulation of ERK1/2 phosphorylation (p 
<0.01). This response was significantly inhibited by the presence of 4-OHTam (p = 0.02) in all 
three patients’ fibroblasts. (i) Western blot image (ii) Densitometry analysis, expression 
normalised to loading control. Representative data from patient 2585 (n=3).  
 
TGF-β stimulation in the presence of vehicle control resulted in significant ERK1/2 
phosphorylation (p <0.01). Treatment with 4-OHTam significantly inhibited ERK1/2 
phosphorylation following TGF-β stimulation (p = 0.02, Figure 56). This was seen 




5.3.6 ERα and ERβ protein expression in primary fibroblast cohort 
 
Protein expression of ERα was not detected in any of the fibroblasts (Figure 57). Low 
level ERβ expression was consistently detected in all of the cohort (Figure 58). There 
was no association with ERβ expression and reduction in FN expression with 4-
OHTam treatment (patients who showed reduced FN expression with 4-OHTam 




Figure 57: Oestrogen receptor alpha (ERα) expression in primary breast fibroblasts (i) Western 
blot image of ERα expression in six patient fibroblast samples (A-F) and MCF7 cells (positive 
control). No ERα expression in seen in any of the fibroblast samples. (ii) Immunocytochemical 
staining for ERα (x20 objective). (A) No ERα seen in primary fibroblasts (B) Rabbit 







Figure 58: Oestrogen receptor beta (ERβ) expression in primary fibroblasts. (i) Western blot 
image of ERβ expression in six patients (A-F) primary fibroblasts (* - patients who showed a 
reduction in fibronectin expression with 4-OHTam) and HepG2 cell lysate (positive control). (ii) 
Immunocytochemical staining for ERβ (x20 objective) (A) weak nuclear and cytoplasmic 
expression in primary fibroblasts (B) Rabbit immunoglobulin (negative control) (C) weak to 
moderate nuclear expression in MCF7 cells.  
	
5.3.7 Effect of fulvestrant on fibroblast expression of fibronectin and 
SMA 
	
Fulvestrant showed a minimal effect on FN expression and no effect on SMA 
expression, whereas 4-OHTam substantially decreased FN expression and 
consistently reduced SMA expression, even in the presence of TGF-β (Figure 59). 




Figure 59: Effect of Fulvestrant (5µM) and 4-OHTam (5µM) on fibroblast expression of FN and 
SMA. Fulvestrant had a minimal effect on FN expression and no effect on TGF-β1 (5ng/ml) 
mediated up-regulation of FN or SMA. 4-OHTam had a substantial effect on FN expression and 
consistently inhibited TGF-β mediated up-regulation of FN and SMA. Example data from patient 
2093 
	
5.3.8 Effect of Fulvestrant on MCF7 Proliferation 
	
The effect of fulvestrant on MCF7 cell proliferation was analysed, as a positive control 
for the drug. MCF7 cells were treated with vehicle control, E2 (10nM), fulvestrant (5µM) 
and E2 plus fulvestrant using phenol red free media and charcoal stripped serum (as 
described is sections 3.3.3 and 4.2.1.2). E2 treatment markedly increased MCF7 
proliferation (Figure 60). Fulvestrant significantly decreased MCF7 cell proliferation, 




Figure 60: Effect of E2 (10nM) and Fulvestrant (F, 5µM) on MCF7 cell proliferation. E2 
markedly increases MCF7 cell proliferation. Fulvestrant has a negative effect on cell 








5.4.1 Effect of 4-OHTam on FN expression 
	
Almost two thirds (62%) of the primary mammary fibroblast cohort showed reduced 
expression of FN with 4-OHTam treatment (Figure 39, Tables 10 - 12).  The variability 
in fibroblast response to 4-OHTam is intriguing, as it parallels the variability in response 
to tamoxifen observed clinically in both the preventive and adjuvant settings. Cuzick 
and colleagues reported just under half of women from a high risk population 
demonstrated a significant (>10%) reduction in MD with tamoxifen and were protected 
from breast cancer [110].  In addition, Li and colleagues reported just 11% of women 
treated with tamoxifen in the adjuvant setting showed a significant (>10%) reduction in 
MD [114].   
 
This group also investigated the association of individuals who demonstrated a 
significant reduction in MD with polymorphisms of the CYP2D6 gene, which facilitates 
the metabolism of tamoxifen to 4-OHTam, a metabolite with far greater affinity for the 
ER. They found that individuals with a less functional CYP2D6 gene were significantly 
less likely to experience a significant reduction in MD (Ptrend = 0.021) [114]. This 
suggests an individual’s ability to metabolise tamoxifen may determine whether they 
will respond well to treatment and receive the protective effect.  
 
4-OHTam was used as the drug treatment in this study, which assumes extensive 
metabolism of tamoxifen. This may explain why the majority (62%) of our cohort of 
primary fibroblasts showed a response to 4-OHTam, a figure much greater than the 
percentage of responders from the clinical studies detailed above.  Interestingly, not all 
patients showed a reduction in FN expression despite using pure 4-OHTam, this 
suggests there may be other biological factors involved in determining susceptibility to 
the protective effect of tamoxifen other than simply the ability to metabolise the drug. 
154	
	
In our fibroblast cohort, reduction in FN expression with 4-OHTam treatment did not 
appear to be related to patient age as both non-responder and responders had a 
similar mean age (41.8 vs 46.6). The type of tissue the cells were derived from did not 
appear to determine ability to respond to 4-OHTam as responders were present in cells 
derived from all tissue types. Reduction mammoplasty and contralateral prophylactic 
mastectomy samples had a greater proportion of responders (75% and 100%) 
however, the numbers present in each tissue type group are small and therefore the 
differences are unlikely to be significant.  
 
Our findings of reduced FN expression with tamoxifen treatment are supportive of 
findings reported by a number of recent studies. Carthy and colleagues found 
tamoxifen reduced FN expression in primary fibroblasts from the skin and breast [313]. 
In addition, Kim and colleagues observed reduced FN expression in mouse model of 
renal fibrosis following tamoxifen treatment [314]. Furthermore, Hattar and colleagues 
reported reduced FN expression in the mammary ECM isolated from rats treated with 
tamoxifen [115]. 
The study by Hattar et al also highlights the potential role of FN in contributing to a pro-
tumourigenic mammary stroma. Cancer cell lines injected into rats with ECM harvested 
from tamoxifen treated rats developed smaller tumours compared to those developing 
in ECM harvested from control rats [115]. Crucially, when exogenous FN was added to 
the ECM harvested from tamoxifen treated rats, this re-established its pro-tumourigenic 
activity and the tumours that developed were larger [115].  
 
Thus tamoxifen-mediated reduction in FN expression in mammary stroma may play an 
important role in generating a microenvironment less permissive to tumour formation. 
 
Primary breast fibroblasts were also treated with 4-OHTam in the presence of E2 to 
create a more physiologically relevant model. Reduction in FN expression was still 
observed in the presence of E2, to a similar degree (p<0.01, Figure 40). E2 alone did 
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not affect FN expression. This suggests there may be more complex mechanisms 
involved in influencing FN expression in fibroblasts rather than simply agonist or 
antagonist interaction at an oestrogen receptor, and that 4-OHTam may be influencing 
a unique pathway which E2 does not affect. 
 
Aida-Yasuoka and colleagues reported an increase in FN expression in primary skin 
fibroblasts following treatment with E2 [327], in contrast to our findings. However, they 
observed this response to be dependent on fibroblast expression of ERα. No 
expression of ERα was seen in any of the primary breast fibroblasts in this study 
(Figure 57), which could account for these differences in response.  
5.4.2 Effect of 4-OHTam on LOX Expression 
	
LOX is a collagen cross linking enzyme which Weaver and colleagues reported to 
contribute to a stiff ECM, enhance focal adhesion formation, integrin signalling and 
facilitate the invasion of premalignant epithelial cells in-vitro and in-vivo [213]. To date, 
there are no reports of whether tamoxifen can modulate LOX activity. 
 
No effect of 4-OHTam on expression of LOX was seen in three patients’ primary 
fibroblasts (Figure 41). These three patients cells were selected as they had previously 
shown a response to 4-OHTam with a reduction in FN expression and thus considered 
‘responders’. 
 
Despite not observing an effect on LOX expression, the functional activity of the 
enzyme may still be affected, thus future work could focus on addressing this. 
Furthermore, the LOX family has several other members (LOX-like 1-4) with similar 
functional activity. Therefore it is possible that tamoxifen may modulate the expression 




5.4.3 Effect of 4-OHTam on fibroblast collagen expression and secretion 
	
Reduced expression of collagen I with 4-OHTam treatment was seen in three patients’ 
fibroblasts that had previously demonstrated reduced FN expression (Figure 42). The 
degree of reduction in collagen expression showed significant variation between the 
three patients.  
 
This heterogeneity in response to 4-OHTam, in terms of collagen I expression, is 
intriguing as it further highlights the complexity and variability in response seen 
between patients. All these three patients had previously shown reduced FN 
expression with 4-OHTam, highlighting that the change in expression of a single 
protein is no guarantee of response in all other proteins of interest.  Once again this 
emphasises that there are complex pathways determining how patients respond to 
tamoxifen beyond simply the ability to metabolise the drug.  
 
Reduced secretion of soluble collagen into the culture media was also observed in the 
fibroblasts treated with 4-OHTam compared to those treated with vehicle control 
(p<0.01, Figure 43) suggesting that collagen synthesis and turn over may also be 
affected.  However, there was no difference in the collagen content of FDM generated 
by vehicle control or 4-OHTam treated fibroblasts (Figure 44). This may be due to the 
use of ascorbic acid in the matrix generation protocol. The ascorbic acid up-regulates 
the activity of the collagen synthesis enzymes prolyl-4-hydroxylase and lysyl 
hydroxylase and this may have masked any effect of 4-OHTam.  
 
Particia Keeley and colleagues have reported that increased collagen density in the 
mammary ECM had tumour promoting properties with a threefold increase in tumour 
burden observed in an animal model of high MD [206]. Thus, reduction of collagen I 
expression by tamoxifen is in keeping with a tumour inhibitory effect. 
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Modulation of collagen by tamoxifen has been reported by a number of studies. Our 
findings are supported by Kim and colleagues found that tamoxifen reduced collagen I 
expression in a mouse model of renal fibrosis [314]. Conversely, Hattar and colleagues 
reported increased collagen I in the mammary ECM of tamoxifen treated rats [115]. 
These findings appear contradictory given the association of increased collagen 
density and tumourigenesis reported by the Keeley group [206]. However, increased 
total collagen within a mammary stroma less permissive to tumour formation has also 
been reported by Pepper Schedin and colleagues [212].  This group reported that 
mammary stroma from parous rats had tumour inhibitory properties and an increased 
collagen content compared to non-parous stroma [212].  
 
A crucial feature of the collagen present in the anti-tumourigenic parous stroma was 
that it was significantly less organised and fibrillar in nature [212]. These observations 
highlight both quantitative and qualitative aspects of the mammary ECM may contribute 
to tumour development. The importance of collagen fibre alignment and organisation 
within high MD stroma has been highlighted in a proteomics study by Streuli and 
colleagues [61]. They found that high MD stroma was characterised by increased 
periductal fibrillar collagen and up-regulation of periostin and collagen XVI - mediators 
of fibril structure and alignment [61].  
 
The influence of collagen fibre orientation within the mammary ECM on the propensity 
for tumour formation may indicate that, whilst not all patients’ primary fibroblasts 
showed a reduction in collagen I expression with 4-OHTam treatment (Figure 42), there 
may have been an effect on fibre orientation that could contribute to the anti-tumour 
effects of tamoxifen. 
Given these data indicating the importance of ECM fibre organisation and in 
contributing to high MD stroma, FDM were generated from cells treated with vehicle 
control or 4-OHTam to determine if 4-OHTam treatment influenced ECM fibre 
organisation. Due to constraints of time, a full analysis of ECM fibre directionality was 
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not undertaken. No significant difference was seen in the FDM thickness in either 
treatment condition (Figure 45). Despite this lack of difference between the two 
conditions, it is possible that tamoxifen may still influence mammary ECM fibre 
organisation in the body through interactions with other stromal cell types, such as 
immune cells, not present in our limited system. A more sophisticated 3D model 
system incorporating a variety of primary stromal cell types may need to be employed 
to appreciate subtle changes in matrix organisation.  
5.4.4 Effect of 4-OHTam on fibroblast activation 
	
Smooth muscle actin (SMA) is considered a key marker of activation [308]. Primary 
fibroblast treatment with 4-OHTam resulted in a significant reduction in SMA 
expression (p <0.01, Figure 48). Given the degree and consistency of response, the 
entire fibroblast cohort were treated with 4-OHTam and a consistent reduction in SMA 
expression was seen, even in those cells who did not show a reduction in FN 
expression.  These findings are supported by Carthy and colleagues who found 
reduced expression of SMA and other myogenic markers, Calponin and Sm22alpha, in 
primary skin and breast fibroblasts with tamoxifen treatment [313]. In addition Kim and 
colleagues found that tamoxifen treatment reduced SMA expression in the renal tissue 
of a mouse model of renal fibrosis [314]. 
 
The consistency of the response of reduced SMA expression following 4-OHTam 
treatment, in contrast to other markers such as FN and collagen I, which have 
demonstrated a degree of variability, further suggests that 4-OHTam may be acting via 
multiple mechanisms to effect fibroblast function. 
 
Fibroblast expression of SMA is indicative of transformation to an activated 
myofibroblast phenotype [308]. This occurs physiologically in the body as part of the 
wound healing process. Myofibroblasts aberrantly secrete growth factors and cytokines 
and have contractile properties to assist with wound healing and closure [308]. The 
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baseline expression of SMA noted in the cultured primary cells (Figure 48) may be due 
to growing the cells on plastic, a material they would not normally be exposed to in the 
body. 
 
SMA is also a marker used to identify CAFs which are believed to behave in a similar 
manner to activated myofibroblasts, secreting growth factors and cytokines to promote 
tumour growth [162].  
 
The most potent factor known to transform fibroblasts to the activated myofibroblast 
phenotype is the pro-fibrotic cytokine TGF-β [308]. To determine whether tamoxifen 
could influence this response, primary breast fibroblasts were stimulated with TGF-β 
with and without 4-OHTam.  
 
Stimulation with TGF-β alone consistently resulted in an increase in SMA expression (p 
<0.01, Figure 49).  In the presence of 4-OHTam, this response was consistently 
inhibited (p<0.01, Figure 49).  These data suggest that tamoxifen may be able to 
prevent the transformation of fibroblasts to an activated myofibroblast-like phenotype 
and thus generate a more quiescent breast microenvironment less permissive to 
tumour formation. 
5.4.5 Effect of 4-OHTam on canonical and non-canonical TGF-β signalling 
pathways 
	
Having observed that 4-OHTam is capable of inhibiting primary breast fibroblast 
activation following stimulation with TGF-β, fibroblasts were stimulated with TGF-β with 
and without 4-OHTam to determine if inhibition of canonical (SMAD) TGF-β signalling 
by 4-OHTam was the mechanism involved.  
 
TGF-β stimulation alone increased phosphorylation of SMAD 2 and SMAD3 (Figures 
52 - 54). The presence of 4-OHTam or E2 had no effect on SMAD2 or SMAD3 protein 
phosphorylation following stimulation with TGF-β (Figures 53 + 54). These findings 
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suggest 4-OHTam may affect fibroblast activation via non-canonical signalling 
pathways.  
 
Carthy and colleagues also observed no effect of tamoxifen on SMAD phosphorylation 
in primary skin and breast fibroblasts following TGF-β stimulation [313]. However, they 
did observe inhibition of non-canonical TGF-β signalling through the ERK1/2 MAP 
kinase pathway [313]. 
 
In contrast to our findings, Kim and colleagues reported inhibition of SMAD signalling 
by tamoxifen in a rat renal fibroblast cell line [314]. However, this response was 
dependent upon expression of ERα in the fibroblast cell line. No protein expression of 
ERα was observed in any of the primary breast fibroblasts (Figure 57), which may 
account for these differences [314].  
 
Given the data from Carthy and colleagues regarding inhibition of non-canonical TGF-β 
signalling through ERK1/2 [313], fibroblasts were stimulated with TGF-β with and 
without 4-OHTam, to analyse the effect on phosphorylation of ERK1/2.  TGF-β 
stimulation increased phosphorylation of ERK1/2 (Figures 55 + 56) and this response 
was consistently inhibited by the presence of 4-OHTam (p=0.02, Figure 56). 
 
These data further suggest that 4-OHTam inhibits fibroblast activation via non-
canonical pathways, in particular through ERK1/2. Carthy and colleagues observed, in 
addition to ERK1/2 phosphorylation, the transcription factor FRA2 was also inhibited by 
tamoxifen and this was a critical event preventing fibroblast expression of myogenic 
proteins following stimulation with TGF-β [313]. Further exploration of these 
mechanisms in primary breast fibroblasts could be a focus of future work.  
5.4.6 Effect of 4-OHTam on fibroblast function 
	
To determine the functional effect of 4-OHTam treatment, fibroblasts were seeded into 
collagen gels, treated with vehicle control or 4-OHTam, and then stimulated with TGF-
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β. The gels with vehicle control treated fibroblasts stimulated with TGF-β showed 
substantial contraction (Figure 50). Treatment with 4-OHTam significantly inhibited gel 
contraction following TGF-β stimulation (p= 0.0085, Figure 50). Carthy and colleagues 
also observed reduced contraction of collagen gels seeded by tamoxifen treated 
fibroblasts from the skin and breast [313].  
 
To further evaluate the effect of 4-OHTam on fibroblast function, scratch assays were 
performed to determine any effects on cell migration. TGF-β treated fibroblasts showed 
enhanced migration compared to those treated with vehicle control (p = 0.0135, Figure 
51) and this effect was inhibited by the presence of 4-OHTam, although the difference 
did not reach statistical significance (p = 0.1789), Figure 51). These findings are 
supported by Kim and colleagues who also found inhibition of TGF-β stimulated 
migration by tamoxifen in a mouse renal fibroblast cell line [314].   
 
These results demonstrate that the inhibition of primary breast fibroblast activation by 
4-OHTam results in functional alterations in cell behaviour. The primary breast 
fibroblasts were less contractile and less migratory following TGF-β stimulation. This 
further suggests that tamoxifen treated breast stroma will be less ‘reactive’ and 
potentially less conducive to tumour formation.  
 
Overall these data have demonstrated significant alterations in fibroblast phenotype by 
tamoxifen, characterised by reduced expression of ECM proteins FN and collagen 1, 
reduced expression of the activation marker SMA and functional alterations in cell 
behaviour. The combined effect of these alterations suggests the generation of a less 
activated breast stroma, less permissive to tumour development. 
 
Not all of these effects were observed consistently across the fibroblast cohort, 
suggesting multiple mechanisms may be involved. One pathway that appears to be 
modulated by tamoxifen is non-canonical TGF-β signalling through ERK1/2. Carthy and 
colleagues observed similar effects and suggest that mechanistically, tamoxifen inhibits 
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the effects of TGF-β via a blockade of non-canonical signalling through ERK1/2 MAP 
kinase and the downstream transcription factor FRA2 [313]. They demonstrated that 
inhibition of MAP kinase signalling using either a specific inhibitor of the MAP kinase 
pathway, siRNA for FRA2 or tamoxifen was sufficient to prevent the expression of 
myofibroblast marker proteins in primary fibroblasts stimulated with TGF-β [313]. A 
focus of future work could be to determine if tamoxifen modulates FRA2 expression in 
the primary breast fibroblasts used in this study.   
Further elucidation of the pathways by which tamoxifen generates a less reactive 
mammary stroma will be crucially important, in order to generate a molecular signature 
with the potential to predict individuals likely to respond well to treatment and be 
protected from developing breast cancer.   
5.4.7 ERα and ERβ protein expression in primary fibroblast cohort 
	
Having observed a variety of effects of 4-OHTam on primary breast fibroblast function, 
the mechanisms by which 4-OHTam exerted these effects was investigated. 
Tamoxifen is classically thought to act as a competitive antagonist at ERα in the 
context of the treatment of an ERα positive breast tumour. The mechanism of 
tamoxifen action in fibroblasts is presently unknown. Mammary and skin fibroblasts 
have been reported to express ERβ [270, 328] and occasional studies report 
expression of ERα in fibroblasts [58]. 
 
Characterisation of the primary breast fibroblast cohort for protein expression of ERα 
and ERβ showed low level expression of ERβ but no expression of ERα in any of the 
patients’ fibroblasts (Figures 57 + 58). The level of expression of ERβ did not correlate 
with reduction in FN expression with 4-OHTam treatment (Figure 58).  
 
Therefore, interaction of tamoxifen with ERβ in primary breast fibroblasts could be a 
potential mechanism by which the observed effects of fibroblast function are mediated. 
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In order to investigate this hypothesis, primary fibroblasts were treated with the pure 
ER antagonist fulvestrant, a drug with high affinity for ER and little known ER-
independent actions [329], to see if similar effects were observed and thus attribute 
these to interaction with ERβ.  
The ability of fulvestrant to target ER-β has been reported in a number of studies. 
Peekhaus and colleagues observed that both fulvestrant and tamoxifen were capable 
of preventing E2-induced degradation of ER-β in MCF7 and HeLa cells [330]. More 
recently, Raza et al observed that 27-hydoxycholesterol was able to drive proliferation 
of prostate cancer cells in an ER-β dependent manner, and that both fulvestrant and 
the specific ER-β inhibitor PHTPP inhibited this response [331].  
In addition, Fan and colleagues observed that ER-β expression promoted metastasis in 
a mouse model of non-small cell lung cancer, and that treatment with fulvestrant (in 
vitro and in vivo) or knock-down of ER-β using siRNA reduced the aggressiveness of 
lung cancer cells [332]. Wang et al also investigated ER-β in a cell line model of non-
small cell lung cancer [333]. They found that transfection of ER-β into lung cancer cells, 
resulting in nuclear and cytoplasmic expression of ER-β, conferred resistance to 
tyrosine kinase inhibitor therapy. Treating these cells with fulvestrant re-sensitised 
them to tyrosine kinase inhibitor therapy [333].  
Furthermore, Mishra and colleagues observed that fulvestrant treatment resulted in a 
negative proliferative effect on triple negative breast cancer cell lines expressing ER-β 
in vitro and in vivo [334]. The effect of fulvestrant was less pronounced in those cell 
lines with an intrinsically lower level of ER-β expression. In addition, when ER-β was 
knocked-in or knocked-down in the cells, their response to fulvestrant changed 
accordingly [334]. They also observed that fulvestrant enhanced the anti-tumour effect 
of tamoxifen on breast cancer cells expressing both ER-α and ER-β by preventing ER-
β degradation. When ER-β expression was increased further by knock-in experiments, 
this further potentiated the effect of fulvestrant [334]. The authors conclude that 
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fulvestrant is an ER-β targeted therapy and suggest a potential therapeutic role in the 
treatment of ER-α negative breast cancers which express ER-β.  
5.4.8 Effect of fulvestrant on fibroblast expression of fibronectin and 
SMA 
	
Fulvestrant treatment had minimal effect on FN expression and no effect at all on SMA 
expression, with or without TGF-β stimulation (Figure 59). Conversely, 4-OHTam 
treatment resulted in a substantial reduction in FN expression and consistent inhibition 
of SMA expression (Figure 59).  Given these vastly differing effects on fibroblast 
protein expression between the two drugs, this implies that the effects of 4-OHTam 
may be mediated, at least in part, by ER-independent mechanisms.  
 
The ability of fulvestrant to act as an ER antagonist was suggested by measuring 
MCF7 cell proliferation in response to E2 (Figure 60). Treatment of MCF7 cells with E2 
results in a significant increase in proliferation, however this response is blocked by 
concurrent treatment with fulvestrant (Figure 60).  
 
Given that fulvestrant appears to act as an ER antagonist, the ability of 4-OHTam to 
reduce FN and SMA expression in the presence of fulvestrant suggests that 4-OHTam 
may be acting via ER-independent mechanisms. In this treatment condition the ER 
could be occupied by fulvestrant, suggesting that 4-OHTam may be acting via 
alternative mechanisms to modulate fibroblast protein expression.   
 
Use of siRNA to knock down the expression of ERβ in the primary fibroblasts was 
attempted but unfortunately was not successful due to technical difficulties. Future work 
could investigate alternative ways to knock down the expression of ERβ to demonstrate 





6 Whole transcriptome analysis of pathways 





Having identified a direct effect of 4-OHTam on primary breast fibroblast function, with 
an indication that the mechanisms involved may be independent of the ER, RNA-Seq 
was performed to gain a global perspective on the pathways modulated by 4-OHTam 
and further dissect potential mechanisms of action. 
 
A pilot experiment was conducted in the first instance to determine the optimum 
concentration of 4-OHTam to use and to assess the quality of data obtained with the 
initial sequencing parameters. Following analysis of the pilot data, a second follow up 
batch of samples were sequenced, the data from the follow up batch was analysed 




6.2 Methods and Materials 
	
6.2.1 RNA Seq Pilot Batch 
	
6.2.1.1 Patient sample selection 
	
Fibroblasts from two reduction mammoplasty patients (1004 and 3078) which 
demonstrated a reduction in FN expression with 4-OHTam treatment were selected for 
the pilot batch RNA-Seq experiment.  
6.2.1.2 Primary fibroblast culture and drug treatment 
	
Primary fibroblasts were treated with vehicle control or 4-OHTam at either low dose 
(100nM) or high dose (5µM) for one week. Cells were then trypsinised and centrifuged 
at 12000 rpm for 2 minutes to form a pellet. Triplicate samples were prepared for each 
treatment condition, giving a total of 9 samples per patient. 
6.2.1.3 RNA extraction 
	
RNA was extracted from the cell pellets using the RNeasy Plus mini kit (Qiagen, 
74134) as per manufacturer’s instructions. 
Briefly, the pellet was re-suspended and vortexed for 30s in 600µl Buffer RLT Plus to 
lyse the cells. The homogenised lysate was then transferred to a gDNA Eliminator spin 
column in a 2ml collection tube and centrifuged at 10000 rpm for 30 seconds. 600µl of 
70% ethanol was added to the flow through, mixed by pipetting, transferred to an 
RNeasy spin column in a 2ml collection tube and then centrifuged for 15 seconds at 
10000 rpm. The flow through was discarded, then 700µl Buffer RW1 was added to the 
spin column and centrifuged at 10000 rpm for 15 seconds. The flow through was 
discarded, 500µl Buffer RPE added to the spin column and centrifuged at 10000 rpm 
for 15 seconds. The flow through was discarded, a further 500µl Buffer RPE added and 
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spun at 10000 rpm for 2 minutes. The spin column was then added to a fresh 2ml 
collection tube and spun empty for 1 minute at 13000 rpm to dry the tube membrane. 
The RNeasy spin column was then transferred to a 1.5ml eppendorf tube and 30µl of 
RNase-free water added directly onto the membrane before centrifuging at 10000 rpm 
to elute the RNA. The final step was repeated using the RNA eluate to maximise the 
RNA yield.  
Following RNA elution, samples were frozen at -80oC. RNA quantity was estimated 
using the Nanodrop system. A minimum total RNA yield of 1ug was required for each 
sample.  
6.2.1.4 Library Preparation 
	
Library preparation was performed by Vertis Biotech, Freising, Germany using the 




Sequencing was performed by Beckman Coulter Genomics, Danvers, MA, USA using 
the Illumina HiSeq 2500 platform (100bp paired end reads) with three samples per 
HiSeq lane, aiming to achieve ~50-60million reads per sample.  
6.2.1.6 Bioinformatics Analysis 
	
Bioinformatics analysis was performed by Dr J Wang and Professor C Chelala, 
Bioinformatics Group, Centre for Molecular Oncology, Barts Cancer Institute, London, 
UK. Raw data reads were aligned to the reference genome hg19 using Tophat2. The 
number of uniquely aligned reads (q>10) aligned to the exonic region of each gene 
were counted using HTSeq based on the Ensembl annotation (version 74). Only genes 
that achieved at least one million reads (CPM) in at least three samples were kept. 
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Read numbers were further normalised using the CQN method, accounting for gene 
length and GC content.  
Differential expression analysis was performed using the edgeR R package, employing 
the generalised linear model (GLM) approach, for each treatment vs control pair-wise 
comparison as well as ANOVA analysis across the three groups, adjusting for baseline 
differences between the two patients.	
6.2.2 Follow up batch 
	
6.2.2.1 Patient sample selection 
	
Primary fibroblasts from three reduction mammoplasty patients (2585, 3137, 2182) and 
one BRCA1 mutation carrier (2093) contralateral prophylactic mastectomy were used 
for the second RNA Seq batch. These patients were selected to be a close age match 
to the pilot batch samples (Table 13). One patient (3137) did not show a reduction in 































































Table 13: Clinical details of primary fibroblast samples used for the RNA Seq experiments 
169	
	
6.2.2.2 Sample Preparation 
	
Primary fibroblasts were treated with vehicle control or 4-OHTam (5µM) for one week. 
In addition, two of the four patients were also treated with fulvestrant (5µM) for one 
week. Cells were then trypsinised and centrifuged at 12000 rpm for 2 minutes to form a 
pellet. Triplicate samples were prepared for each treatment condition, giving a total of 6 
samples per patient (9 samples for those additionally treated with fulvestrant). RNA 
was extracted and quantified as described previously (Section 6.2.1.3)  
6.2.2.3 Library Preparation 
	
Library preparation was performed by the Wellcome Trust Centre for Human Genetics 
in Oxford, United Kingdom using the Tru Seq Stranded Total RNA Library Prep Kit 
(Illumina, RS-122-2202) according to manufacturer’s instructions. Depletion of 
ribosomal RNA was performed using Ribo-Zero (Illumina).  
6.2.2.4 Sequencing 
	
Sequencing was performed by the Wellcome Trust Centre for Human Genetics in 
Oxford, United Kingdom using the Illumina HiSeq 4000 platform (100bp paired end 
reads) with five samples per HiSeq lane, aiming to achieve ~50-60million reads per 
sample.  
6.2.2.5 Bioinformatics analysis 
 
Bioinformatics analysis was performed by Dr J Wang and Professor C Chelala, 
Bioinformatics Group, Centre for Molecular Oncology, Barts Cancer Institute, UK. The 
same analysis pipeline was used as per the pilot batch (Section 6.2.1.6) 
In addition, pathway analysis was performed using the gene set enrichment analysis 






6.3.1 RNA Seq Pilot Batch 
 
6.3.1.1 Data Quality Control  
	
The pilot batch was sequenced by Beckman Coulter Genomics, achieving on average 
28M reads per sample. The read alignment data for all samples is displayed in 
Appendix 1. Unexpectedly, a significant proportion of reads (range 29.9% - 45.2%) 
mapped to the mitochondrial genome (Table 14). Fortunately this did not affect the 







1004	C1	 22537318	 49811420	 45.2	
1004	C2	 20317021	 52192895	 38.9	
1004	C3	 20762493	 51046616	 40.6	
1004	Low	T1	 22672281	 56578263	 40.0	
1004	Low	T2	 16670387	 45785890	 36.4	
1004	Low	T3	 24834516	 69698915	 35.6	
1004	High	T1	 19572427	 50664546	 38.6	
1004	High	T2	 18047157	 55810896	 32.3	
1004	High	T3	 9830853	 30900244	 31.8	
3078	C1	 16091988	 49613100	 32.4	
3078	C2	 16066074	 52369081	 30.6	
3078	C3	 15551013	 51953928	 29.9	
3078	Low	T1	 18347529	 52247522	 35.1	
3078	Low	T2	 14943004	 46009384	 32.4	
3078	Low	T3	 17843236	 50805865	 35.1	
3078	High	T1	 16407265	 52003071	 31.5	
3078	High	T2	 14573007	 44785140	 32.5	
3078	High	T3	 18394273	 51790860	 35.5	
Table 14: Number and percentage (highlighted in red) of HiSeq reads per pilot batch sample 
mapping to the mitochondrial genome. 
	





6.3.1.2 Preliminary analysis of differential gene expression 
	
The multidimensional scaling (MDS, Figure 61) plot shows the significant heterogeneity 
in the baseline gene expression between the two pilot batch patients (Tissue Bank IDs 
1004 and 3078), indicated by the clear separation of their respective samples, 
clustering together at opposite sides of the plot.  
Both patients show a similar response to the higher dose 4-OHTam treatment, with 
significant changes in gene expression compared to vehicle control and low dose 4-
OHTam treated samples - indicated by the higher dose 4-OHTam samples clustering 
together on the plot, distinctly separated from the other treatment groups (highlighted 
by blue circles).  
There was no significant difference in the gene expression of low dose 4-OHTam 
treated fibroblasts and vehicle control fibroblasts, indicated by the overlapping 






Figure 61: Multidimensional scaling (MDS) plot of global gene expression using all 13,396 
filtered genes. Clear evidence of heterogeneity is seen between the two patients (3078 and 
1004) with samples respectively clustering at opposing sides of the plot. In both patients, the 
samples treated with the higher 4-OHTam (HighT, red colour) dose cluster distinctly separate 
from the other treatment conditions (circled in blue). This indicates significant changes in gene 
expression between the samples treated with the higher dose of 4-OHTam and both the 
samples treated with the lower dose 4-OHTam (LowT, yellow colour) and those treated with 
vehicle control (NoT, green colour). No separation is seen between the samples treated with the 
lower dose of 4-OHTam and those treated with vehicle control, indicating no significant changes 
in gene expression between these conditions.   
 
6.3.1.3 ANOVA analysis of differential gene expression 
	
Analysis of variance (ANOVA) was performed to compare the gene expression 
between the three treatment groups and once again there were significant differences 
in the gene expression of the higher dose 4-OHTam treated groups compared to lower 
dose treatment and untreated groups. Using false discovery rate (FDR) <0.001, 904 
differentially expressed genes were identified and using FDR <0.0001 513 differentially 
expressed genes were identified, displayed in the heat map below (Figure 62).  There 
was no significant difference in gene expression between the low dose 4-OHTam 




Figure 62: Heat map of 508 differentially expressed genes identified with ANOVA using FDR 
<0.0001. There is clear clustering of the higher dose treatment samples on the left side of the 
plot (HighT- pink colour) from the lower dose treatment (LowT- red colour) and vehicle control 
(NoT – blue colour) samples, clustered towards the right side. 
 
The baseline heterogeneity in gene expression between the two patient samples is 
once again evident from the variation in position of the vehicle control treated samples 
on the heat map, they are not uniformly clustered together. One sample in particular 
(S02) shows a notable difference in gene expression from the other vehicle control 
treated samples. 
The most significantly differentially expressed genes identified by ANOVA are 
displayed in Appendix 2. The top differentially expressed genes showed a ‘metabolic’ 
signature with many involved in cholesterol and lipid synthesis and metabolism. The 
top genes were investigated for potential mechanisms by which they might contribute 
towards a tumour-inhibitory mammary stroma. 
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6.3.2 RNA-Seq Follow up Batch 
	
6.3.2.1 Experimental Considerations and data quality control 
	
Having observed significant changes in gene expression only between vehicle treated 
samples and those treated with the higher tamoxifen dose (5µM), this dose was 
selected as the tamoxifen treatment condition for the follow up batch. 
In order to further substantiate our hypothesis that tamoxifen may be acting via ER-
independent mechanisms, a fulvestrant treatment condition was added in two of the 
four patient samples from the follow up batch.  
A different sequencing provider – the Wellcome Trust Centre for Human Genetics in 
Oxford - was selected to perform the library preparation and sequencing given the 
issues experienced with the pilot batch data quality where many reads mapped to the 
mitochondrial genome. The read alignment data is displayed in Appendix 1. A greater 
proportion of sequencing reads for each sample of the follow up batch was successfully 
aligned to the genome (range 65.1% - 78.78%) compared to sequencing reads from 
samples in the pilot batch (range 46.69% – 60.56%). 
6.3.2.2 Preliminary analysis of differential gene expression 
	
14,311 genes were filtered to the stage of differential expression analysis. A principle 
component analysis (PCA) plot was constructed to visualise the differences in gene 




Figure 63: PCA plot of the overall gene expression of the four patient samples in the follow up 
batch (Vehicle control treated samples – blue, 4-OHTam treated samples – green, Fulvestrant 
treated samples – red). There is clear heterogeneity in the baseline gene expression between 
the four patients. The samples from each patient cluster in distinct regions of the plot (each blue 
circle contains all the samples from a particular patient). 
 
Once again, there was clear evidence of heterogeneity in the baseline gene expression 
between patients, demonstrated by the clustering of the same patient’s samples 
together in distinct regions of the plot (Figure 63, each blue circle represents one 
patient’s samples). 
In addition to the significant inter-patient heterogeneity, there were clear differences in 
gene expression in the 4-OHTam treated samples of all four patients compared to the 
samples treated with vehicle control and the two patients’ samples treated with 
fulvestrant. This is highlighted by the distinct clustering of the green (4-OHTam) 
samples away from the blue (vehicle control) and red (fulvestrant) samples on the PCA 
plot (Figure 64). No significant differences in gene expression were noted between 
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fulvestrant and vehicle control samples, highlighted by the overlapping of the blue and 
red samples on the PCA plot (circled in red in Figure 64 below).  
 
Figure 64: PCA plot of follow up RNA Seq batch showing clear differences in gene expression 
in the 4-OHTam (green) treated samples of all four patients compared to those treated with 
vehicle control (blue) and fulvestrant (red). The green samples cluster distinctly separate on the 
plot. No significant difference in gene expression was seen between the vehicle control and 
fulvestrant treated samples, highlighted by overlapping red and blue samples on the plot 
(highlighted in red circles).  
	
6.3.2.3 ANOVA analysis of differential gene expression 
 
Across the four patients from the follow up batch 184 genes were identified to be 
differentially expressed between the 4-OHTam treated and vehicle control groups at 
FDR <0.05 and absolute fold change in expression >2.   
When comparing the vehicle control and fulvestrant treated samples, only two genes 
showed significant differential expression – TPPP3 and ADAMTS8. A heat map of the 




Figure 65: Heat map based on 184 differentially expressed genes across the four patient 
samples in the follow up batch at FDR<0.05 and absolute fold change >2. The baseline 
heterogeneity between the four patients is evident from the variation in gene expression in the 
vehicle control (red) samples. The 4-OHTam treated samples (blue) cluster together at the right 
side of the heat map. The vehicle control and fulvestrant (green) samples show less distinct 
separation from each other and cluster together on the left side. 
 
The top differentially expressed genes from the follow up batch are displayed in 
Appendix 3. Once again, the list of top differentially expressed genes showed a 
‘metabolic’ gene signature, with many genes involved in cholesterol and lipid synthesis 
and metabolism. Many of the top genes from the pilot batch also featured in the 
extended list of all 184 differentially expressed genes, using FDR<0.05 and absolute 
fold change >2, including the two top hits from the pilot batch - DHCR7 and DHCR24. 
The top differentially expressed gene in the follow up batch was leptin, which showed 
significantly down-regulated expression. 
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6.3.2.4 Comparison and merging of the pilot and follow up batch datasets 
	
The two datasets were compared for similarities in differential gene expression 
between the vehicle control and 4-OHTam treated samples. Similar genes were 
significantly differentially expressed in both batches (eg DHCR7, DHCR24 and 
cholesterol/lipid metabolic genes). In addition, there was good correlation in the log2 
fold changes for commonly differentially expressed genes between the pilot and follow 
up batches (Figure 66). This correlation improved when the thresholds of FDR <0.05 




Figure 66: Plot of log2 fold change for commonly differentially expressed genes in the pilot and 






Figure 67: (i) Venn diagram of shared differentially expressed genes (n = 962) between the pilot 
(red circle) and follow up batches (green circle) at FDR < 0.05. (ii) Plot of log2 fold change for 
the 962 commonly differentially expressed genes in the pilot and follow up batches at FDR < 
0.05. A good correlation is seen (r = 0.83).  
 
Figure 68: (i) Venn diagram of shared differentially expressed genes (n=42) between the pilot 
(red) and follow up (green) batches at FDR <0.05 and absolute fold change > 2. (ii) Plot of log2 
fold change for the 42 commonly differentially expressed genes in the pilot and follow up 
batches at FDR < 0.05 and absolute fold change > 2.  
 
The data from all 48 samples in the pilot and follow up batches was then merged. 
14,960 genes were sufficiently profiled across all the merged samples to be filtered to 
the differential expression analysis. There was clear evidence of batch effect between 
the pilot and follow up samples on the initial PCA plot (Figure 69). All the samples from 
the pilot batch clustered distinctly on the right side of the plot whilst all samples from 
the follow up batch were clustered on the left.   
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Figure 69: Initial PCA plot of the overall gene expression of samples from the pilot and follow 
up batches. There is clear batch effect between the pilot batch (samples clustered on right hand 
side of the plot) and follow up batch (samples clustered on left side of the plot). 
 
The bioinformatics tool Combat was used to successfully remove the batch effect 
(Figure 70). Combat uses an extended empirical Bayes method to ‘borrow information’ 
across genes and experimental conditions between batches to achieve stable 
inferences for gene expression estimates. Combat includes a parametric prior method 
(ComBat_p) and a non-parametric method (ComBat_n), based on the prior 
distributions of the estimated parameters. The method is robust to outliers in small 




Figure 70: PCA plot of overall gene expression of all 6 patient samples from the pilot and follow 
up batches. The bioinformatics tool Combat successfully removed the batch effect present 
between the two cohorts.  
The corrected plot maintained the previously observed inter-patient heterogeneity as 
the samples clustered together on the plot by patient of origin (Figure 71 – each blue 
circle contains the sample from one patient, BRCA1 mutation carrier circled in red).  
Clear overlapping of the fulvestrant treated samples (green) with vehicle control 
samples (red) once again demonstrated a lack of significant differential gene 
expression between these treatment groups (Figure 71). A smaller degree of 
overlapping was seen with the low dose 4-OHTam and vehicle control treated samples 
from the pilot batch (Figure 71). Distinct separation of the higher dose 4-OHTam 
treated samples (aqua blue) was seen in all patients, demonstrating significant 




Figure 71: PCA plot of overall gene expression from all 6 patients from the pilot and follow up 
batches following a correction for batch effect. Each of the six patients’ samples are highlighted 
within a separate blue circle. Note BRCA1 mutation carrier circled in red. 
 
6.3.2.5 Differential gene expression analysis of the merged dataset 
	
Differential gene expression analysis was performed using ANOVA on the merged 
dataset of six patients. At the FDR < 0.05 level, there were no significantly differentially 
expressed genes between the fulvestrant and vehicle control treated samples. 4,332 
differentially expressed genes were identified between the higher dose 4-OHTam and 
vehicle control treated samples. 59 differentially expressed genes were identified 
between the low dose 4-OHTam and vehicle control treated samples.  
 
When double thresholds of FDR < 0.05 and absolute fold change > 2 were applied, 149 
differentially expressed genes remained between the higher dose and vehicle control 
treated samples. In addition, 12 differentially expressed genes remained between the 
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low dose 4-OHTam and vehicle control treated samples. A heat map of the 149 
differentially expressed genes is shown in Figure 72. Clear evidence of heterogeneity 
across the six patients is seen (samples from patient with BRCA1 mutation highlighted 
in green box), however a consistent change in gene expression with 4-OHTam is seen 
across all the samples despite the baseline inter-patient variability.  
 
Figure 72: Heat map of 149 differentially expressed genes between higher dose 4-OHTam and 
vehicle control samples from the six patients at FDR < 0.05 and absolute FC > 2. Clear 
evidence of heterogeneity in gene expression is seen between the six patients, however they all 
show a consistent switch in expression with 4-OHTam treatment. Green box highlights samples 
from BRCA1 mutation carrier. 
	
The top differentially expressed genes are displayed in Appendix 4. The differential 
gene expression analysis from the merged dataset comparing higher dose 4-OHTam 
and vehicle control samples once again showed a metabolic signature. Many of the top 
hits are involved in metabolism, in particular metabolism and synthesis of cholesterol 
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and lipids. The two most differentially expressed genes from the pilot batch – DHCR7 
and DHCR24 were also in the top ten most differentially expressed genes from the 
merged dataset (Appendix 4).  
6.3.2.6 Pathway analysis 
 
The Gene Set Enrichment Analysis (GSEA) tool was used along with the KEGG and 
REACTOME biological pathway resources to identify deregulated pathways in the 4-
OHTam treated fibroblasts compared to those treated with vehicle control, based on 
the merged dataset.  
6.3.2.6.1 Up-regulated pathways 
	
The pathways identified to be up-regulated in the 4-OHTam treated fibroblasts reflected 
the metabolic ‘signature’ seen in the differential gene expression analysis. The vast 
majority of the up-regulated pathways identified using REACTOME involved cholesterol 
and lipid synthesis and metabolism (displayed in Appendix 5). The remaining up-
regulated pathways involved other aspects of metabolism, highlighting the metabolic 
‘signature’ of gene expression 
The KEGG biological pathways resource also identified up-regulated pathways 
involved in metabolism (Appendix 6).  
6.3.2.6.2 Down-regulated pathways 
	
The pathways identified to be down-regulated in the 4-OHTam treated fibroblasts 
involved a more diverse array of processes than the up-regulated pathways which were 
predominantly metabolic processes.   
Selected down-regulated pathways identified using REACTOME are displayed 
Appendix 7. Many of the significantly down-regulated pathways identified using 
REACTOME involve the cell cycle, DNA replication and mRNA processing. Many other 
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cellular processes also feature including; protein synthesis and collagen formation, 
inflammatory cell signalling, muscle contraction and integrin signalling.  
The down-regulated pathways identified using KEGG also reflected a wide variety of 
cellular processes including; DNA replication and cell cycle, mismatch repair, Wnt 
signalling, Hedgehog signalling, cytoskeleton regulation, ECM- receptor interaction and 






6.4.1 Pilot batch data quality control 
	
A significant proportion of sequencing reads from the pilot batch (range 29.9 - 45.2% of 
reads per sample) mapped to the mitochondrial genome. Such a high proportion of 
reads mapping to mitochondrial regions was unexpected. Data regarding the ability of 
tamoxifen to modulate transcription of mitochondrial genes is limited. One study has 
observed that 4-OHTam and E2 can modulate the transcription of nuclear respiratory 
factor 1 (NRF-1) in mouse mammary gland and uterine tissue [335]. NRF-1 in turn, is 
reported to stimulate the transcription of nuclear-encoded genes that regulate 
mitochondrial gene transcription [335].  
Sequencing data from an unrelated project obtained from the same sequencing 
provider was also found to show significant over-representation of reads mapping to 
the mitochondrial genome. This study did not involve any treatment of samples with 
tamoxifen or 4-OHTam. Following discussion with our Bioinformatics colleagues, it was 
felt the over-representation of these reads was most likely due to the fact that the 
samples in both these projects had not undergone ribosomal RNA depletion prior to 
sequencing. This was supported by the fact that the data from the follow up batch, 
(where the samples did undergo ribosomal RNA depletion) did not show any over-
representation of reads mapping to the mitochondrial genome.  
6.4.2 Batch effect between pilot and follow up data 
	
A significant batch effect was observed between the sequencing data obtained from 
the pilot and follow up batches. For each batch, the cells were cultured and treated with 
vehicle/4-OHTam/fulvestrant at differing times, however all the RNA was extracted and 
frozen at the same time. The cells used in each batch were also all at the same culture 
passage. The pilot and follow up batch samples were prepared approximately 9 
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months apart using the same RNA extraction kit. Despite using the same preparation 
conditions and bioinformatics analysis pipeline, a significant batch effect was still 
observed between the pilot and follow up datasets. This difference may therefore be 
due to the sensitivity and innate variability encountered when using primary cells. Small 
variations in culture conditions and environmental conditions in the laboratory at the 
time of RNA extraction may also have contributed to the batch effect. In addition, 
ribosomal RNA depletion was undertaken in the follow up batch but not the pilot and 
this may also have contributed to the variation between the two datasets.  
6.4.3 Heterogeneity in the primary fibroblast cohort 
	
In both the pilot and follow up RNA Seq experiments significant inter-patient 
heterogeneity in baseline fibroblast gene expression was observed (Figure 71 +Figure 
72). This clearly demonstrates the value of using primary cell culture models to capture 
the variability and complexity of gene expression that exists between individual 
patients. 
There are a number of clinical factors which could account for the variability in gene 
expression between patients. Five (Tissue bank ID 1004, 3078, 3137, 2182, 2585) of 
the six patients are from reduction mammoplasty cases however, one patient is a 
known BRCA1 mutation carrier (Tissue Bank ID 2093) who underwent prophylactic 
mastectomy. The samples from the BRCA1 mutation carrier cluster distinctly in the top 
right region of the merged dataset PCA plot (Figure 71 - red circle) and show a 
conspicuous pattern of gene expression on the merged dataset heat map (Figure 72 – 
green box).  
These data suggest that the breast microenvironment in BRCA1 mutation carriers may 
display a unique biology and could potentially contribute to the aggressive behaviour 
and early age of onset of tumours in these patients. Loss of BRCA1 expression in an 
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immortalised fibroblast cell line has been shown to promote the growth of tumours in a 
mouse model of triple negative breast cancer [336] 
A significant degree of heterogeneity was also observed in the gene expression 
between the five reduction mammoplasty patients’ fibroblasts. There was a wide 
variation in age between these patients (24-58 years). This could account for some of 
the inter-individual differences in gene expression. Other clinical factors that may also 
have contributed to the variation include ethnicity, parity, menopausal status and 
smoking history. The variation in these clinical factors between the six patients is 
displayed in Table 13.  
6.4.4 Effect of fulvestrant on fibroblast gene expression 
	
No significant differential gene expression was seen between the fibroblasts treated 
with fulvestrant and those treated with vehicle control (Figure 65 + Figure 71). The lack 
of response of the fibroblasts to the pure ER antagonist correlates with experimental 
work showing no effect of fulvestrant on fibroblast activation (Figure 59), and suggests 
that 4-OHTam could be working via unique ER-independent mechanisms to affect 
primary fibroblast gene expression.  
6.4.5 Up-regulated pathways in 4-OHTam treated fibroblasts 
	
6.4.5.1 Metabolic gene signature of 4-OHTam treated fibroblasts 
	
A ‘metabolic’ gene signature was observed in the analysis of RNA Seq data from the 
pilot, follow up and merged datasets. The majority of the up-regulated pathways in the 
4-OHTam treated fibroblasts, compared to those treated with vehicle control, involve 
cholesterol and lipid synthesis and metabolism (Appendices 5 + 6). The most 
significantly up-regulated pathways using REACTOME included; cholesterol 
biosynthesis (NOM p = 0, FDR q = 0), glycosphingolipid metabolism (NOM p = 0, FDR 
q = 0), metabolism of lipids and lipoproteins (NOM p= 0, FDR q = 0), sphingolipid 
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metabolism (NOM p= 0, FDR q = 0), phospholipid metabolism (NOM p = 0, FDR q = 
<0.001), triglyceride biosynthesis (NOM p = 0, FDR q = 0.003) and fatty acyl coA 
biosynthesis (NOM p = 0.004, FDR q = 0.050). Significant up-regulation of sphingolipid 
metabolism was also identified using the KEGG biological pathway resource (NOM p = 
0.002, FDR q = 0.017).  
These data are supported by findings from Morad and colleagues who have observed 
tamoxifen to be a potent regulator of acid ceramidase activity and sphingolipid 
metabolism in a variety of cancer cell types [297, 337]. Furthermore, Corriden and 
colleagues have reported that modulation of sphingolipid metabolism by tamoxifen can 
affect neutrophil behaviour [298], suggesting that tamoxifen may be capable of altering 
immune cell activity in the breast microenvironment. Hattar and colleagues observed 
alteration in immune cell content of mammary stroma from tamoxifen treated rats [115]. 
In addition, neutrophil activity has been proposed to contribute to the pro-tumourigenic 
activity of high collagen density mammary stroma in a mouse model [231]. Therefore 
modulation of stromal immune cell activity could play an important role in tumour 
inhibitory activity of tamoxifen.  
 
The up-regulation of cholesterol biosynthesis and metabolism pathways in response to 
breast cancer endocrine therapy has also recently been reported by Martin and 
colleagues [338]. They propose that the cholesterol metabolites 25- and 27- 
hydroxycholesterol (HC) might contribute to the development of resistance to endocrine 
treatments in ER positive breast cancer [338]. They observed that levels of 25- and 27- 
HC were elevated in a cell line model of ER positive breast cancer treated with long 
term oestrogen deprivation therapy [338]. In addition, 25- and 27-HC were capable of 
inducing the recruitment of the ER to the promoter regions of two oestrogen-regulated 
genes (TTF1 and GREB1) and were found to be capable of binding to the ligand 
binding domain of the ER [338].  The authors suggest that 25- and 27-HC may be 
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capable of substituting for oestradiol in the setting of long term oestrogen deprivation 
therapy [338]. 
 
In addition to the many up-regulated pathways involving cholesterol and lipid 
metabolism, up-regulation of alternative metabolic processes was also observed. 
Significant up-regulation of iron uptake and transport was identified using REACTOME 
(NOM p = 0, FDR q = 0) and KEGG identified drug (NOM p = 0.002, FDR q = 0.002) 
and xenobiotic cytochrome P450 metabolic pathways (NOM p = 0, FDR q = 0.003) 
6.4.5.2 Cholesterol metabolism and cancer biology 
	
Reflecting the up-regulation of cholesterol biosynthesis in the pathway analysis, two of 
the top differentially expressed genes between 4-OHTam and vehicle control treated 
fibroblasts were DHCR7 (p = <0.001) and DHCR24 (p = <0.001, Appendix 4). The 
products of both these genes are enzymes involved in the terminal (post lanosterol) 
stages of cholesterol synthesis [339].  
Enhanced cholesterol biosynthesis has been reported as a key feature of cancer cell 
biology [340]. Malignant cells require high levels of cholesterol in order to synthesise 
new cell membranes and are the principle component of ‘lipid rafts’ which help to 
activate membrane bound receptor signalling pathways [340]. Cancer cells 
demonstrate a number of adaptations in order to maintain high intracellular cholesterol 
levels including; accelerated endogenous production of cholesterol via steroid 
response element binding proteins (SREBP); reduced efflux via ATP-binding cassette 
(ABC) class A transporters and increased uptake of low density lipoprotein particle 
(LDL) [340].  
This study is focused on the fibroblasts within the tumour microenvironment rather than 
the tumour cells. Unlike the tumour cells, fibroblasts do not demonstrate the same 
propensity for invasion and metastasis. Instead, activated fibroblasts within the local 
tumour microenvironment facilitate tumour growth via secretion of paracrine growth 
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factors and ECM proteins, as discussed in Chapter 1. Currently the role of cholesterol 
biosynthesis in mediating fibroblast activation in cancer is uncertain. Outside of the 
cancer biology field, modulation of cholesterol biosynthesis in cardiac fibroblasts by 
statins has been suggested to inhibit myofibroblast differentiation [341], fibroblast 
proliferation [342] and alter ECM production [343]. 
 
Given that enhanced cholesterol synthesis is a key feature of malignant cells, it may 
seem contradictory that 4-OHTam, an anticancer treatment, would result in up-
regulation of these processes. However, a number of recent studies from the Poirot 
group have shed new light on unique biological properties of the sterol metabolites 
involved in the cholesterol synthesis pathway which may help to explain this apparent 
paradox [340]. The main findings are summarised in the sections below.  
6.4.5.3 Role of DHCR7 
	
In addition to functioning as a terminal stage cholesterol synthesis enzyme (3β-
hydroxysteroid-Δ7-isomerase), recent studies have demonstrated that DHCR7 also 
forms a hetero-oligomeric complex with another cholesterol synthesis enzyme 
(D8D71/EBP, 3β-hydroxysteroid-Δ8Δ7-isomerase). Together, these two molecules carry 
out a unique third enzyme activity – cholesterol-5,6-epoxide hydrolase (ChEH) activity 




Figure 73: DHCR7 forms a hetero-oligomeric complex with D8D71 and together carry out cholesterol 
epoxide hydrolase (ChEH) activity.  
	
The epoxide hydrolase family transform epoxide containing lipids via the addition of 
water [344, 345]. ChEH is located within the endoplasmic reticulum and is very specific 
for the conversion of cholesterol (5,6α,5,6β) epoxide (EC) to cholestane -3β,5α6β-triol 
(CT) [345]. EC have been proposed to be anti-tumourigenic metabolites and to 
promote the differentiation and growth inhibition of breast cancer cells, whereas CTs 
have been proposed to be up-regulated in cancer [340].  
6.4.5.4 Modulation of ChEH activity by 4-OHTam and SERMS 
	
Intriguingly, modulation of ChEH activity has been reported with a number of clinically 
prescribed drugs, of which one of the major groups are the SERMs including tamoxifen 





Figure 74: Drugs known to modulate the activity of cholesterol epoxide hydrolase, adapted from 
Poirot and Silvente-Poirot [345]. One of the most potent inhibitors of ChEH activity are the 
SERMs. 
 
It has been proposed that the binding of these drugs to ChEH inhibits its activity and 
results in the accumulation of ECs (Figure 75) [345]. 
 
Figure 75: Tamoxifen (TAM) binds to the cholesterol epoxide hydrolase (ChEH) complex and 





The ability of tamoxifen and 4-OHTam to modulate ChEH activity reported by the Poirot 
group highlights the complex pharmacology of tamoxifen and suggests that the drug 
may have significant ER-independent mechanisms of action. 
6.4.5.5 The microsomal anti-oestrogen binding site (AEBS) 
	
Sutherland and colleagues first reported the existence of a high affinity binding site for 
tamoxifen within the endoplasmic reticulum in 1980 [346]. This binding site has been 
designated the microsomal anti-oestrogen binding site (AEBS) and significant progress 
in understanding the molecular identity and biology of the AEBS has recently been 
made by the Poirot group [264, 292, 293]. Significantly, they observed that the AEBS 
was capable of ChEH enzyme activity, suggesting that the AEBS and ChEH are in fact 
the same entity [264, 293]. They suggest the binding of tamoxifen and other SERMs to 
the AEBS results in inhibition of ChEH activity [264].  
6.4.5.6 Consequences of ChEH inhibition by tamoxifen 
	
The binding of tamoxifen to the AEBS, and subsequent inhibition of ChEH activity, has 
been proposed to result in the growth control and differentiation of human breast 
cancer cells due to the accumulation of cholesterol epoxides [295]. The potential 
mechanisms by which the cholesterol epoxides exert their re-differentiating effects 
have recently been explored by the Poirot group [347].  
The proposed pathway involves further metabolism of the 5,6α cholesterol epoxide 
isomer by histamine to form a key tumour inhibitory molecule - dendrogenin A (DDA) 
[347].  
6.4.5.7 Biological properties of dendrogenin A (DDA) 
	
DDA is a steroidal alkaloid which has been proposed to have potent re-differentiating 
effects on a number of tumour cell types in-vitro including breast, melanoma and 
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glioblastoma [347, 348]. Furthermore, when breast and melanoma cell lines were 
injected into immunocompetent mice, administration of low dose DDA reduced tumour 
size and prolonged survival [347]. DDA treatment stimulated T lymphocyte and 
dendritic cell infiltration into the engrafted tumours, suggesting there may be a 
significant immunomodulatory role in the observed anti-tumour effects [347]. This 
hypothesis was supported by the observation that DDA showed no effect on tumour 
size or survival in immunodeficient mice [347]. 
 
DDA was also quantified in human breast tissue and was found in fivefold lower 
concentration in cancer tissue compared to adjacent uninvolved breast tissue, 
suggesting deregulation of DDA metabolism in cancer [347]. 
 
DDA itself has been proposed to be a very potent and selective inhibitor of ChEH 
activity, more efficacious than the SERMs [294, 347]. This suggests that DDA may 
further potentiate the inhibition of ChEH activity and promote the formation of 
cholesterol epoxides. In addition, 5,6α cholesterol epoxides have been reported to be a 
direct modulator of liver X receptor (LXR) signalling [349]. 5-6α cholesterol epoxides 
are also the substrate of cholesterol sulphotransferase SULT2B1b [350], and the 
resulting product of this reaction is 5,6α-EC-3-sulphate – another known modulator of 
LXR signalling [351]. Human and mouse tumours have been observed to produce LXR 
agonists which impair the ability of dendritic cells to initiate an immune response 
against the tumour [352]. Significantly, modulation of LXR agonist activity via the 
addition of SULT2B1b resulted in tumour growth control by preventing evasion from the 
immune system [352]. Therefore modulation of LXR signalling could potentially be a 
key mechanism by which DDA (and inhibition of ChEH activity by tamoxifen) exert their 
anti-tumour effects. Alteration of the immune cell content of the mammary stroma by 
tamoxifen has been observed in animal models [115].  
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The inhibition of ChEH activity by tamoxifen has been proposed by the Poirot group to 
contribute to the overall anti-cancer effect of tamoxifen in the adjuvant treatment setting 
of breast cancer patients, in addition to the classical mechanism of action as a 
competitive ER antagonist [296].  
Whilst this pathway highlights an intriguing potential mechanism independent of the ER 
by which SERMs could exert anti-tumour effects, there are a number of other important 
factors to consider. Firstly, the vast majority of the data supporting the anti-tumour 
properties of this pathway has originated from a single laboratory and has yet to be 
widely replicated and validated by others. In addition, all the previous studies have 
focused on tumour cells and, to date, there is no evidence that ChEH is present in 
fibroblasts, or that inhibition of ChEH activity and accumulation of cholesterol 
metabolites in stromal cells would result in similar anti-tumour effects to those 
described in malignant epithelial cells. Furthermore, both the differential gene 
expression and pathway analyses show up-regulation of many genes across the entire 
cholesterol metabolism pathway (Appendices 2 - 6). Thus, the findings may simply 
reflect a generalised up-regulation of cholesterol biosynthesis.  Notably, the sterol 
regulatory element binding protein 1 and 2 (SREBP 1/2) genes both show significantly 
up-regulated expression (Appendices 2 - 4). These genes encode proteins which act 
as transcription factors for numerous genes involved in sterol metabolism [353].  
6.4.5.8 Up-regulation of DHCR7 expression may be a consequence of a 
feedback loop 
	
In this study DHCR7, one of the two components of the AEBS/ChEH, showed 
significantly up-regulated gene expression (p = <0.001, Appendix 4) in the 4-OHTam 
treated fibroblasts compared to those treated with vehicle control. This result initially 
appears to contradict the data from the Poirot group suggesting that 4-OHTam inhibits 
the activity of ChEH, as it might be expected that increased gene expressed would 
enhance ChEH activity.  
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These conflicting results could potentially be explained by a feedback loop driven by 
the binding of 4-OHTam to the AEBS. The resulting inhibition of ChEH activity and 
accumulation of cholesterol epoxides could drive enhanced transcription of the DHCR7 
gene (Figure 76). It may also be plausible that there is an increase in the translation of 
the DHCR7 enzyme product, but it is rendered functionally inactive due to the binding 




Figure 76: Increased DHCR7 gene expression was identified in the 4-OHTam treated 
fibroblasts. This could potentially be explained by a feedback loop driving increased expression 
of DHCR7 in response to 4-OHTam binding to the AEBS, inhibiting the activity of ChEH and the 
accumulation of cholesterol epoxides. However, there is limited data to support his hypothesis 
and increased DHCR7 expression may also simply reflect a generalised up-regulation of many 
genes in the cholesterol biosynthesis pathway.  
 
Up-regulation of DHCR7 gene expression was only noted in the higher dose (5µM) 4-
OHTam treated samples (Figure 62), suggesting there might be a critical threshold 
concentration at which inhibition of ChEH activity by 4-OHTam occurs. The Poirot 
group report threshold concentrations for inhibition of ChEH activity of 140nM for 4-
OHTam and 34nM for tamoxifen [345]. These data correlate well with the findings of 
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this study where the lower dose (100nM) 4-OHTam treatment showed little effect on 
fibroblast gene expression compared to the higher dose (5µM).  
Accumulation of the anti-tumorigenic cholesterol epoxides within the fibroblasts could 
potentially contribute to a tumour-inhibitory breast microenvironment, and may 
contribute to the breast cancer preventing properties of tamoxifen in high risk 
individuals [113], and the tumour-inhibitory phenotype of tamoxifen treated stroma 
observed in animal models [115].  
There is, however, limited evidence to support this hypothesis and it is also possible 
that the up-regulated expression of DHCR7 simply reflects the generalised up-
regulation of many genes involved in the cholesterol biosynthesis pathway. In addition, 
the other component of the AEBS (D8D71) does not feature in the top differentially 
expressed genes (Appendices 2 - 4) and one might expect to see a similar level of up-
regulated expression as with DHCR7. Further work is required in order to demonstrate 
that ChEH activity is inhibited by 4-OHTam in fibroblasts.  
6.4.5.9 Inhibition of ChEH activity could contribute to the anti-proliferative and 
de-activating effect of 4-OHTam on fibroblasts 
	
The inhibition of ChEH activity could potentially explain the observed response of 
primary breast fibroblasts to 4-OHTam. A consistent, dose dependent negative effect 
on fibroblast proliferation was observed (Figures 23 + 24). This is consistent with the 
reported growth inhibitory properties of cholesterol epoxide accumulation due to ChEH 
inhibition [295]. In addition, concentrations of > 6µM were observed to be toxic to the 
fibroblasts (Figures 23, 24 + 32). Cholesterol epoxides have been reported to induce 
apoptosis and autophagy when present in sufficient concentrations within cells [344]. 
Thus both the growth inhibitory and toxic properties of 4-OHTam may be attributable to 
ChEH inhibition and cholesterol epoxide accumulation. However, at present there is 
limited evidence to support the presence of cholesterol epoxides within the 4-OHTam 
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treated fibroblasts. Thus, the anti-proliferative and toxic properties may also be due to 
alternative effects of 4-OHTam on the fibroblasts, unrelated to cholesterol metabolism.  
The characteristic 4-OHTam-treated fibroblast phenotype (Figure 33) might also be 
related to inhibition of ChEH activity. The accumulation of perinuclear cytoplasmic 
vesicles may reflect the accumulation of cholesterol epoxides and other cholesterol 
precursors due to the inhibition of ChEH, DHCR7 and DHCR24 enzyme activity. This 
hypothesis is supported by observations from the Poirot group that breast cancer cell 
lines treated with commercially available specific inhibitors of ChEH demonstrate a 
similar accumulation of small vesicles in the cell cytoplasm [296]. These findings need 
to be interpreted with caution as the presence of cholesterol epoxides within the 4-
OHTam treated fibroblasts has not been confirmed. Future work to identify to content of 
these vesicles is required. Interestingly the pathway analysis revealed significant up-
regulation of the trans-golgi network vesicle budding pathway using the REACTOME 
pathway gene sets (NOM p = 0, FDR q = 0.025, Appendix 5). Up-regulation of this 
pathway could explain the accumulation of vesicles within the 4-OHTam treated 
fibroblasts. It is possible that 4-OHTam is able to stimulate this pathway via 
mechanisms unrelated to cholesterol biosynthesis. 
6.4.5.10 Relationship to a reduction in mammographic density 
	
The attenuation of ChEH activity in fibroblasts could potentially help to contribute to a 
tumour-inhibitory stromal phenotype, but it is less clear how this may contribute to the 
reduction in MD observed clinically in patients treated with tamoxifen [110]. The 
possible mechanisms that may be involved are discussed below. Other potentially 
contributory pathways unrelated to cholesterol metabolism are discussed in Section 
6.4.6. 




Given the observations by the Poirot group that ChEH enzyme inhibition and 
cholesterol epoxide accumulation in a variety of different tumour cell types can promote 
their differentiation [347], it is possible that cholesterol epoxide accumulation may 
promote fibroblast differentiation from an activated ‘myofibroblast like’ phenotype to a 
more quiescent state, and potentially towards adipogenic differentiation. Stimulating the 
fibroblasts towards adipogenic differentiation could gradually increase the fatty content 
of the breast and thus reduce the overall MD. 
The differentiation of the fibroblasts to a more quiescent state is consistent with the 
observed reduction in SMA expression (Figure 48) and inhibition of non-canonical 
TGF-β signalling (Figure 56) with 4-OHTam treatment.  
There is limited evidence from the RNA Seq differential gene expression and pathway 
analysis to support fibroblasts being pushed towards adipogenic differentiation by 4-
OHTam. Firstly, there are some key markers of early stage adipogenic differentiation 
that are up-regulated in the differential gene expression analysis. Figure 77 below 





Figure 77. Genes involved in early stage adipogenesis, adapted from Cristancho et al [354].  
 
Canonical Wnt signalling is a potent inhibitor of adipogenesis [354]. Significant down-
regulation of Wnt signalling was observed in the pathway analysis (NOM p = 0, FDR q 
= 0.009) and DKK1, a potent inhibitor of Wnt signalling, was significantly up-regulated 
(p = <0.001) in the differential gene expression analysis. In addition, up-regulation of 
BMP2 (p = <0.001) and MMP14 (p = <0.001), genes associated with early stage 
adipogenesis [354], was also observed.  
 
Peroxisome proliferator-activated receptor - gamma (PPARγ), a key mediator of 
adipogenesis [354], was also up-regulated in our differential gene expression analysis 
(p = <0.001). In addition, PPAR signalling was identified using the KEGG biological 
pathways resource (Appendix 6) as being significantly up-regulated (NOM p = 0.004, 
FDR q = 0.028) in the 4-OHTam treated fibroblasts.   
Despite the up-regulation of the pathways described above, the evidence to support 
adipogenic differentiation of the fibroblasts by 4-OHTam is limited. An alternative 
explanation is that the cells simply synthesise and accumulate lipid in response to 4-
OHTam treatment, without any differentiation. Furthermore, the pathway analysis 
(Appendices 5 + 6) shows a number of pathways related to lipid metabolism are up-
regulated. This again may simply indicate a generalised increased in lipid synthesis, in 
parallel with cholesterol synthesis, within the treated cells, rather than differentiation.  
 
A key observation from the differential gene expression analysis that conflicts with the 
hypothesis that 4-OHTam may promote adipogenic differentiation, is that leptin – a key 
gene involved in the terminal stages of adipogenesis [354] – shows significantly down-
regulated expression (p = <0.001) in the 4-OHTam treated fibroblasts. This finding 
emphasises that the 4-OHTam treated cells are not undergoing full adipogenic 
differentiation. It is possible that 4-OHTam treatment may simply ‘deactivate’ the 
fibroblasts to a more quiescent ‘pre-adipocyte-like’ state. In the context of the correct 
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biochemical and biophysical cues these deactivated ‘pre-adipocyte – like’ fibroblasts 
might then progress on to full adipogenic differentiation. The fact that the 4-OHTam 
treated fibroblasts do not resemble adipocytes (Figure 33) also supports this modified 
hypothesis, summarised in Figure 78.  
 
 
Figure 78: Tamoxifen may promote ‘deactivation’ of fibroblasts to more quiescent pre-adipocyte 
like cells, which may undergo further adipogenic differentiation. Increasing the fatty content of 
the breast would reduce the overall breast density. This proposed mechanism could explain the 
observed reduction in MD with tamoxifen treatment in high risk women [109]. It is important to 
note that the evidence to support differentiation of the fibroblasts by 4-OHTam is very limited 
and an alternative explanation may be that the fibroblasts simply synthesise more lipid in 
response to 4-OHTam treatment.  
 
The down-regulation of leptin gene expression in the 4-OHTam treated fibroblasts is 
also intriguing as, in addition to its role in the terminal stages of adipocyte 
differentiation, leptin has also been implicated in contributing to a pro-tumourigenic 
breast microenvironment [355]. Ando and colleagues have recently reviewed the 
literature and suggest that leptin may act in an autocrine, endocrine and paracrine 
manner to enhance tumour cell proliferation, acquisition of mesenchymal phenotype, 
migration and invasion [355]. Thus, down-regulation of leptin gene expression in the 4-
OHTam treated fibroblasts may contribute to a stroma less permissive to tumour 
formation. 




In addition to DHCR7, gene expression of DHCR24, another enzyme involved in the 
terminal stages of cholesterol synthesis, was significantly up-regulated in the 4-OHTam 
treated fibroblasts (p = <0.001, Appendix 4). DHCR24 enzyme activity has been 
observed by the Poirot group to be inhibited by 4-OHTam [293]. This supports the 
hypothesis that up-regulated expression may be due a compensatory feedback loop 
due to inhibition of enzyme activity. In addition, DHCR24 is known to be a co-factor of 
DHCR7 and the two enzymes interact physically to enhance each other’s activity [356]. 
Thus it is possible that DHCR24 gene expression is also up-regulated in an attempt to 
improve the functional activity of DHCR7. However, it is also possible that the up-
regulated expression may simply be part of a generalised increased in the whole 
cholesterol biosynthesis pathway.  
6.4.6 Down-regulated pathways in 4-OHTam treated fibroblasts 
	
A more diverse array of pathways were observed to be down-regulated with 4-OHTam 
treatment compared to the up-regulated pathways which predominantly involved 
cholesterol and lipid synthesis and metabolism. Many of these down-regulated 
pathways may also contribute to the generation of an anti-tumour breast 
microenvironment and the reduction in MD observed clinically with tamoxifen 
treatment.  
6.4.6.1 Cell cycle and DNA replication 
	
Down-regulation of many pathways related to cell cycle and DNA replication were 
identified using both the REACTOME and KEGG biological pathway resources 
(Appendices 7 + 8). These data are consistent with the experimental findings of 
reduced fibroblast proliferation with 4-OHTam treatment (Figures 23 + 24). Pathways 
involving mRNA processing, homologous recombination, mismatch repair were also 
significantly down-regulated (Appendices 7 + 8), further highlighting the growth 
inhibitory properties of 4-OHTam treatment. The Ki67 gene showed significantly 
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reduced expression in the 4-OHTam fibroblasts (p = <0.001), consistent with the 
experimental findings described in Chapter 4 of reduced Ki67 immunocytochemical 
staining in the 4-OHTam treated fibroblasts compared to those treated with vehicle 
control (Figure 30). 
 
6.4.6.2 Wnt and Hedgehog signalling 
	
The down-regulation of Wnt and Hedgehog signalling pathways was identified using 
the KEGG biological pathway resource (Appendix 8). These data are intriguing as both 
Wnt and Hedgehog are established pro-tumourigenic and pro-fibrogenic pathways 
[357-360]. Therefore down-regulation of these pathways could contribute to a more 
quiescent, less fibrotic and less ‘dense’ breast microenvironment.  
Wnt signalling has recently been proposed to be a key mediator of stromal-epithelial 
cell cross talk in the breast microenvironment by Isacke and colleagues, who observed 
Wnt7a modulated TGF-β signalling in stromal fibroblasts [169]. Experimental results 
from this study showed inhibition of non-canonical TGF-β signalling through ERK1/2 
(Figure 56) in 4-OHTam treated fibroblasts. Thus, this attenuation of TGF-β signalling 
could potentially be related to a corresponding down-regulation of Wnt signalling. 
Intriguingly, Hedgehog signalling has also been shown to overlap with TGF-β signalling 
at the level of the GLI transcription factors [361, 362]. Furthermore, inhibition of 
Hedgehog signalling by DHCR7 has been reported [363], and modulation of Hedgehog 
signalling has also been observed in patients treated with Haloperidol – another drug 
known to alter ChEH activity [364]. Thus, the Hedgehog signalling pathway may also 
potentially contribute to the observed inhibition of non-canonical TGF-β signalling in 4-
OHTam treated fibroblasts (Figure 56).  
Modulation of the TGF-β-Wnt-Hedgehog signalling axis by tamoxifen may contribute to 
the remodelling of the mammary stroma to a tumour-inhibitory phenotype. Due to the 
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pro-fibrotic properties of the Wnt and Hedgehog signalling pathways, their down-
regulation by tamoxifen may also contribute to the reduction in MD observed in high 
risk women treated with the drug [110]. Tamoxifen induced down-regulation of Wnt and 
hedgehog signalling may also contribute to the anti-fibrotic effects of tamoxifen 
observed in a variety of other organ systems [315-318], and thus may be of value in 
developing targeted therapies for pro-fibrogenic disorders. 
6.4.6.3 ECM protein synthesis, remodelling and mechanotransduction 
	
Down-regulation of collagen formation in the 4-OHTam treated fibroblasts was 
identified using the REACTOME biological pathway resource (Appendix 7). These data 
are in keeping with the experimental findings of reduced collagen I protein expression 
in 4-OHTam treated fibroblasts (Figure 42) and reduced soluble collagen in the 
conditioned media from 4-OHTam treated fibroblasts (Figure 43). Increased stromal 
collagen density increased tumour burden in a mouse model of high MD [206], 
therefore a reduction in fibroblast collagen I expression with 4-OHTam treatment is 
consistent with a stromal phenotype less permissive to tumour formation. 
Modulation of collagen expression by tamoxifen has been reported in a number of 
studies with conflicting observations [115, 314]. Kim and colleagues found reduced 
collagen expression with tamoxifen treatment in a mouse model of renal fibrosis [314], 
whereas Hattar and colleagues found increased total collagen in the ECM of rats 
treated with tamoxifen [115]. Increased total collagen expression has been reported in 
a mammary stroma less permissive to tumour formation due to the collagen being less 
organised and fibrillar in nature [212]. 
The ability of tamoxifen to alter the biophysical properties of the breast ECM is further 
suggested by the down-regulation of ECM-receptor interaction, focal adhesion and 
integrin signalling pathways identified using both KEGG and REACTOME (Appendices 
7 + 8). Weaver and colleagues observed increased ECM stiffness was associated with 
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increased focal adhesion and integrin signalling and pro-tumourigenic PI3 kinase 
activity [213]. Thus tamoxifen may be able to attenuate pro-tumourigenic signalling 
pathways by remodelling the ECM to a more quiescent phenotype with less mammary 
epithelial cell mechanotransduction. Remodelling of the breast ECM could also 
potentially contribute to the decrease in MD observed clinically with tamoxifen 
treatment.  
6.4.6.4  Immune cell signalling 
	
CTLA4 inhibitory signalling was identified to be significantly down-regulated in the 4-
OHTam treated fibroblasts using the REACTOME biological pathway resource 
(Appendix 7). This suggests that tamoxifen may also be able to influence the 
interaction of fibroblasts with immune cells within the breast microenvironment. Hattar 
and colleagues observed changes in the immune cell content in the mammary ECM of 
tamoxifen treated rats [115]. In addition, cholesterol epoxides generated via the 
inhibition of ChEH activity by tamoxifen are known to modulate LXR signalling [351]. 
Modulation of LXR signalling has been suggested to influence immune cell behaviour 
within the tumour microenvironment [352].  
Thus, tamoxifen may be acting via down-regulating multiple, diverse pathways to 
generate a tumour-inhibitory and less ‘dense’, breast microenvironment (summarised in 




Figure 79: Summary of down-regulated pathways in fibroblasts with 4-OHTam treatment 
identified using RNA Seq and potential contributions of these to a tumour inhibitory breast 
microenvironment. 
	
6.4.7 Expression of lysyl oxidase (LOX) 
	
LOX, LOX like 1 (LOXL1) and LOX like 4 (LOXL4) showed reduced expression in 4-
OHTam treated fibroblasts in the differential gene expression analysis (adjusted p-
values 0.0033, <0.001 respectively). This contrasts with the experimental findings of no 
significant alteration in LOX protein expression with 4-OHTam treatment (Figure 41). It 
is possible that a longer treatment time may be required for the reduction in LOX gene 
expression to be translated into a significant reduction in protein expression.  
6.4.8 Expression of FN 
	
Interestingly, significant differential expression of fibronectin 1 (FN1) gene was not 
observed in the RNA Seq analysis, in contrast to the observed reduction of FN protein 
expression in a proportion of the primary fibroblast cohort (Figure 39). This could be 
explained by 4-OHTam promoting degradation of existing FN molecules with no effect 
on overall gene expression. Alternatively 4-OHTam may inhibit translation of the FN 
mRNA transcript, thus resulting in lower protein expression levels. 4-OHTam may also 
influence splicing of the FN mRNA transcript, resulting in the translation of different 
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isoforms of the protein which may not be recognised by the antibody used in western 
blotting. Thus the protein expression would appear to decrease whilst the mRNA levels 
remain constant. Another important consideration is that FN is a highly insoluble 
protein and the changes in protein expression detected with 4-OHTam treatment via 
western blotting may be artefactual and thus may not accurately represent the FN 
protein content pre- and post-treatment. This could also potentially account for the 
discrepancy observed between the RNA Seq and western blotting results.  
6.4.9 RNA Seq experimental design considerations 
	
The RNA Seq analysis highlighted a plethora of diverse pathways by which tamoxifen 
may be acting to generate a breast microenvironment less permissive to tumour 
formation, and which may contribute to a reduction in MD.  It is not clear whether some 
of the pathways identified, such as increased cholesterol biosynthesis (Appendix 5), 
may simply be generalised effects seen in any cell treated with 4-OHTam rather than 
pathways which are driving the anti-tumour and density lowering effects of the drug. 
 One way in which the design of the RNA Seq analysis could be repeated to try and 
delineate the key pathways involved would be to compare the differentially expressed 
genes between a group of patients’ fibroblasts who showed a reduction in FN 
expression with 4-OHTam treatment (responders) and a group of those who did not 
(non-responders). Pathways and genes significantly differentially expressed in the 
responders compared to the non-responders may highlight some of the crucial 
mechanisms by which tamoxifen exerts the density lowering and tumour-inhibitory 
effects. Only a single non-responder was included in this RNA Seq study, thus any 





7 Investigation of RNA Seq findings and proposed ER-





The RNA Seq data from this study showed marked up-regulation of pathways involved 
in cholesterol metabolism in 4-OHTam treated fibroblasts, including components of the 
microsomal AEBS (Appendix 4). Binding to the AEBS and inhibition of ChEH activity by 
SERMs has been proposed by the Poirot group to be anti-tumourigenic and to promote 
differentiation of tumour cells [347]. Thus, this pathway could contribute to an 
antitumourigenic breast microenvironment and promote differentiation of fibroblasts to 
a less activated stat, and potentially towards adipogenic differentiation. Increased 
adipogenic differentiation of the breast stroma could result in a reduction in MD.  
In order to test this hypothesis, fibroblasts were treated with tamoxifen (another SERM) 
and a commercially available inhibitor of ChEH – tesmilifene (DPPE), to determine if 
these drugs modulated fibroblast function in a similar manner to 4-OHTam. Analysis of 
the cholesterol metabolite content of fibroblasts treated with these drug regimens was 




7.2 Methods and materials 
	
7.2.1 Quantitative reverse transcription and real time polymerase chain 
reaction (qRT-PCR) 
	
7.2.1.1 RNA extraction and quantification 
	
RNA was extracted from cultured cells using the QuickPrep miniprep kit (Zymo 
Research, R1054) according to manufacturer’s instructions. Briefly, culture media was 
removed and cells washed in PBS. 400µl of lysis buffer was added to the plate and 
cells scraped before transferring the lysate to a 1.5ml eppendorf tube and briefly 
centrifuging at 12000 rpm for 30 seconds. The supernatant was then transferred to a 
DNA eliminating spin column and briefly centrifuged at 10000 rpm for 1 minute. 320µl 
of absolute ethanol (Fisher Scientific, E/0650DF/17) was mixed with the flow through 
and the entire amount transferred to another spin column. The column was centrifuged 
at 10,000 rpm for 1 minute before discarding the flow through and adding 400µl RNA 
Prep buffer and centrifuging in the same manner. The samples were then centrifuged 
with 800µl and 400µl RNA wash buffer in succession before centrifuging the spin 
column for 2 minutes in an empty collection tube to remove all wash buffer. The column 
was then transferred to a 1.5ml eppendorf tube and 25µl RNase free water added 
directly onto the column membrane. The tube was left to stand for 1 minute before 
centrifuging at 12000 rpm for 30 seconds to elute the RNA.  
The RNA was quantified (ng/µl) using the Nanodrop system (Thermo Scientific) and 
then diluted to a concentration of 50ng/µl using RNAse-free water.  
7.2.1.2 cDNA synthesis 
	
cDNA synthesis was carried out as a two-step process using 50ng RNA per reaction. 
The first step involved adding 50ng of RNA (1µl) to a PCR eppendorf along with 1µl 
random hexamer primers (Sigma, H0268), 1µl dNTPs (10mM, Sigma, GE28-4065 57) 
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and 7µl RNAse free water (Fisher, 11506281). The samples were then incubated for 10 
minutes at 70oC and 5 minutes at 4oC using a pre-set program on a PCR machine 
(Eppendorf).  
The second step involved adding 2µl of reverse transcriptase enzyme buffer (Sigma, 
M1302-40KU), 1µl of reverse transcriptase enzyme (Sigma, M1302-40KU) and a 
further 7µl of RNAse free water to each reaction. The samples were then incubated at 
22oC for 10 minutes, 37oC for 50 minutes and 90oC for 10 minutes. cDNA samples 
were stored at 4oC until required.  
7.2.1.3 Quantitative real time PCR 
	
Real time PCR was carried out using SYBR Green (Applied Biosystems, 4367659) 
according to manufacturer’s instructions. 1µl of cDNA was used per reaction. Primers 
(Integrated DNA technologies) were stored as a 100µM stock and used at 0.3mM final 
concentration, the sequences are listed below in Table 15. 18S was used as a 
housekeeping gene. A PCR master mix was prepared for each reaction including; 5µl 
SYBR Green, 1µl forward primer, 1µl reverse primer and 2µl RNAse free water to give 
a 10µl total reaction volume per tube.	Each reaction was perfomed in triplicate within 
the same plate for each all genes. Reactions were run using a Step One Plus 
instrument (Applied Biosystems)	using the following conditions: for one cycle 95oC for 












7.2.1.3.1 Determining relative expression level 
	
Relative changes in gene expression were determined using the comparative cycle 
threshold method. The cycle threshold level (Ct) is the point at which fluorescence can 
be detected. The average Ct value for the sample triplicates (vehicle control and drug 
treated) and housekeeping gene samples (18S) was determined.  The change in cycle 
threshold (ΔCt) was then calculated by subtracting the average Ct for the 
housekeeping gene from the average Ct of the target gene. The ΔCt of the vehicle 
control was then subtracted from the ΔCt of the drug treated sample to give a ΔΔCt 
value. The relative change in gene expression was then calculated using the arithmetic 
formula 2-(ΔΔCt) where 2 is a constant that assumes 100% efficiency.  
 
7.2.2 Oil Red O staining  
	
7.2.2.1 Preparation of stock and working solutions 
	
Oil Red O stock solution was prepared by dissolving 0.5g Oil Red O (Sigma, O-0625) 
in 100ml isopropanol (Acros Organics, 38971002S). 
A working solution was prepared fresh prior to staining. 6ml of stock solution was 
mixed with 4ml distilled water and left to sit at room temperature for 1 hour. The 
solution was then filtered through Whatmann paper to remove any undissolved 
granules. 
7.2.2.2 Staining procedure 
	
Fibroblasts were seeded into triplicate wells on a 12 well plate (5 x 104 cells per well), 
hormone deprived for 24 hours and then treated for 1 week with vehicle control, 
tamoxifen (5µM), 4-OHTam (5µM), tesmilifene (20µM), fulvestrant (5µM) or E2 (10nM).  
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Culture media was removed and cells were washed with PBS before fixing in 10% NBF 
for 10 minutes. The cells were washed twice with PBS for 1 minute and then 1ml of Oil 
Red O working solution added to each well for 1 hour at room temperature. The 
working solution was then removed and the cells washed three times with distilled 
water. The cells were then counterstained with Mayer’s haematoxylin for 2 minutes 
before washing a further five times with distilled water.  
7.2.2.3 Quantification 
		
Oil Red O staining was quantified by adding 500µl of isopropanol to each well to 
solubilise Oil Red O bound to lipid. The optical density of the isopropanol solution was 
then measured on a plate reader at 510nm.  
7.2.3 Filipin staining 
		
8 well chamber slides were pre-treated with 0.2% gelatin for 1 hour at 37oC before 
seeding 1 x 104 fibroblasts into each chamber. The cells were hormone deprived for 24 
hours and then treated for 1 week with either vehicle control, tamoxifen (5µM), 4-
OHTam (5µM) or tesmilifene (20µM). 
Filipin complex (Sigma, F9765) working solution was prepared (0.05mg/ml in PBS/10% 
FBS) and stored protected from light. 
The culture media was removed and cells washed twice with PBS before fixing in 10% 
NBF for 10 minutes. The cells were washed with PBS three times before incubating 
with 1ml glycine (1.5mg/ml in PBS) for 2 hours at room temperature. The glycine was 
removed and the cells incubated with 1ml of filipin working solution for 2 hours at room 
temperature protected from light. The filipin was then removed and the cells washed 




Images were acquired on confocal microscope LSM510. Filipin was excited using the 
UV laser at 350nm. Images were captured at 1024 x 1024 resolution. 
7.2.4 Mass spectrometry 
	
7.2.4.1 Treatment conditions 
	
The sterol content of primary fibroblasts (one normal reduction mammoplasty patient 
2585) treated with the following treatment conditions was determined by mass 
spectrometry: 
• Vehicle control 
• Tamoxifen (5µM) 
• 4-OHTam (5µM) 
• Tamoxifen (2.5µM) and 4-OHTam (2.5µM) 
• Tesmilifene (20µM) 
• Fulvestrant (5µM) 
 
7.2.4.2 Sample Preparation 
	
Fibroblasts were seeded into T175 flasks, grown to 70% confluence and hormone 
deprived for 24 hours. 6 flasks were prepared for each fibroblast treatment condition. A 
minimum of 10 x 106 cells was required for the analysis. 
The cells were treated for 48 hours then trypsinised and counted using a 
haemocytometer. After counting, the cells were centrifuged at 12000 rpm for 2 minutes 
and the cell pellets immediately frozen at -80oC. 
7.2.4.3 Mass spectrometry analysis 
	
The sterol profiling was performed by Dr Marc Poirot and Dr Sandrine Silvente-Poirot, 
Toulouse Centre for Cancer Research, Toulouse, France in collaboration with Dr 
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Antonin Lamaziere, Sorbonne Universités- Université Pierre et Marie Curie, Paris, 
France. 
Sterols in cell homogenates were extracted with a solvent mixture containing 
chloroform/methanol 2/1 (v/v) spiked with epicoprostanol as an internal standard. Lipids 
were partitioned in chloroform after addition of saline, saponified by methanolic 
potassium hydroxide (0.5 N, 60oC, 15 minutes). The fatty acids released were 
methylated with BF3-methanol (12%, 60oC, 15 minutes) in order not to interfere with 
the chromatography of sterols. The sterols were re-extracted in hexane and silylated as 
described previously [365]. The trimethylsilylether derivatives of the sterols were 
separated by gas chromatography (GC, Hewlett–Packard 6890 series) in a medium 
polarity capillary column RTX-65, (65% diphenyl 35% dimethyl polysiloxane, length 30 
m, diameter 0.32 mm, film thickness 0.25 µm (Restesk, Evry, France)). The mass 
spectrometer (Agilent 5975 inert XL) in series with the GC was set up for detection of 
positive ions. Ions were produced in the electron impact mode at 70 eV. The sterols 
were identified by the fragmentogram in the scanning mode and quantified by selective 
monitoring of the specific ions after normalisation with the internal standard 
epicoprostanol and calibration with weighed standards. 
7.2.5 Electron microscopy 
	
7.2.5.1 Preparation of fixation solution 
	
Primary fibroblasts were fixed prior to transmission electron microscopy (TEM) using a 
freshly prepared gluteraldehyde (2%, Sigma, G6257) / Sorensen’s buffer (0.1M, pH7.4) 
fixation solution.  
0.1M pH 7.4 Sorensen’s buffer was prepared as follows:  
35.6g of sodium hydrogen phosphate dibasic dihydrate (Na2HPO4.2H2O, Sigma, 
30435) was dissolved in 1 litre distilled water – Solution A 
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27.6g of sodium phosphate monobasic monohydrate (NaH2PO4.H2O, Sigma, S9638) 
was dissolved in 1 litre distilled water – Solution B 
40.5ml of solution A was added to 9.5ml of solution B to give 50ml of 0.2M Sorensen’s 
buffer. The pH was checked to ensure it was 7.4 before 50ml of this solution was 
diluted with 50ml of distilled water to give 100ml of 0.1M pH 7.4 Sorensen’s buffer.  
7.2.5.2 Sample preparation 
	
Primary fibroblasts were seeded in T175 flasks and grown to 70% confluence, 
hormone deprived for 24 hours, then treated for one week with vehicle control, 
tamoxifen (5µM), 4-OHTam (5µM) or tesmilifene (20µM). The cells were viewed on an 
inverted phase contrast microscope to ensure perinuclear cytoplasmic vesicles were 
clearly visible before being trypsinised and centrifuged at 1500 rpm for 3 minutes. The 
supernatant was carefully removed and the cells were re-suspended in 1.5ml freshly 
prepared fixation solution before being transferred to a 1.5ml eppendorf and stored at 
room temperature.  
7.2.5.3 Cell imaging 
	
Cell imaging was performed by Dr Marc Poirot and Dr Sandrine Silvente-Poirot, 
Toulouse Centre for Cancer Research, Toulouse, France. 
Following fixation  with 2% glutaraldehyde in 0.1M Sorensen’s phosphate buffer (pH 
7.4), the cells were washed with the Sorensen’s phosphate buffer (0.1 M) for 12 hours 
and then post-fixed with 1% OsO4 in Sorensen’s phosphate buffer (Sorensen’s 
phosphate 0.05 M, glucose 0.25 M, OsO4 1%) for 1 hour. 
The cells were then washed twice with distilled water, and pre-stained with an aqueous 
solution of 2% uranyl acetate for 12 hours. Samples were then treated exactly as 
described previously [296]. Observations were performed with a Hitachi HT7700 





7.3.1 Investigating differential gene expression of DHCR7 and DHCR24 
	
qRT-PCR was performed to determine relative mRNA expression of DHCR7 and 
DHCR24, two cholesterol synthesis enzymes consistently highlighted to show up-
regulated expression with 4-OHTam treatment in the pilot and follow up RNA Seq 
datasets. Three patients’ primary fibroblasts were examined (1004, 2182, 2585). 
 
 
Figure 80: DHCR7 mRNA expression in fibroblasts treated with vehicle control, tamoxifen, 4-
OHTam, tesmilifene and fulvestrant (n = 3). Significant up-regulation of DHCR7 was seen in 





Figure 81: DHCR24 mRNA expression in fibroblasts treated with vehicle control, tamoxifen, 4-
OHTam, tesmilifene and fulvestrant (n = 3). Significant up-regulation of DHCR24 was seen in 
fibroblasts treated with tamoxifen (p = 0.001) and 4-OHTam (p = 0.03).  
 
Up-regulated expression of DHCR7 and DHCR24 mRNA was identified in fibroblasts 
treated with tamoxifen and 4-OHTam (Figure 80 + Figure 81). No significant increased 
expression was seen in fibroblasts treated with tesmilifene or fulvestrant.  
7.3.2 Confirming lipid accumulation in 4-OHTam treated fibroblasts 
	
Oil Red O staining was undertaken to determine if the perinuclear cytoplasmic vesicles 
noted in the 4-OHTam treated fibroblasts contained lipid. Fibroblasts from three 




Figure 82: Lipid droplet accumulation in 4-OHTam treated fibroblasts. (i) Phase contrast image 
of perinuclear cytoplasmic vesicles seen in 4-OHTam treated fibroblasts (x40 objective) (ii) Oil 
Red O staining (A) No staining in vehicle control treated fibroblasts (x40 objective) (B) Positive 
Oil Red O staining in the perinuclear vesicles of 4-OHTam treated fibroblasts (x40 objective) (C) 
Positive Oil Red O staining in lipid droplets of all trans retinoic acid (ATRA) treated pancreatic 
stellate cells (positive control, x40 objective). (iii) Quantification of Oil Red staining following 
solubilisation in isopropanol, normalised to the vehicle control. Triplicate wells of a 24 well plate 
were analysed for each treatment condition in three patients’ fibroblasts (n = 3).  Significantly 
more Oil Red O is present in the 4-OHTam treated fibroblasts (p = 0.0021, example of patient 
1004) 
	
4-OHTam treated fibroblasts showed significantly more positive staining with Oil Red O 
(p = 0.0021, Figure 82) in the perinuclear cytoplasmic vesicles than the fibroblasts 





7.3.3 Investigating potential ER-independent effect of 4-OHTam via 
inhibition of ChEH activity 
 
In order to test our hypothesis that 4-OHTam is potentially acting via ER-independent 
mechanisms to affect ChEH activity, fibroblasts were treated with tamoxifen (another 
SERM), tesmilifene (commercially available inhibitor of ChEH) and fulvestrant (Pure ER 
antagonist).  
7.3.3.1 Effect on fibroblast proliferation 
 
The effect of tamoxifen, tesmilifene and fulvestrant on fibroblast proliferation was 
assessed with the Alamar Blue assay using three patients’ primary fibroblasts (1004, 

































































































































































































































Tamoxifen showed a similar dose dependent, negative effect on fibroblast proliferation, 
as had been observed with 4-OHTam (Figure 83). Similarly, high concentrations of 
tamoxifen and 4-OHTam were toxic to the cells. Tesmilifene and fulvestrant showed no 
significant effect in fibroblast proliferation (Figure 83).  
7.3.3.2 Effect on fibroblast activation 
	
Protein expression of FN and SMA was assessed in primary fibroblasts from three 
patients (1004, 2093, 2585) treated with tamoxifen (5µM), 4-OHTam (5µM), tesmilifene 
(DPPE) (10µM), fulvestrant (5µM) and oestradiol (10nM).  
 
   
Figure 84: Expression of FN and SMA in primary fibroblasts treated with tamoxifen (5µM), 4-
OHTam (5µM), tesmilifene (DPPE) (10µM), fulvestrant (5µM) and oestradiol (10nM). (i) Western 
blot image showing reduced FN expression in fibroblasts treated with tamoxifen and 4-OHTam. 
No effect on FN expression was seen with tesmilifene, fulvestrant or oestradiol (n= 3, example 
of patient 2093). (ii) Western blot image showing reduced expression of SMA in fibroblasts 
treated with tamoxifen, 4-OHTam and tesmilifene. No effect on SMA expression was seen with 




Reduced FN expression was consistently seen in fibroblasts treated with tamoxifen and 
4-OHTam (Figure 84 (i)). No effect on fibroblast expression of FN was evident with 
tesmilifene, fulvestrant or oestradiol. Reduction in SMA expression was consistently 
seen in fibroblasts treated with tamoxifen, 4-OHTam and tesmilifene (Figure 84 (ii)). No 
effect on SMA expression as seen with fulvestrant or oestradiol.   
In addition, SMA expression in three patients’ primary fibroblasts (2090, 2182, 2585) 
was analysed following three days treatment with tamoxifen (5µM), 4-OHTam (5µM), 
tesmilifene (10µM) and fulvestrant (5µM) with and without TGF-β stimulation (5ng/ml).  
 
Figure 85: Fibroblast expression of SMA following treatment with vehicle control, tamoxifen 
(5µM), 4-OHTam (5µM), tesmilifene (10µM) and fulvestrant (5µM) with and without TGF-β 
stimulation (5ng/ml). Tamoxifen, 4-OHTam and tesmilifene treatment resulted in a significant 
reduction in SMA expression. No effect on SMA expression was seen with fulvestrant. 
Tamoxifen and 4-OHTam supressed SMA expression following stimulation with TGF-β. No 
reduced expression was seen in cells treated with tesmilifene or fulvestrant following TGF-β 
stimulation (n = 3, example of patient 2090).  
 
Consistent with previous experiments, tamoxifen, 4-OHTam and tesmilifene treatment 
resulted in reduced expression of SMA (Figure 85). No effect was seen with fulvestrant. 
Following TGF-β stimulation, reduced expression of SMA was only seen in cells treated 




7.3.3.3 Effect on fibroblast phenotype 
	
Primary fibroblasts from three patients (1004, 1890, 2182) were treated with vehicle 
control, tamoxifen (5µM), tesmilifene (10µM), fulvestrant (5µM) and oestradiol (10nM) 
for one week to determine if a similar phenotype to the 4-OHTam (5µM) treated 
fibroblasts was observed.  
 
Figure 86: Effect of tamoxifen (5µM), 4-OHTam (5µM), tesmilifene (10µM), fulvestrant (5µM) 
and oestradiol (10nM) on primary fibroblast morphology after one week of treatment. Phase 
contrast images (x40 objective) showing accumulation of small perinuclear cytoplasmic vesicles 
(red arrows) in the fibroblasts treated with tamoxifen, 4-OHTam and tesmilifene. No vesicles 
were seen in the cells treated with fulvestrant and oestradiol. Example of patient 2182. 
 
Accumulation of small perinuclear cytoplasmic vesicles was seen in the fibroblasts 
treated with tamoxifen, 4-OHTam and tesmilifene (Figure 86). No vesicles were 




7.3.3.4 Effect on fibroblast accumulation of lipid droplets 
	
Primary fibroblasts from three patients (1004, 2090, 2093) were treated with vehicle 
control, tamoxifen (5µM), 4-OHTam (5µM), tesmilifene (10µM), fulvestrant (5µM) and 




Figure 87: Oil Red O staining of fibroblasts treated with vehicle control, tamoxifen (5µM), 4-
OHTam (5µM), tesmilifene (10µM), fulvestrant (5µM) and oestradiol (10nM) for one week. (i) 
Brightfield microscopy images (x20 objective) showing positive Oil Red O staining in cells 
treated with tamoxifen, 4-OHTam and tesmilifene. No significant positive staining was seen in 
cells treated with fulvestrant or oestradiol. (ii) Quantification of Oil Red O staining confirmed 
significant positive staining in the cells treated with tamoxifen (p = 0.0033), 4-OHTam (p = 
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0.0021) and tesmilifene (p = 0.0136), normalised to vehicle control. No significant positive 
staining was seen in the cells treated with fulvestrant or oestradiol. Triplicate wells of a 24 well 
plate were analysed for each treatment condition in three patients’ fibroblasts (n = 3), example 
of patient 1004.   
 
Positive Oil Red O staining was identified in the cells treated with tamoxifen, 4-OHTam 
and tesmilifene (Figure 87). No significant lipid droplet accumulation was identified in 
the cells treated with fulvestrant or oestradiol.  
7.3.4 Investigating potential accumulation of cholesterol precursors (free 
sterols) in fibroblasts 
	
7.3.4.1 Filipin staining for free sterols 
	
To test the hypothesis that tamoxifen modulates cholesterol metabolism by inhibiting 
the activity of enzymes in the cholesterol synthesis pathway (DHCR7, DHCR24, 
ChEH), Filipin staining was performed to detect the presence of free sterols in two 
patients’ fibroblasts (2090, 2585) treated with tamoxifen (5µM), 4-OHTam (5µM) and 
tesmilifene (10µM) for one week. Filipin is a highly fluorescent antibiotic which 




Figure 88: Filipin staining of fibroblasts treated with vehicle control, tamoxifen (5µM), 4-OHTam 
(5µm) and tesmilifene (10µM) for one week (x20 objective). Positive filipin staining was seen in 
the perinuclear cytoplasmic vesicles (white arrows) of the cells treated with tamoxifen, 4-
OHTam and tesmilifene. Example of patient 2858.  
 
Positive filipin staining was seen in the perinuclear cytoplasmic vesicles of cells treated 
with tamoxifen, 4-OHTam and tesmilifene (white arrows, Figure 88).  
7.3.4.2 Electron microscopy for multilamellar bodies and lipid droplets 
	
To investigate the presence of free sterols accumulating in mutlilamellar bodies within 
the fibroblasts (previously described in tumour cells by the Poirot group [296]), and the 
presence of lipid droplets, transmission electron microscopy (TEM) was undertaken on 
fibroblasts from one patient (2182) treated with vehicle control, tamoxifen (5µM), 4-
OHTam (5µM) and tesmilifene (10µM) for 4 days. Multilamellar bodies contain 
unesterified sterols, which correspond to the positive perinuclear vesicles visualised by 
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filipin staining. Lipid droplets are amorphous organelles with no membrane containing 
neutral lipids (triglycerides) and correspond to the positive droplets visualised by Oil 








Figure 89: Transmission electron microscopy images of primary fibroblasts from one patient 
(2182) treated for 4 days with vehicle control, tamoxifen (5µM), 4-OHTam (5µM) and tesmilifene 
(20µM). (i) Whole cell images of each treatment condition. Multilamellar bodies (MLB, red 
arrows) are visible in 100% of cells treated with tamoxifen, 4-OHTam and tesmilifene. (ii) High 
magnification image of MLB and associated lipid droplet from a tamoxifen treated cell. Lipid 
droplets were present in 100% of cells treated with tamoxifen, 4-OHTam and tesmilifene.  
 
Multilamellar bodies and lipid droplets were observed in 100% of the cells treated with 
tamoxifen, 4-OHTam and tesmilifene (Figure 89).  
7.3.4.3 Mass spectrometry quantification of cholesterol metabolites 
	
To investigate the potential accumulation of cholesterol precursors in the primary 
fibroblasts from one patient (2182) treated with tamoxifen, 4-OHTam, tesmilifene and 




Figure 90: Mass spectrometry analysis of cholesterol precursor accumulation in primary 
fibroblasts from one patient (2182) treated for one week with vehicle control, tamoxifen (5µM), 
4-OHTam (5µM), tamoxifen (2.5µM) and 4-OHTam (2.5µM), tesmilifene (20µM) and fulvestrant 
(5µM). Tamoxifen treatment resulted in increased accumulation of zymostenol and zymosterol 
whereas 4-OHTam treatment resulted in accumulation of zymosterol. Co-treatment with 
tamoxifen and 4-OHTam showed a similar pattern of precursor accumulation to 4-OHTam 
alone. Tesmilifene treatment resulted in accumulation of cholesterol and very mild accumulation 
of 8-dehydrocholesterol (8DHC) and 7-dehydrocholesterol (7DHC). Fulvestrant showed a weak 
accumulation of lathosterol and desmosterol (n=1).  
 
Tamoxifen treatment resulted in increased accumulation of zymostenol and zymosterol 
in primary fibroblasts, whereas 4-OHTam stimulated the accumulation of zymosterol 
(Figure 90). Co-treatment with tamoxifen and 4-OHTam showed a similar pattern of 
cholesterol precursor accumulation to 4-OHTam alone (Figure 90). Tesmilifene 
treatment resulted in accumulation of cholesterol and a very mild accumulation of 8-
dehydrocholesterol (8DHC) and 7-dehydrocholesterol (7DHC). Fulvestrant showed a 
weak accumulation of lathosterol and desmosterol (Figure 90). 
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7.3.5 Assessment of DHCR7 protein expression 
	
DHCR7 protein expression in three patients’ primary fibroblasts (1004, 2090, 2585) 
treated with vehicle control, tamoxifen, 4-OHTam, tesmilifene, fulvestrant and 
oestradiol for three days was determined, to see if the increased DHCR7 mRNA 
expression observed by RNA Seq and qRT-PCR in the 4-OHTam treated fibroblasts 
was translated into protein.  
 
Figure 91: Protein expression of DHCR7 in primary breast fibroblasts treated with vehicle 
control, tamoxifen, 4-OHTam, tesmilifene, fulvestrant and oestradiol. No significant changes in 
protein expression were seen in any of the treatment conditions. Example of patient 2585. 
 
No significant alteration in DHCR7 protein expression was observed in any of the 





7.4.1 Investigation of differentially expressed genes (DHCR7 and 
DHCR24) identified from RNA Seq analysis 
 
qRT-PCR confirmed up-regulated mRNA expression of both DHCR7 and DHCR24 in 
the tamoxifen and 4-OHTam treated fibroblasts (Figure 80 + Figure 81). This suggests 
that both 4-OHTam and tamoxifen are acting via similar mechanisms to affect fibroblast 
function involving cholesterol metabolism. Notably however, up-regulated expression of 
DHCR7 and DHCR24 was not observed in the fibroblasts treated with tesmilifene. 
Given that tesmilifene is a commercially available inhibitor of ChEH, it might be 
expected that the drug would have identical effects to tamoxifen and 4-OHTam, which 
are also proposed to be inhibitors of ChEH by the Poirot group [345]. These data 
suggest that that the up-regulated expression of DHCR7 and DHCR24 observed with 
the SERMS may not be due to inhibition of ChEH activity and could represent an 
alternative, more generalised effect on the cholesterol biosynthesis pathway. Thus, the 
anti-tumourigenic and density lowering effects of tamoxifen may be due to alternative 
mechanisms rather than the proposed accumulation of anti-tumorigenic cholesterol 
epoxides resulting in fibroblast differentiation (Figure 76 + Figure 78). The RNA Seq 
pathway analysis has highlighted numerous other potentially contributory pathways 
modulated by 4-OHTam (Appendices 7 + 8).  
Alternatively, the lack of significant up-regulation of DHCR7 and DSHCR24 gene 
expression with tesmilifene could be explained by the fact that tesmilifene is known to 
have a much weaker ability to inhibit ChEH activity [294] and the pathway analysis has 
revealed multiple effects of 4-OHTam outside of cholesterol metabolism (Appendices 7 
+ 8). Therefore, these combined effects may explain why an identical pattern of 
differential gene expression was not seen with tesmilifene and the SERMs. Thus 
inhibition of ChEH activity could still be a key mechanism mediating the anti-tumour 




No significant change in DHCR7 protein expression was seen with 4-OHTam or 
tamoxifen treatment (Figure 91), suggesting that the up-regulated mRNA expression 
may not be being translated into increased functional protein.  
Tamoxifen is well documented to affect serum levels of cholesterol in patients receiving 
adjuvant therapy [366] and altered cholesterol metabolism has recently been proposed 
by Martin et al to be a mechanism by which resistance to anti-oestrogen therapy occurs 
in breast cancer patients [338]. Thus our findings are in agreement with these data that 
cholesterol metabolism is a crucial pathway modulated by tamoxifen that may have 
significant clinical implications.  
Interestingly, a small but non-significant increase in DHCR7 and DHCR24 mRNA 
expression was also identified by qRT-PCR in cells treated with fulvestrant (Figure 80 + 
Figure 81). This is suggestive of a potential mild effect of fulvestrant on cholesterol 
metabolism. However, no significant differential gene expression of cholesterol 
metabolism enzymes were detected in the fulvestrant treated cells in the RNA Seq 
analysis (Figure 65 + Figure 71). Crucially, there is once again a clear difference 
between the effect of the SERMS and fulvestrant, supporting a mechanism of action 
independent of the ER.  
7.4.2 Effects of SERMs, tesmilifene and fulvestrant on fibroblast 
proliferation and activation 
 
To investigate the hypothesis that 4-OHTam and tamoxifen are acting via ER-
independent mechanisms to alter fibroblast proliferation and activation, fibroblasts were 
treated with tamoxifen, 4-OHTam (SERMs), tesmilifene (selective ChEH/AEBS ligand) 
and fulvestrant (Pure ER-antagonist), to determine if the drugs exerted similar effects 
on fibroblast function.  
234	
	
A dose dependent, negative effect on fibroblast proliferation was observed in cells 
treated with tamoxifen and 4-OHTam, with no effect on proliferation demonstrated with 
tesmilifene and fulvestrant (Figure 83). These data further suggest that tamoxifen and 
4-OHTam are acting via similar mechanisms. Once again, tesmilifene treatment 
resulted in different findings to the SERMs. This disparity in the effect of tesmilifene 
and the SERMs suggests that the effect on proliferation may not be mediated via 
inhibition of ChEH activity and accumulation of cholesterol precursors, and potential 
some of the other pathways highlighted in the RNA Seq analysis may account for the 
anti-proliferative effects (Figure 79). The disparity between the effect of the SERMS 
and tesmilifene on fibroblast proliferation is also reflected in the mass spectrometry 
analysis, where the cells treated with tesmilfiene show a markedly different cholesterol 
metabolite profile compared to the SERMS (Figure 90). It is possible that the 
accumulation of zymosterol in the cells treated with SERMS could exert an anti-
proliferative effect.  
The disparity between the effects of the SERMs and tesmilifene on fibroblast 
proliferation could also be due to the weak ability of tesmilifene to inhibit ChEH activity. 
The weak inhibitory activity of tesmilifene could be insufficient to result in sufficient 
cholesterol metabolite accumulation to affect proliferation. Fulvestrant had no effect on 
fibroblast proliferation, this further supports the hypothesis that the SERMs may affect 
fibroblast proliferation via ER independent mechanisms.  
Reduced expression of SMA was observed in the fibroblasts treated with tamoxifen, 4-
OHTam and tesmilifene, with no effect of fulvestrant or oestradiol (Figure 84). In 
contrast to the effects on DHCR7/24 gene expression and fibroblast proliferation, these 
data support a similar mechanism of action of the SERMs and tesmilifene. This could 
potentially be via inhibition of ChEH or other cholesterol enzyme activity. These data 
suggest that inhibition of cholesterol metabolite enzyme activity may be crucial to 
mediating the potent ‘deactivating’ effects of tamoxifen on the mammary stroma. 
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However, it is also possible that the ‘deactivating’ effect may also be due to the 
deregulation of other pathways identified via the RNA Seq analysis (Appendices 7 + 8) 
which tesmilifene may also be able to influence. Overall, these data are consistent with 
the observations of others of the ‘deactivating’ effect of tamoxifen on fibroblast function 
[313, 314]. 
Crucially, these data also support the hypothesis that tamoxifen and 4-OHTam are 
acting independently of the ER to modulate fibroblast activity, as tesmilifene has purely 
ER-independent actions and no effect on SMA expression was observed with the pure 
ER antagonist fulvestrant or indeed with oestradiol itself (Figure 84).  
Interestingly, when primary fibroblast SMA expression was assessed following drug 
treatment and stimulation with TGF-β, only the SERMs prevented TGF-β mediated up-
regulation of SMA expression (Figure 85). Tesmilifene treated fibroblasts showed up-
regulation of SMA following TGF-β stimulation (Figure 85).  
This further highlights the differing effects on fibroblast function between the weak 
AEBS ligand tesmilfene and the SERMs - which have stronger affinity for the AEBS 
and impact on numerous other pathways (Appendices 7 + 8). The ability of the SERMs 
to inhibit TGF-β mediated fibroblast activation may be due to their ability to affect non-
canonical TGF-β signalling (Figure 56). In addition, the RNA Seq pathway analysis 
revealed down-regulation of Wnt and Hedgehog signalling pathways by 4-OHTam 
(Appendix 8). These pathways are both known to overlap with TGF-β signalling [358, 
361, 362] and thus may explain why only the SERMs, and not tesmilifene, were 
capable of preventing TGF-β mediated fibroblast activation. However, it also possible 
that this disparity in the response of the tesmilifene treated fibroblasts to TGF-β 
stimulation compared to the SERMs reflects an alternative mechanism of action, rather 
than ChEH inhibition. 
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The disparity between the effects of tesmilifene and the SERMs is further emphasised 
in the data showing down-regulation of FN expression only in the cells treated with 
SERMs (Figure 84). These data again suggest that there may be differing mechanisms 
of action between the SERMs and tesmilifene out with inhibition of ChEH activity. The 
complex interaction of the various pathways modulated by SERMs (Appendices 5 - 8) 
may account for their differing effects on FN expression compared to tesmilifene.  
Overall, these data highlight that the SERMs and tesmilifene share some similarities in 
their effects on fibroblast function, however important differences remain. These 
differences could be accounted for by the interaction of multiple pathways identified in 
the RNA Seq analysis by which SERMs affect fibroblast function (Appendices 5 – 8). 
However, these data also suggest that the inhibition of ChEH activity may not be the 
most crucial pathway for exerting the anti-tumour and density-lowering effects of 
tamoxifen. Thus, future work is required to establish which of these pathways is of 
greatest clinical significance.  In addition, the lack of effect on fulvestrant on fibroblast 
proliferation and expression of SMA or FN further highlights that the observed effects 
SERM and tesmilifene treatment may be due to ER independent mechanisms.  
7.4.3 Confirming lipid droplet and cholesterol precursor accumulation in 
4-OHTam treated fibroblasts 
 
4-OHTam treated primary fibroblasts displayed a characteristic phenotype with 
accumulation of small perinuclear cytoplasmic vesicles (Figure 33). The RNA Seq 
analysis indicated that 4-OHTam treatment was profoundly influencing cholesterol and 
lipid metabolism (Appendices 2 - 6). Thus, it was hypothesised that the vesicles 
accumulating in the 4-OHTam treated fibroblasts may contain lipid or cholesterol 
metabolite precursors. The Poirot group have previosuly demonstrated the 
accumulation of both lipid droplets and free sterols (cholesterol precursors) in breast 
and melanoma tumour cells treated with tamoxifen [296, 347].  
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Oil Red O staining demonstrated significant, extensive accumulation of lipid droplets 
within the perinuclear cytoplasmic vesicles observed in the 4-OHTam treated cells (p = 
0.0021, Figure 82). This demonstrates that 4-OHTam treatment of primary breast 
fibroblasts induces lipid accumulation. It is not possible to conclude whether the lipid 
accumulation is related to ‘differentiation’ of the fibroblasts and future work to establish 
the significance of the up-regulation of several key early stage adipogenic markers 
(Figure 77) and PPAR signalling observed in the RNA Seq analysis (Appendix 6).  
To investigate if the vesicles and lipid accumulation were a result of ER-independent 
actions of 4-OHTam, fibroblasts were treated with tamoxifen, 4-OHTam, tesmilifene, 
fulvestrant and oestradiol. Accumulation of perinuclear cytoplasmic vesicles was 
observed in the cells treated with tamoxifen, 4-OHTam and tesmilifene. No vesicles 
were seen in cells treated with fulvestrant or oestradiol (Figure 86).  
Furthermore, Oil Red O staining confirmed significant lipid droplet accumulation in only 
fibroblasts treated with tamoxifen, 4-OHTam and tesmilifene (Figure 87).  The similarity 
of the fibroblast response to SERM and tesmilifene treatment suggests lipid droplet 
accumulation is a result of a similar mechanism of action, potentially via inhibition of 
ChEH. The lack of effect with fulvestrant and oestradiol once again suggests an ER 
independent mechanism of action.  
In addition to the accumulation of lipid droplets, filipin antibiotic staining highlighted the 
accumulation of free sterols within the perinuclear cytoplasmic vesicles of fibroblasts 
treated with tamoxifen, 4-OHTam and tesmilfene (Figure 88). These observations 
suggest that both SERM and tesmilifene treatment can induce sterol accumulation in 
primary fibroblasts.  The findings are also in keeping with the proposed ER-
independent actions of tamoxifen and 4-OHTam via inhibition of ChEH activity, leading 
to antitumourigenic cholesterol precursor accumulation [367]. 
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To confirm the accumulation of lipid droplets and free sterols within fibroblasts treated 
with SERMS and tesmilifene, suggested by the positive Oil Red O and filipin staining, 
transmission electron microscopy was performed. Multilamellar bodies (MLB) 
containing unesterified sterols and amorphous lipid droplets were clearly identified in 
100% of the cells treated with tamoxifen, 4-OHTam and tesmilifene (Figure 89).  
 
These data confirm that fibroblasts treated with SERMs and tesmilifene accumulate 
both cholesterol precursors and lipid droplets, corresponding to the perinuclear 
cytoplasmic vesicles identified in the cells treated with these drugs. The similar actions 
of SERMs and tesmilifene once again suggest that these effects could due to ER-
independent mechanisms, potentially via inhibition of ChEH activity.  
The accumulation of lipid droplets and free sterols in tumour cells treated with 
tamoxifen has been extensively characterised by the Poirot group [294, 295, 347]. 
They propose that the accumulation of cholesterol precursors within cells may 
stimulate their differentiation [295]. They have observed differentiating effects on a 
number of different tumour cells including breast, melanoma and glioma [295, 347, 
348].  
The appearance of lipid droplets suggests the production of cholesterol epoxides 
(oxysterols), which arise via the autoxidation of cholesterol precursors by reactive 
oxygen species (ROS) [344]. As discussed previously, cholesterol epoxides undergo 
further metabolism with histamine to form dendrogenin A (DDA) – a modulator of LXR 
signalling [347]. LXR signalling has been proposed to have potent cell differentiating 
capabilities [347] and is also known to stimulate the expression of lipogenic enzymes 
[368].  
Thus, the appearance of lipid droplets within the fibroblasts treated with SERMs and 
tesmilifene could suggest potential inhibition of ChEH activity, cholesterol precursor 
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accumulation, generation of cholesterol epoxides, and modulation on LXR signalling 
via DDA leading to cell differentiation.  However, the results may also simply indicate 
that fibroblasts treated with these drugs begin to accumulate lipids and sterols. 
Therefore future work is crucially needed to determine the effect on ChEH enzyme 
activity and any effect on cell differentiation.  
Mass spectrometry was utilised in order to characterise and quantify the accumulation 
of cholesterol precursors within fibroblasts treated with SERMs, tesmilifene and 
fulvestrant. Each of the drugs showed a distinct profile of cholesterol metabolite 
accumulation (Figure 90). These data support the RNA Seq results (Appendices 2 – 8), 
by confirming deranged cholesterol metabolism and accumulation of metabolites within 
the cells.   
The cells treated with a combination of tamoxifen and 4-OHTam showed a similar 
cholesterol metabolite profile to those treated with 4-OHTam alone (Figure 90). The 
variation in cholesterol precursor accumulation between drug treatments can potentially 
be attributed to different combinations of cholesterol enzymes inhibited by the different 
drugs (Figure 90/Appendix 9 – Diagram of the cholesterol metabolism pathway). It is 
important to note that this experiment was only carried out once and thus slight 
variations in fibroblast cholesterol metabolite content between drug treatments may not 
be significant.  
These data suggest that there may be dual inhibition of both D8D71/EBP and DHCR24 
by tamoxifen leading to the accumulation of zymosterol and zymostenol (Figure 
90/Appendix 9). These data are entirely in keeping with the findings of the Poirot group 
who reported accumulation of zymostenol in cells treated with tamoxifen [295], which 
subsequently led to the generation of antitumourigenic cholesterol epoxides 
(oxysterols) via autoxidation by ROS [295]. It is, however, important to note that these 
observations were in tumour cells and there is currently no evidence to suggest a 
similar effect in fibroblasts. Furthermore, the presence of cholesterol epoxides was not 
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examined in the mass spectrometry analysis, therefore the accumulation of these 
proposed anti-tumourigenic molecules cannot be confirmed.  
Interestingly, 4-OHTam treatment shows accumulation of zymosterol and no 
accumulation of zymostenol (Figure 90). This suggests that perhaps 4-OHTam is a 
slightly less potent inhibitor of D8D71/EBP than tamoxifen. This would be in keeping 
with observations from the Poirot group that 4-OHTam is a marginally less potent 
inhibitor of the AEBS/ChEH than tamoxifen [345]. 4-OHTam induces a greater 
accumulation of zymosterol than tamoxifen (280 vs 200 ng/106 cells approximately), 
suggesting 4-OHTam may be a more potent inhibitor of DHCR24 activity than 
tamoxifen. These data are also in keeping with data from the Poirot group suggesting 
4-OHTam potently inhibits DHCR24 [293].  
D8D71/EBP is the second component of the AEBS/ChEH (Figure 76) alongside 
DHCR7 – one of the top differentially expressed genes in the RNA Seq analysis. This 
potentially suggests that the up-regulated expression of DHCR7 may also be as a 
consequence of the inhibition of functional enzyme activity of its counterpart 
component in the AEBS. However, D8D71/EBP also functions as an enzyme alone, 
thus the findings may simply reflect a global effect on the cholesterol metabolism 
pathway. 
DHCR24 was another top differentially expressed gene from the RNA Seq analysis 
(Appendix 4), thus the mass spectrometry data showing accumulation of cholesterol 
precursors specifically regulated by the DHCR24 enzyme potentially suggests that up-
regulated DHCR7/24 expression could be related to inhibition of enzyme activity. 
Further work is needed to clarify the relationship between gene expression and 
enzyme activity.  
The accumulation of different cholesterol precursors in the cells treated with tamoxifen 
and 4-OHTam is also intriguing, as it is possible that this may contribute to the variation 
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in clinical response to tamoxifen in the preventive setting. Data from Cuzick et al 
showed only approximately half of the high risk women who took tamoxifen significantly 
reduced their MD by ≥10% [110]. Cytochrome p450 enzymes regulate tamoxifen 
metabolism [271]. Thus, those individuals who extensively metabolise tamoxifen, and 
generate more 4-OHTam, may accumulate different cholesterol precursors. It is also 
possible that here may be variation in the autoxidation of the different precursors to 
form antitumourigenic cholesterol epoxides, and thus variation in modulation of LXR 
signalling and cell-differentiating capability. Future work to investigate cholesterol 
epoxide levels in the breast tissue of women treated with tamoxifen, and correlation 
with imaging and clinical outcome, is required to substantiate this hypothesis. 
The difference between the cholesterol metabolites accumulating in the tesmilifene 
treated fibroblasts and the SERMs parallels the differences seen in proliferation and 
gene expression (Figure 80, Figure 81 + Figure 83). As previously discussed, these 
differences suggest that the effects of SERMs on fibroblast function may not be due to 
inhibition of ChEH activity, but potentially one of the other pathways identified in the 
RNA Seq analysis (Appendices 5 - 8). However, it also possible that the weaker ability 
of tesmilifene to inhibit ChEH activity and interacting effects from the other pathways 
modulated by SERMs could account for these differences. Future work to determine 
the clinical significance of the various pathways modulated by SERMs is required.  
Fulvestrant treatment resulted in minimal variations in cholesterol metabolite levels 
(Figure 90) and future work is required to determine if these differences are significant. 
However, significant differential expression of cholesterol metabolite genes was not 
identified in the RNA Seq analysis with fulvestrant treatment (Figure 65 + Figure 71). 
Overall these data suggest that SERMs have a profound effect on fibroblast function, 
including deregulation of cholesterol metabolism, resulting in the accumulation of 
cholesterol precursors and lipid droplets. The lack of cholesterol and lipid accumulation 
in cells treated with fulvestrant, suggests that these effects could potentially be 
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independent of the ER. In addition, there are a number of significant differences in the 
effect of the SERMs compared to the AEBS-ligand tesmilifene. Thus, it is not clear 
whether the observed effects can be attributed to inhibition of ChEH activity and 
fibroblast ‘differentiation’, or to one or more of the other pathways revealed in the RNA 
Seq analysis. Future work is therefore required to dissect which of these pathways is 
responsible for mediating the anti-tumourigenic and density-lowering effects of 
tamoxifen treatment.	  
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In this study, 4-OHTam treatment of primary breast fibroblasts resulted in a variety of 
effects on fibroblast function including; reduced proliferation, ECM protein expression 
and response to the pro-fibrogenic cytokine TGF-β with inhibition of non-canonical 
signalling through ERK1/2. Functionally, 4-OHTam treated fibroblasts showed reduced 
ability to contract collagen gels and showed less migration following TGF-β stimulation.  
RNA Seq analysis highlighted numerous pathways mediated by 4-OHTam, including a 
possible ER-independent mechanism by which 4-OHTam may modulate cholesterol 
metabolism and potentially promote fibroblast differentiation.  
In order to evaluate the tumour inhibitory phenotype of 4-OHTam   treated   fibroblasts, 
epithelial cell lines were co-cultured with pre-treated fibroblasts in 3D collagen   gels. 
The effect on epithelial colony size and proliferation were assessed. In addition, effect 
of conditioned media and FDM from 4-OHTam treated fibroblasts on epithelial cell 




8.2 Methods and Materials 
	
8.2.1 Cell Lines  
	
The normal epithelial cell line HB2 and HB2 cells overexpressing Her2 protein were 
used as models of normal and pre-malignant epithelium for these experiments. The ER 
positive cell line MCF7 was used as a model of low grade ER positive breast cancer. 
8.2.2 Fibroblast pre-treatment prior to 3D co-culture 
	
Fibroblasts from patient 2585 were seeded into T175 flasks and grown until 70% 
confluent. The cells were hormone deprived for 24 hours then treated with vehicle 
control or 4-OHTam (5µM) for 48 hours. The cells were then removed from the flask 
using trypsin and counted using a haemocytometer prior to seeding into the collagen 
gels with epithelial cells.  
8.2.3 Co-culture conditions 
	
The following combinations of cells were used in the co-culture experiments: 
(i)        Normal HB2 cells alone 
(ii)        Normal HB2 cells and vehicle control pre-treated fibroblasts 
(iii)        Normal HB2 cells and 4-OHTam pre-treated fibroblasts 
 
(iv)        Her2 over expressing HB2 cells alone 
(v)        Her2 over expressing HB2 cells and vehicle control pre-treated 
fibroblasts 
(vi)        Her2 over expressing HB2 cells and 4-OHTam pre-treated fibroblasts 
 
(vii)       MCF7 cells alone 
 
(viii) MCF7 cells and vehicle control pre-reated fibroblasts 
 




In all conditions, cells were seeded into the collagen gels at a density of approximately 
350,000 cells per gel.  
8.2.4 Collagen gel preparation 
	
Gels were prepared at two densities – 1mg/ml and 3mg/ml. For three gels, a 1ml gel 







Table 16: Collagen gel components 
	
The 1ml gel mixture was combined with 1ml of media containing the relevant cells for 
the particular co-culture condition, to give a total volume of 2ml. 600µl was plated in 
triplicate format in the 24 well plates.  
The gels were left to set at 37oC for half an hour then 500µl phenol red free DMEM F12 
and 5% DCSS was added on top each gel. The co-cultures were left for 5 days at 37oC 
with media changed on day 3.  
Following 5 days of co-culture, the media was removed and 1.5ml 10% neutral buffered 
formalin was added to each well to fix the gels. After one hour, the media was changed 
to sterile PBS. The gels were then carefully removed from the edge of the wells, 
processed and paraffin embedded for subsequent analysis.  
8.2.5 Analysis of Proliferation and colony size 
	
Cell proliferation was determined using Ki67 immunohistochemistry, as described 
below. Colony size was assessed by counting the mean number of cells present in 
each epithelial colony per H+E stained section.  
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8.2.6 Ki67 immunohistochemistry  
	
8.2.6.1 Dewaxing, rehydration of sections and antigen retrieval 
 
Unstained paraffin sections were dewaxed by warming the slides to 60oC in an 
incubator for 10 minutes and then placing them in xylene (Fisher Scientific, X/0250/17) 
for 10 minutes with periodic agitation. The sections were re-hydrated through a series 
of graded alcohol solutions and placed in 3% hydrogen peroxide solution (Fisher 
Scientific, H/1750/15) for 10 minutes to block endogenous peroxidase activity. Antigen 
retrieval was performed by boiling the sections in citrate buffer (2.94g trisodium citrate 
(Sigma, S1084) in 1l dH2O) pH 6.0 for 5 minutes twice in succession.  
8.2.6.2 Blocking, antibody incubation and developing 
 
After washing in PBS, the sections were covered in 3% BSA/5% NHS in PBS for 15 
minutes at room temperature to block non-specific antibody binding. Cells were then 
incubated overnight at 4oC with Ki67 primary antibody (Dako, M7240) diluted 1:100 in 
3% BSA/5%NHS in PBS. Cells were then washed three times in PBS, incubated with 
biotinylated secondary anti-mouse secondary antibody (Vector Laboratories, 1:200 in 
1% BSA/PBS) for 40 minutes at RT, washed in PBS a further three times before 
incubating with avidin-biotinylated peroxidase complex (Vectastain ABC kit, Vector 
Laboratories, PK 6101, 6102) for 30 minutes at RT. Cells were washed with PBS three 
more times before developing using a DAB kit (Vectastain, Vector Laboratories, SK 
4100). Cells were then washed twice with PBS and counterstained with Haematoxylin 
for 2 minutes, rinsed in tap water and then dehydrated through the graded alcohol 
series before placing in xylene for 10 minutes. Coverslips were mounted with DPX 







10 random fields were examined at x10 objective and the number of positive cells were 
counted and expressed as a percentage of the total number of cells present per field. 
8.2.7 Preparation of fibroblast conditioned media (FCM) 
	
Primary fibroblasts from two patients (1923, 1989) were seeded in T175 flasks and 
grown to 70% confluence, hormone deprived for 24 hours and then treated with vehicle 
control, 5µM tamoxifen, 5µM 4-OHTam, 10µM tesmilifene or 5µM fulvestrant for 48 
hours. The cells were then trypsinised off the flask and reseeded into 10cm dishes at a 
density of 0.8 x106 cells per flask along with 5ml serum and phenol-red free media. The 
cells were left to condition the media for 48 hours. The media was then harvested and 
centrifuged at 1500 rpm for 3 minutes to remove any dead cells and the supernatant 
frozen immediately at -20oC. 
8.2.8 Conditioned media proliferation assay 
	
Epithelial cells (normal HB2, HB2 overexpressing Her2 and MCF7) were seeded in 
triplicate in 24 well plates at a density of 4x104 cells per well, allowed to adhere to the 
plastic for 3 hours then serum starved overnight with phenol red free media. Triplicate 
wells were then treated with 0.5ml of either serum free media, FCM from vehicle 
control, tamoxifen, 4-OHTam, tesmilifene or fulvestrant treated fibroblasts. Proliferation 
was measured using the Alamar Blue assay immediately prior to treatment with FCM 
(time 0) and after 48 hours treatment. Absorbance values were normalised to time 0.  
8.2.9 FDM proliferation assay 
	
FDM were generated from patient 2182 in the presence of either vehicle control or 4-
OHTam as described previously (section 5.2.3) in triplicate wells of a 12 well plate. 
Primary fibroblasts from patient 2182 (2 x104 cells per well) and MCF7 cells (5 x104 
cells per well) were then seeded onto the FDM and into triplicate empty wells onto 
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plastic. Proliferation was measured using the Alamar Blue assay with measurements 
taken at time 0, 24 hours, 48 hours and 72 hours. Values were normalised to the time 0 







8.3.1 Fibroblast-epithelial cell 3D co-culture assays 
	
The lower density collagen gels (1mg/ml) contracted substantially during culture, 
hindering assessment of colony size and proliferation. Thus these gels were not 
analysed further. 
8.3.1.1 Comparison of epithelial cell line models 
	
Her2 protein levels were assessed in the two HB2 cell lines to confirm overexpression 
of Her2 in the ‘Her2 overexpressing’ HB2 cell line (Figure 92).  
 
Figure 92: Western blot image confirming overexpressing of Her2 protein in the Her2 
overexpressing HB2 cell line compared to the normal HB2 cells.  
 
Each epithelial cell line was cultured alone in the collagen gels and assessed for colony 
size and proliferation. The normal HB2 cells formed large cohesive colonies with very 
few single cells. HB2 cells overexpressing Her2 formed cohesive colonies with 
scattered single cells (Figure 93). The colonies formed by the normal HB2 cells were 
significantly larger than the HB2 cells overexpressing Her2 (p<0.0001). The MCF7 cells 
formed a mixture of small cohesive colonies and numerous scattered single cells. The 
MC7 cell colonies were smaller than the normal HB2 and HB2 cells overexpressing 




Figure 93: Epithelial cell line colony size in 3D collagen gels. (i) Representative H+E stained 
colony images (x20 objective). (A) Normal HB2 cells form large cohesive groups with very few 
single cells (B) HB2 cells overexpressing Her2 form cohesive groups with scattered single cells 
(C) MCF7 cells form small cohesive groups and numerous single cells (blue arrows).  (ii) Graph 
quantifying mean colony size per cell line. Normal HB2 cell colonies are significantly larger 
(p<0.0001) than the Her2 overexpressing HB2 cells and MCF7 cells. 
	
The normal HB2 and Her2 overexpressing HB2 cell lines showed similar levels of 
proliferation, assessed by Ki67 staining. MCF7 cells showed slightly higher proliferation 




Figure 94: Proliferation of epithelial cell lines in collagen gels assessed by Ki67 
immunohistochemistry. (i) Representative images of colonies showing positive staining for Ki67 
(x20 objective).(A) Normal HB2 cells, (B) Her2 overexpressing HB2 cells, (C) MCF7 cells (blue 
arrows = single cells). (ii) Graph quantifying % Ki67 positive cells per epithelial cell line. (iii) (A) 
Tonsillar lymphoid tissue, x10 objective (Ki67 positive control) (B) Tonsillar lymphoid tissue, x10 
objective (negative control – mouse immunoglobulin) 
 
8.3.1.2 Co-culture of epithelial cell lines and pre-treated fibroblasts 
	
Both the normal HB2 cells and the Her 2 overexpressing HB2 cells formed significantly 
smaller epithelial colonies when cultured with 4-OHTam pre-treated fibroblasts 
compared to those cultured with fibroblasts pre-treated with vehicle control (p<0.0001, 




Figure 95: Effect of co-culture of normal HB2 cells with control and 4-OHTam pre-treated 
fibroblasts on epithelial colony size (i) Representative H+E stained images of epithelial colonies 
and fibroblasts (red arrows). A+B – Normal HB2 cells and vehicle control pre-treated fibroblasts, 
C+D – Normal HB2 cells and 4-OHTam pre-treated fibroblasts (x20 objective). (ii) Graph 
quantifying mean epithelial colony size. Co-culture with 4-OHTam pre-treated fibroblasts 




Figure 96: Effect of co-culture of Her 2 overexpressing HB2 cells with control and 4-OHTam 
pre-treated fibroblasts on epithelial colony size. (i) Representative H+E stained images of 
epithelial colonies and fibroblasts (red arrows). A+B – Her2 overexpressing HB2 cells and 
vehicle control pre-treated fibroblasts, C+D – Her2 overexpressing HB2 cells and 4-OHTam pre-
treated fibroblasts (x20 objective). (ii) Graph quantifying mean epithelial colony size. Co-culture 
with 4-OHTam pre-treated fibroblasts resulted in significantly smaller epithelial colony size 





No significant difference in MCF7 cell colony size was observed when cultured with 
either vehicle control or 4-OHTam pre-treated fibroblasts (Figure 97). Numerous single 
cells were present in both conditions.  
 
Figure 97: Effect of co-culture of MCF7 cells with control and 4-OHTam pre-treated fibroblasts 
on epithelial cell colony size. (i) Representative H+E stained images of epithelial colonies and 
fibroblasts (red arrows) with numerous single cells (blue arrows). A+B – MCF7 cells and vehicle 
control pre-treated fibroblasts, C+D – MCF7 cells and 4-OHTam pre-treated fibroblasts (x20 
objective). (ii) Graph quantifying mean epithelial colony size. Co-culture with 4-OHTam pre-
treated fibroblasts had no significant effect on epithelial colony size (p=0.1462).   
 
No difference in the proliferation of normal HB2, Her2 overexpressing HB2 or MCF7 
cells was observed between those cultured with fibroblasts pre-treated with vehicle 




Figure 98: Effect of co-culture of normal HB2 cells with vehicle control and 4-OHTam pre-
treated fibroblasts on epithelial cell proliferation (Ki67 immunohistochemistry). (i) Representative 
Ki67 stained images of epithelial colonies and fibroblasts (red arrows). A+B – Normal HB2 cells 
and vehicle control pre-treated fibroblasts, C+D – Normal HB2 cells and 4-OHTam pre-treated 
fibroblasts (x20 objective). (ii) Graph quantifying mean % Ki67 positive cells. No difference in 
epithelial cell proliferation was seen between fibroblast pre-treatment conditions. 
 
 
Figure 99: Effect of co-culture of Her2 overexpressing HB2 cells with vehicle control and 4-
OHTam pre-treated fibroblasts on epithelial cell proliferation (Ki67 immunohistochemistry). (i) 
Representative Ki67 stained images of epithelial colonies and fibroblasts (red arrows). A+B – 
Her2 overexpressing HB2 cells and vehicle control pre-treated fibroblasts, C+D – Her2 
overexpressing HB2 cells and 4-OHTam pre-treated fibroblasts (x20 objective). (ii) Graph 
quantifying mean % Ki67 positive cells. No difference in epithelial cell proliferation was seen 






Figure 100: Effect of co-culture of MCF7 cells with vehicle control and 4-OHTam pre-treated 
fibroblasts on epithelial cell proliferation (Ki67 immunohistochemistry). (i) Representative Ki67 
stained images of epithelial colonies and fibroblasts (red arrows) with numerous single cells 
(blue arrows). A+B – MCF7 cells and vehicle control pre-treated fibroblasts, C+D – MCF7 cells 
and 4-OHTam pre-treated fibroblasts (x20 objective). (ii) Graph quantifying mean % Ki67 
positive cells. No difference in epithelial cell proliferation was seen between fibroblast pre-
treatment conditions. 
 
8.3.2 Effect of fibroblast conditioned media on epithelial cell proliferation 
	
The normal HB2 cells did not survive 48 hours culture in FCM or serum free media. 
Treatment with FCM increased proliferation of both the Her2 overexpressing HB2 cells 
and MCF7 cells compared to treatment with serum and phenol red free media alone 
(negative control). No significant difference in proliferation of either epithelial cell line 
was observed between the different conditioned media fibroblast pre-treatment 




Figure 101: Effect of 48 hours treatment with FCM on the proliferation of Her2 overexpressing HB2 cells 
and MCF7 cells. Treatment with FCM increased epithelial cell proliferation compared to serum and phenol 
red free media (SFM, negative control). No significant difference in proliferation of either epithelial cell line 
was observed between the conditioned media fibroblast pre-treatment conditions. Example of FCM from 
patient 1923.  
	
8.3.3 Effect of FDM on fibroblast and epithelial cell proliferation 
	
Primary fibroblasts (patient 2182) seeded onto FDM showed reduced proliferation 
compared to those seeded onto plastic (Figure 102). Fibroblasts seeded onto FDM 
generated in the presence of 4-OHTam showed less proliferation than those seeded 






Figure 102: Effect of FDM on primary fibroblast (patient 2182) proliferation. Fibroblasts seeded 
onto FDM showed reduced proliferation compared to those seeded onto plastic. Fibroblasts 
seeded onto 4-OHTam FDM showed less proliferation than those seeded onto control FDM. 
 
MCF7 cells seeded onto FDM showed reduced proliferation compared to those seeded 
onto plastic (Figure 103). There was no difference in proliferation between cells seeded 
onto FDM generated in the presence of either vehicle control or 4-OHTam.  
 
 
Figure 103: Effect of FDM on MCF7 cell proliferation. Cells seeded onto FDM showed reduced 
proliferation compared to those seeded onto plastic. There was no difference in proliferation 






8.4.1 Epithelial cell lines 
	
Cell lines representing a spectrum of epithelial abnormality - normal (normal HB2), 
premalignant (Her2 overexpressing HB2) and low grade malignant (MCF7) were 
selected in order to detect subtle changes in behaviour following fibroblast co-culture, 
that may not be demonstrable if using only aggressive cancer cell lines.  
The normal HB2 cells behaved in a benign manner when cultured in collagen alone, 
forming large cohesive colonies with very few single cells (Figure 93). The Her2 
overexpressing cells showed smaller cohesive groups and scattered single cells. 
Whereas the MCF7 cells showed the most aggressive behaviour with only very small 
cohesive colonies and numerous single cells (Figure 93). It is not clear whether these 
individual cells represent tumour infiltration of the stroma or simply no growth of poorly 
cohesive individual cells.    
The premalignant (Her2 overexpressing HB2) cell line showed no significant difference 
in proliferation than the normal HB2 cells (Figure 94). This highlights the disadvantages 
of using immortalised cell lines to represent normal epithelial cell behaviour, as normal 
epithelial cells would not demonstrate such high proliferative activity. Future work could 
use primary luminal epithelial cells as an alternative.  
8.4.2 Fibroblast pre-treatment 
	
8.4.2.1 Co-culture assay 
	
Primary fibroblasts were pre-treated with vehicle control and 4-OHTam prior to adding 
to the collagen co-culture gels, and no drugs were present in the culture media for the 
gels. This ensured that the epithelial cell lines were not directly exposed to any of the 
drugs, therefore, any effect on epithelial cell behaviour could not be attributed to a 
direct effect of drug treatment. 
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Without additional drug dosing after the initial pre-treatment, the co-culture time was 
limited to 5 days, after which is was assumed that the effect of the drug pre-treatment 
on the fibroblasts would have worn off. This assumption was based on the reversibility 
of the 4-OHTam treated fibroblast phenotype observed when the drug was removed 
from the culture media (Section 4.3.8). After 5 days of treatment with control media, the 
fibroblasts had lost most of the perinuclear cytoplasmic vesicles which accumulated 
following 4-OHTam treatment (Figure 35). 
8.4.2.2 Conditioned media assay 
	
Primary fibroblasts were pre-treated with tamoxifen, 4-OHTam, tesmilifene and 
fulvestrant for 2 days prior to reseeding into a 10cm dish (0.8 x 106 cells/dish). The 
cells were allowed to adhere to the plastic, then washed with PBS twice before 
changing the media to serum free media to begin harvesting conditioned media. This 
was performed in order to ensure no drugs would be present in the conditioned media 
that may directly affect epithelial cell proliferation, and to ensure the same number of 
fibroblasts were present in each dish. 4-OHTam and tamoxifen were both observed to 
have negative effects on fibroblast proliferation (Figure 83), thus reseeding the pre-
treated cells immediately prior to harvesting CM at a defined cell number ensured this 
effect on proliferation was accounted for.  
8.4.3 Co-culture of fibroblasts and epithelial cells 
	
Both the normal HB2 and Her2 overexpressing HB2 cells formed smaller colonies 
when co-cultured with 4-OHTam treated fibroblasts with no increase in number of 
single cells, suggesting that 4-OHTam treated fibroblasts may be less supportive of 
epithelial cell growth and proliferation (Figure 95 + Figure 96).  These findings are 
consistent with data from Hattar and colleagues who found that cancer cell lines co-
injected into mouse mammary fat pads with tamoxifen treated ECM formed smaller 
tumours than those co-injected with untreated ECM [115].  
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Despite these effects on colony size, no difference was seen in the proliferative activity 
of the colonies co-cultured with vehicle control or 4-OHTam pre-treated fibroblasts 
(Figure 98 + Figure 99). This may be due to the intrinsic proliferative activity of the cell 
lines used.  
No difference in colony size or proliferative activity was seen with MCF7 cells (Figure 
97 + Figure 100). Thus, 4-OHTam pre-treated fibroblasts may only be able to exert 
effects on epithelial cell behaviour at earlier stages of tumourigenesis.  
The 3D co-culture model used in this study has several weaknesses. Firstly, no 
myoepithelial cells are present. These unique components on the breast 
microenvironment have been proposed to exert both tumour suppressor and tumour 
promoting behaviour and also synthesise basement membrane to form a physical 
barrier between the epithelial cells and fibroblasts [369, 370]. Thus the potential 
influence of the myoepithelial cells and basement membrane on epithelial-stromal 
crosstalk is not accounted for. In addition, many other cells present in the breast 
microenvironment, which may influence epithelial-stromal crosstalk, such as 
inflammatory cells and blood vessels, are also lacking. Furthermore, the collagen ECM 
that formed the 3D environment was present at a uniform density and stiffness. This is 
unlikely to be representative of the dynamic changes in ECM stiffness and orientation 
that occur during tumourigenesis. The co-culture time was also limited at only 5 days, 
therefore subtle changes in epithelial behaviour as a result of fibroblast-epithelial cell 
crosstalk may not have time to manifest within this period.  
8.4.4 Effect of conditioned media on epithelial cell proliferation 
	
Despite FCM increasing the proliferation of both the Her2 overexpressing HB2 cells 
and MCF7 cells compared to treatment with serum free media alone, no difference in 
proliferation was seen between cells treated with conditioned media from different 
fibroblast pre-treatment conditions (Figure 101). This lack of difference may be due to 
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the intrinsic proliferative activity of these cell lines. In addition, the presence of a 3D 
environment with multiple cell types present may be required in order to appreciate the 
effect of tamoxifen treated fibroblasts on epithelial cell behaviour. The assay was also 
only run for 48 hours which may not have sufficient time for subtle differences in 
proliferation between the pre-treatment conditions to be evident.  
	
8.4.5 Effect of FDM on epithelial cell proliferation 
	
Both fibroblasts and MCF7 cells seeded onto FDM showed less proliferation than those 
seeded onto plastic (Figure 102 + Figure 103). This may be due to the cells having 
unrestricted space to grow in the empty wells compared to the wells filled with matrix 
fibres. No difference in MCF7 proliferation was evident between the cells seeded on 
vehicle control or 4-OHTam FDM (Figure 103). These observations are consistent with 
the lack of difference in FDM thickness seen between the matrices generated under 
the different conditions – suggesting a similar ability to modulate cell behaviour. 
Therefore it is somewhat surprising that fibroblasts seeded onto 4-OHTam FDM show 
reduced proliferation compared to those seeded onto control FDM (Figure 102). 
However, this difference may also indicate the increased sensitivity of primary cells 
compared to immortalised cell lines. Thus more subtle effects of FDM on cell behaviour 




9 Final Conclusions and Future Work 
 
The aims of this study were to: 
(i) To use in-vitro models of primary human breast fibroblasts to dissect the effect of 
tamoxifen on stromal cell function. 
(ii) To use RNA Seq to carry out a whole transcriptome analysis of the effect of 
tamoxifen on fibroblast gene expression. 
(iii) Investigation of selected pathways modulated by tamoxifen and the role of the ER 
in these pathways. 
(iv) To explore the impact of tamoxifen-modified fibroblasts on epithelial cell behaviour 
 
9.1 Dissecting the effect of tamoxifen on primary breast 
fibroblast function 
	
4-OHTam, the active metabolite of tamoxifen, was observed to have a profound effect 
on primary breast fibroblast function, acting via multiple, diverse pathways.  
A direct effect of 4-OHTam on fibroblast function was initially noted after observing a 
consistent, dose dependent, negative effect on proliferation. In addition, 4-OHTam 
modulated the expression of stromal markers fibronectin and collagen I in a proportion 
of patients’ cells.  These findings were in keeping with data from animal models 
suggesting that tamoxifen may modify expression of stromal proteins [115, 314].  
Furthermore, 4-OHTam treatment resulted in a striking, consistent reduction in 
expression of the key fibroblast activation marker SMA, and was able to inhibit 
fibroblast activation following stimulation with TGF-β. Further investigation revealed 
that this effect was not via inhibition of canonical SMAD signalling, instead non-
canonical signalling through ERK1/2 was affected.  Functionally, 4-OHTam treatment 
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resulted in the fibroblasts being less contractile and less migratory following TGF-β 
stimulation. 
These observations are consistent with the anti-fibrotic effects of tamoxifen reported in 
the literature [313] and observations that tamoxifen treated stroma has a more 
quiescent phenotype [115, 313]. 
The differing responses of the primary fibroblasts to 4-OHTam and the pure ER 
antagonist fulvestrant suggest that the effects of 4-OHTam on fibroblast function may 
be due to ER-independent mechanisms.  
RNA Seq differential gene expression and pathway analysis highlighted a plethora of  
pathways modulated by 4-OHTam which may contribute to the overall anti-tumour and 
density-lowering effects. These include a potential novel ER-independent pathway by 
which 4-OHTam affects fibroblast function - via modulation of cholesterol metabolism.  
Significant differential expression of the cholesterol metabolite enzyme DHCR7 was 
consistently observed in two separate RNA Seq experiments. This enzyme is a 
component of the microsomal anti-oestrogen binding site (AEBS). Binding of tamoxifen, 
4-OHTam and other SERMs to the AEBS has been proposed to be anti-tumourigenic 
[296, 347]. The proposed anti-tumour effects are mediated via inhibition of cholesterol 
epoxide hydrolase (ChEH) activity and accumulation of cholesterol precursors with 
potent cell differentiating capabilities. So far the evidence for the significance of this 
pathway has been limited to the work of a single laboratory and has yet to be widely 
replicated and validated by others. Furthermore, the effect of SERM inhibition of ChEH 
activity has only previously been investigated in tumour cells and there is no data 
regarding any effect in fibroblasts. 
Nevertheless, the modulation of this pathway is an intriguing possibility and a proposed 




Figure 104: Summary of proposed possible ER-independent mechanism by which tamoxifen 
may bind to the AEBS and inhibit ChEH activity. This could result in the accumulation of anti-
tumourigenic cholesterol metabolite precursors, including dendrogenin A (DDA), formed via 
metabolism with histamine, which may exert potent cell differentiating properties.  
 
The inhibition of ChEH activity and accumulation of anti-tumourigenic precursors within 
fibroblasts could lead to the differentiation of activated fibroblasts to a more quiescent 
state, and potentially towards early adipogenic differentiation. Increased adipogenic 
differentiation of the mammary stroma could increase the fatty content of the breast 





Figure 105: Possible mechanism by which tamoxifen could exert differentiating effects on 
fibroblasts to a more quiescent state, and possibly towards early adipogenic differentiation. 
Increased fatty tissue in the breast could lower the overall MD. 
	
Despite this intriguing possible mechanism, there is limited to support that modulation 
of this pathway in fibroblasts could be responsible for the density-lowering and anti-
tumour effects of tamoxifen. 
Whilst fibroblast treatment with a commercially available inhibitor of ChEH, tesmilifene, 
resulted in some similar effects to those seen with SERMs, a significant number of 
differing effects were also seen. This suggests that other pathways modulated by 
tamoxifen may mediate the risk lowering effects of the drug. There are many down-
regulated pathways identified in the RNA Seq analysis that could potentially modify the 
mammary stroma and contribute to a change in MD such as collagen formation, 
integrin cell surface interaction, ECM receptor interaction, Wnt and Hedgehog 
signalling.  Future work to dissect which of these pathways are the most clinically 
significant is required.  
Altered cholesterol metabolism and accumulation of precursors within the fibroblasts 
was identified with mass spectrometry, electron microscopy and filipin staining. Oil Red 
O staining and electron microscopy also identified accumulation of lipid droplets within 
the fibroblasts. Up-regulation of some early adipogenic markers was also observed in 
the RNA Seq analysis. The evidence in this study to support a ‘differentiating’ effect of 
4-OHTam on fibroblasts is weak and future work is required to investigate this 
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hypothesis further. It is possible that SERM treatment simply induces accumulation of 
lipid and cholesterol metabolites within the fibroblasts without any effect on cell 
differentiation. Accumulation of lipids (steatosis) in liver hepatocytes is a recognised 
complication of tamoxifen treatment [371].  
 
9.2 Impact of 4-OHTam treatment on fibroblast-epithelial 
crosstalk 
	
Data from animal models suggest that tamoxifen treated stroma can exert tumour 
inhibitory effects [115]. The effect of 4-OHTam pre-treated fibroblasts on epithelial cell 
behaviour was investigated using 3D co-cultures, conditioned media and FDM.  Co-
culture with 4-OHTam pre-treated fibroblasts resulted in smaller epithelial colony sizes 
in normal and premalignant cells only and no significant effect on proliferation was 
noted. No significant effect of conditioned media from tamoxifen or 4-OHTam pre-
treated fibroblasts or 4-OHTam FDM was observed. 
The lack of conclusive findings in the co-culture experiments are most likely due to 
many key breast microenvironment components such as myoepithelial cells, immune 
cells and blood vessels not being present in the co-culture system. The breast 
microenvironment is heavily complex and epithelial-stromal crosstalk relies on 
interaction and coordination of multiple stromal cell types. It is likely that many 
autocrine and paracrine factors that control epithelial cell function are lacking in such a 
reductionist model. 
In addition, dynamic changes in ECM stiffness and orientation could not be modelled in 
the co-culture system, thus the impact of tamoxifen on the biophysical properties of the 
mammary ECM and epithelial cell mechanotransduction could not be assessed. 
Furthermore, immortalised epithelial cell lines have unlimited proliferative and 
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replicative potential, and thus may not respond to subtle signals in the 
microenvironment as the normal mammary epithelial cells would. 
Future work to dissect out the precise influence of tamoxifen treated stroma on 
epithelial-stromal crosstalk and ECM remodelling in breast tumourigenesis is required. 
A more sophisticated 3D model using a variety of primary cell types with an ability to 
modulate the biophysical properties of the ECM would be required. The Weaver group 
have recently described a 3D tension bioreactor platform capable of precise control of 
ECM stiffness [372].  
The findings from the RNA Seq pathway analysis suggest that tamoxifen may modulate 
key signalling pathways within the ECM, which may be crucial to establish a tumour-
inhibitory microenvironment. Thus, further work to fully characterise these pathways is 
urgently needed.  
	
9.3 Clinical significance of findings 
	
This study has identified novel, potentially ER-independent mechanisms of tamoxifen 
action in modulating the stromal microenvironment. Now future work is required to 
validate the clinical utility of the study findings. 
A significant challenge to validating these findings in human tissue samples is obtaining 
matched tissue samples pre- and post- tamoxifen treatment. Given that this study is 
focused on the preventive setting, a tissue biopsy would need to be obtained pre- and 
post- tamoxifen treatment from women with no active breast disease. This is an 
invasive and painful procedure which many women would find unacceptable. However, 
a proportion of women may consent if provided with sufficient counselling over the 
intended benefits.  
In our Breast Unit, a clinic has been established for women at moderate and high risk 
of breast cancer in which they are offered tamoxifen and the opportunity to donate 
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blood and tissue samples for research. Thus this clinic may provide an opportunity to 
validate the findings of this study in tissue samples from high risk women. 
Another significant challenge to translational research focusing on MD relates to the 
heterogenous nature of MD. There may be significant local variations in density 
throughout an individual’s breast tissue. Thus close correlation with radiology 
colleagues would be required when selecting a region of the breast to biopsy and 
obtain a tissue sample reflective of an individual’s overall MD. There is currently no 
way of measuring MD from paraffin embedded or frozen tissue sections, thus input 
from radiology colleagues is essential.  
Given the challenges associated with tissue validation, an alternative approach using 
patient serum samples could be utilised. A blood sample is much less invasive and 
therefore more acceptable to patients with no active breast disease than a tissue 
biopsy, therefore it would be expected that many more patients would consent.  
The Poirot group have recently performed a proof of concept study, demonstrating that 
oxysterols (cholesterol precursors) can be successfully quantified in patient serum 
samples [373]. Therefore an important focus of future work, to evaluate the clinical 
significance of potential inhibition of ChEH activity by tamoxifen, will be to establish 
whether changes in the levels of oxysterols in patient serum samples pre- and post- 
tamoxifen treatment correlate with reduction in MD and protection from breast cancer. 
Serum samples for a pilot analysis are already being obtained through collaborations 
with the IBIS study, Manchester prevention study and the local high risk clinic. 
Using changes in a biomarker, such as cholesterol metabolites, in the serum to predict 
response to tamoxifen could potentially provide a cost effective and rapid tool for 
predicting tamoxifen efficacy in the preventive setting. Presently change in MD after 
one year of treatment is the most rapid and reliable method of predicting response 
[247]. Changes in serum biomarker levels could be detectable much earlier, this would 
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allow individuals unlikely to respond to tamoxifen to be identified rapidly and offered 
alternative treatments. Crucially, these individuals would be spared the debilitating side 
effects of tamoxifen treatment.  
A focus of future work could also be the development of alternative prevention 
strategies that target ER-independent pathways, as suggested by results from this 
study. This would avoid the anti-oestrogen side effects associated with tamoxifen, other 
SERMs and aromatase inhibitors. An alternative prevention strategy with an improved 
side effect profile would be invaluable to increase uptake of chemoprevention and 
prevent substantially more breast cancer.  
Another focus of future work is to investigate the mechanism by which aromatase 
inhibitors prevent breast cancer, as these drugs appear to show greater efficacy than 
tamoxifen [122]. Understanding and comparing these preventive mechanisms would 
also be invaluable for the development of improved chemoprevention strategies.  
A further area to be explored in future work is whether a possible ER-independent 
mechanism of tamoxifen action on the breast stroma observed in this study could be of 
clinical benefit in both the prevention and treatment of ER negative breast tumours. 
The epidemiological data from Cuzick and colleagues suggests that tamoxifen is 
effective at preventing ER positive tumours only [113]. However, given the ER-
independent mechanisms of action suggested by this study, the effect on the 
development of ER negative tumours should also be investigated.  
Reduction in MD with tamoxifen treatment of ER positive tumours in the adjuvant 
setting is also associated with an improved outcome [111], therefore the ER-
independent actions of tamoxifen may also be of benefit in the treatment of ER 
negative tumours. This is an important consideration of future work as many more 
women may be able to benefit from the tamoxifen treatment than are currently eligible.  
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If tamoxifen is able to generate a microenvironment less permissive to tumour 
development and progression via ER-independent mechanisms, then it is possible that, 
in addition to ER negative breast cancer, tamoxifen may also be of benefit to tumours 
arising in other organ systems that have a significant stromal component. A recent 
study has reported that combined treatment of chemotherapy with tamoxifen was 
effective at overcoming resistance in an animal model of pancreatic cancer [374]. 
Finally, the clinical significance of the findings of this study go beyond the breast 
cancer field. Tamoxifen has been described in many studies to have anti-fibrotic effects 
and can be used to treat a number of fibrogenic disorders [315-318].  
In addition to the effects on cholesterol metabolism observed in this study, many 
additional pathways were highlighted in the RNA Seq analysis that could contribute to 
these anti-fibrotic effects, such as down-regulation of Wnt and Hedgehog signalling. 
Therefore future work to dissect these antifibrotic mechanisms is a priority and may 
allow many more patients outside of the cancer research field to benefit from the 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 1: Sequence alignment data for all samples used in the 
































1004	P	 Control	1	 49812192	 23256317	 22537318	 1417166	 2601391	 46.69%	
1004	P	 Control	2	 52193855	 27590213	 20317021	 1593375	 2693246	 52.86%	
1004	P	 Control	3	 51047351	 26117505	 20762493	 1512038	 2655315	 51.16%	
1004	P	 Tamoxifen	
(low)	1	
56579414	 29239825	 22672281	 1706634	 2960674	 51.68%	
1004	P	 Tamoxifen	
(low)	2	
45786985	 25340910	 16670387	 1475440	 2300248	 55.35%	
1004	P	 Tamoxifen	
(low)	3	
69700261	 39118083	 24834516	 2218173	 3529489	 56.12%	
1004	P	 Tamoxifen	1	 50665774	 26691372	 19572427	 1640373	 2761602	 52.68%	
1004	P	 Tamoxifen	2	 55812238	 32593446	 18047157	 2094356	 3077279	 58.40%	
1004	P	 Tamoxifen	3	 30901029	 18233015	 9830853	 1185842	 1651319	 59.00%	
3078	P	 Control	1	 49613970	 28748424	 16091988	 1943477	 2830081	 57.94%	
3078	P	 Control	2	 52370040	 31080622	 16066074	 2047255	 3176089	 59.35%	
3078	P	 Control	3	 51954877	 31463724	 15551013	 2054315	 2885825	 60.56%	
3078	P	 Tamoxifen	
(low)	1	
52248496	 28750171	 18347529	 1992928	 3157868	 55.03%	
3078	P	 Tamoxifen	
(low)	2	
46010089	 26634870	 14943004	 1771163	 2661052	 57.89%	
3078	P	 Tamoxifen	
(low)	3	
50806631	 28336338	 17843236	 1900832	 2726225	 55.77%	
3078	P	 Tamoxifen	1	 52003924	 30141436	 16407265	 2155413	 3299810	 57.96%	
3078	P	 Tamoxifen	2	 44785891	 25595618	 14573007	 1888238	 2729028	 57.15%	
3078	P	 Tamoxifen	3	 51791718	 28173414	 18394273	 1994421	 3229610	 54.40%	
3137	F	 Control	1	 61007667	 45057463	 7580260	 2004370	 6365574	 73.86%	
3137	F	 Control	2	 60057274	 43047234	 7586746	 1653640	 7769654	 71.68%	
3137	F	 Control	3	 61741102	 45945653	 7843009	 1857273	 6095167	 74.42%	
3137	F	 Tamoxifen	1	 62790155	 44837388	 10048984	 1698534	 6205249	 71.41%	
3137	F	 Tamoxifen	2	 70574527	 50750566	 10105473	 1775713	 7942775	 71.91%	
3137	F	 Tamoxifen	3	 73116122	 47647753	 14894465	 1821705	 8752199	 65.17%	
3137	F	 Fulvestrant	
1	
68103001	 50797362	 8024760	 2029768	 7251111	 74.59%	
3137	F	 Fulvestrant	
2	
67491290	 50069973	 8552568	 1616881	 7251868	 74.19%	
3137	F	 Fulvestrant	
3	
65597477	 48140997	 8732503	 1998018	 6725959	 73.39%	
2182	F	 Control	1	 67292791	 52403702	 6624517	 1777909	 6486663	 77.87%	
2182	F	 Control	2	 66298517	 51466997	 6537484	 1681878	 6612158	 77.63%	
2182	F	 Control	3	 71183621	 50962142	 8799133	 2019723	 9402623	 71.59%	
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2182	F	 Tamoxifen	1	 62758311	 46395403	 8462253	 1902874	 5997781	 73.93%	
2182	F	 Tamoxifen	2	 80753089	 52629857	 14629380	 1855127	 11638725	 65.17%	
2182	F	 Tamoxifen	3	 68990566	 46248885	 12042623	 2149983	 8549075	 67.04%	
2093	F	 Control	1	 62750752	 47154311	 7742534	 1753985	 6099922	 75.15%	
2093	F	 Control	2	 67702432	 45326146	 10935391	 2614244	 8826651	 66.95%	
2093	F	 Control	3	 70671437	 48617923	 11148584	 2064471	 8840459	 68.79%	
2093	F	 Tamoxifen	1	 64801725	 44930919	 10916063	 1990804	 6963939	 69.34%	
2093	F	 Tamoxifen	2	 68346102	 49886834	 8783707	 2378905	 7296656	 72.99%	
2093	F	 Tamoxifen	3	 67530857	 49717254	 8056751	 2441902	 7314950	 73.62%	
2585	F	 Control	1	 60196080	 45196111	 7426754	 1453479	 6119736	 75.08%	
2585	F	 Control	2	 59901293	 44203147	 7321873	 2125376	 6250897	 73.79%	
2585	F	 Control	3	 76145088	 54916405	 9941469	 2037355	 9249859	 72.12%	
2585	F	 Tamoxifen	1	 80739568	 56090866	 13100987	 2063977	 9483738	 69.47%	
2585	F	 Tamoxifen	2	 66761513	 52593443	 5745927	 1694683	 6727460	 78.78%	
2585	F	 Tamoxifen	3	 73770650	 55965842	 6827047	 2748775	 8228986	 75.86%	
2585	F	 Fulvestrant	
1	
61162571	 42039938	 8933301	 1439671	 8749661	 68.73%	
2585	F	 Fulvestrant	
2	
70401756	 48324104	 10832858	 1934188	 9310606	 68.64%	
2585	F	 Fulvestrant	
3	
67475392	 50496037	 7454634	 1879601	 7645120	 74.84%	





Appendix 2: Most significantly differentially expressed genes 
identified by ANOVA between high dose 4-OHTam treated samples 









-0.363	 1.625	 6.313	 1.04E-53	 1.39E-49	
DHCR7	 7-dehydrocholesterol	
reductase	
-0.116	 1.765	 5.812	 2.58E-51	 1.73E-47	
FASN	 fatty	acid	synthase	 -0.168	 1.611	 5.476	 2.94E-37	 1.31E-33	
FADS2	 fatty	acid	desaturase	2	 -0.259	 1.285	 6.930	 8.54E-35	 2.86E-31	




-0.295	 1.075	 6.933	 4.80E-31	 1.07E-27	
DMKN	 dermokine	 -0.770	 2.069	 2.651	 9.20E-31	 1.76E-27	
HMOX1	 heme	oxygenase	
(decycling)	1	
-0.317	 1.605	 4.760	 5.00E-30	 8.37E-27	
NPC1	 Niemann-Pick	disease,	
type	C1	
-0.334	 0.922	 6.627	 2.12E-29	 3.15E-26	
INSIG1	 insulin	induced	gene	1	 -0.222	 1.743	 6.765	 4.57E-29	 6.13E-26	
ACACA	 acetyl-CoA	carboxylase	
alpha	
-0.151	 0.736	 7.930	 3.27E-26	 3.98E-23	
C1orf85	 chromosome	1	open	
reading	frame	85	




-0.145	 0.985	 6.332	 8.97E-25	 9.24E-22	
SCD	 stearoyl-CoA	desaturase	
(delta-9-desaturase)	
-0.490	 1.868	 8.869	 1.25E-24	 1.20E-21	
GPNMB	 glycoprotein	
(transmembrane)	nmb	
-0.605	 1.610	 9.292	 1.42E-24	 1.27E-21	
CLCN7	 chloride	channel,	
voltage-sensitive	7	




0.050	 1.131	 3.272	 9.05E-24	 7.13E-21	
LDLR	 low	density	lipoprotein	
receptor	
-0.261	 1.175	 7.174	 1.68E-23	 1.25E-20	




-0.166	 1.027	 4.742	 2.56E-22	 1.71E-19	
FADS1	 fatty	acid	desaturase	1	 -0.191	 1.125	 8.155	 2.96E-22	 1.89E-19	
FTH1	 ferritin,	heavy	
polypeptide	1	
0.035	 1.095	 4.231	 1.51E-21	 9.17E-19	
NPC2	 Niemann-Pick	disease,	
type	C2	





-0.414	 2.541	 -0.475	 7.70E-21	 4.30E-18	
OSBPL8	 oxysterol	binding	
protein-like	8	
-0.308	 0.847	 11.072	 3.26E-20	 1.75E-17	
VAT1	 vesicle	amine	transport	
1]	




-0.319	 1.604	 5.881	 4.04E-20	 2.01E-17	




-0.357	 -1.663	 6.541	 8.84E-20	 4.08E-17	
GRN	 granulin	 -0.095	 0.790	 6.297	 1.49E-19	 6.67E-17	
PCSK9	 proprotein	convertase	
subtilisin/kexin	type	9	






Appendix 3: Top differentially expressed genes across the four 
patients from the RNA Seq follow up batch identified by ANOVA 































1.219	 2.947	 260.159	 1.58E-58	 3.24E-55	
EVI2B	 ecotropic	viral	
integration	site	2B	













-2.603	 0.081	 218.023	 2.44E-49	 3.18E-46	
KLF15	 Kruppel-like	factor	
15	





-1.263	 5.498	 194.831	 2.81E-44	 3.09E-41	





1.423	 5.394	 178.250	 1.17E-40	 1.04E-37	








2.267	 7.562	 166.491	 4.32E-38	 3.25E-35	
FHL1	 four	and	a	half	LIM	
domains	1	
-1.371	 6.582	 158.729	 2.15E-36	 1.40E-33	
PLIN2	 perilipin	2	 -1.145	 7.982	 154.119	 2.18E-35	 1.25E-32	







1.255	 1.998	 143.375	 4.87E-33	 2.32E-30	
WFDC1	 WAP	four-disulfide	
core	domain	1	
-2.426	 -0.720	 137.839	 7.90E-32	 3.53E-29	
SCUBE3	 signal	peptide,	CUB	
domain,	EGF-like	3	
-1.499	 3.031	 129.386	 5.58E-30	 2.22E-27	
ACP5	 acid	phosphatase	
5,	tartrate	resistant	
1.558	 1.684	 128.098	 1.07E-29	 4.03E-27	
DRD1	 dopamine	receptor	
D1	




-2.450	 0.612	 124.138	 7.86E-29	 2.50E-26	
ART5	 ADP-
ribosyltransferase	5	
1.700	 0.081	 117.257	 2.52E-27	 7.22E-25	
AC1446
52.1	





-1.158	 5.333	 108.443	 2.15E-25	 5.49E-23	
NPPB	 natriuretic	peptide	
B	





Appendix 4: Top differentially expressed genes across all six 








QPRT	 quinolinate	phosphoribosyltransferase	 1.6843	 2.97E-19	 2.23E-15	
DMKN	 dermokine	 2.213	 1.24E-18	 6.18E-15	




DRD1	 dopamine	receptor	D1	 -2.749	 6.35E-17	 1.28E-13	







DHCR24	 24-dehydrocholesterol	reductase	 1.128	 6.37E-16	 7.33E-13	




FHL1	 four	and	a	half	LIM	domains	1	 -1.389	 1.77E-14	 9.45E-12	
INSIG1	 insulin	induced	gene	1	 1.460	 1.85E-14	 9.55E-12	






Appendix 5: Significantly up-regulated pathways from the merged 
dataset using the GSEA tool and REACTOME pathway resource.  
 








20	 0.889	 2.484	 0	 0	 0	
REACTOME_GLYCOSPHINGOLIPID_META
BOLISM	
28	 0.745	 2.292	 0	 0	 0	
REACTOME_IRON_UPTAKE_AND_TRANS
PORT	
28	 0.714	 2.256	 0	 0	 0	
REACTOME_METABOLISM_OF_LIPIDS_A
ND_LIPOPROTEINS	
365	 0.477	 2.246	 0	 0	 0	
REACTOME_SPHINGOLIPID_METABOLIS
M	
54	 0.614	 2.211	 0	 0	 0	
REACTOME_PHOSPHOLIPID_METABOLIS
M	
















































Appendix 6: Significantly up-regulated pathways from the merged 
dataset identified using GSEA and the KEGG biological pathways 
resource.  
 






KEGG_LYSOSOME	 106	 0.679	 2.735	 0	 0	 0	
KEGG_GLYCOSAMINOGLYCAN_DEGRADA
TION	
18	 0.722	 2.026	 0	 0.003	 0.008	
KEGG_DRUG_METABOLISM_CYTOCHRO
ME_P450	
33	 0.611	 2.023	 0.002	 0.002	 0.008	
KEGG_METABOLISM_OF_XENOBIOTICS_
BY_CYTOCHROME_P450	
31	 0.596	 1.937	 0	 0.003	 0.019	
KEGG_SPHINGOLIPID_METABOLISM	 30	 0.573	 1.791	 0.002	 0.017	 0.127	
KEGG_PPAR_SIGNALING_PATHWAY	 43	 0.503	 1.729	 0.004	 0.028	 0.233	





Appendix 7: Selected significantly down-regulated pathways 
identified from the merged dataset using GSEA and the 
REACTOME biological pathways resource. 
 






REACTOME_DNA_REPLICATION	 182	 -0.646	 -3.012	 0	 0	 0	
REACTOME_MITOTIC_M_M_G1_PHAS
ES	
162	 -0.639	 -2.947	 0	 0	 0	
REACTOME_CELL_CYCLE_MITOTIC	 300	 -0.576	 -2.888	 0	 0	 0	
REACTOME_MITOTIC_PROMETAPHAS
E	
82	 -0.704	 -2.877	 0	 0	 0	
REACTOME_CELL_CYCLE	 379	 -0.553	 -2.808	 0	 0	 0	
REACTOME_CHROMOSOME_MAINTE
NANCE	
105	 -0.625	 -2.681	 0	 0	 0	
REACTOME_MUSCLE_CONTRACTION	 33	 -0.639	 -2.223	 0	 5.94E-
05	
0.001	















51	 -0.533	 -2.004	 0	 0.002	 0.043	
REACTOME_SMOOTH_MUSCLE_CONT
RACTION	
23	 -0.627	 -1.979	 0	 0.002	 0.057	
REACTOME_MRNA_SPLICING	 106	 -0.458	 -1.974	 0	 0.002	 0.061	
REACTOME_MITOTIC_G2_G2_M_PHA
SES	
77	 -0.481	 -1.972	 0	 0.003	 0.063	
REACTOME_MRNA_PROCESSING	 151	 -0.425	 -1.966	 0	 0.003	 0.068	
REACTOME_COLLAGEN_FORMATION	 46	 -0.513	 -1.868	 0	 0.007	 0.202	
REACTOME_INTEGRIN_CELL_SURFACE
_INTERACTIONS	
61	 -0.478	 -1.858	 0	 0.008	 0.218	
REACTOME_GRB2_EVENTS_IN_ERBB2
_SIGNALING	








17	 -0.601	 -1.753	 0.002	 0.020	 0.512	





63	 -0.440	 -1.747	 0.003	 0.020	 0.522	
REACTOME_NCAM_SIGNALING_FOR_
NEURITE_OUT_GROWTH	
50	 -0.466	 -1.747	 0.002	 0.020	 0.522	
REACTOME_APOPTOTIC_EXECUTION_
PHASE	





17	 -0.608	 -1.719	 0.021	 0.024	 0.612	
REACTOME_APC_CDC20_MEDIATED_
DEGRADATION_OF_NEK2A	
21	 -0.563	 -1.715	 0.002	 0.024	 0.622	
REACTOME_GLUCONEOGENESIS	 23	 -0.516	 -1.651	 0.016	 0.039	 0.828	
REACTOME_HS_GAG_BIOSYNTHESIS	 18	 -0.542	 -1.628	 0.014	 0.042	 0.892	
REACTOME_G_ALPHA_S_SIGNALLING
_EVENTS	
49	 -0.430	 -1.622	 0.006	 0.044	 0.901	
REACTOME_INTEGRIN_ALPHAIIB_BET
A3_SIGNALING	





Appendix 8: Significantly down-regulated signalling pathways 
identified from the merged dataset using GSEA and the KEGG 
biological pathways resource.  
 








81 -0.587 -2.443 0 0 0 
KEGG_CELL_CYCLE 118 -0.549 -2.434 0 0 0 
KEGG_DNA_REPLICATION 35 -0.679 -2.332 0 0 0 
KEGG_OOCYTE_MEIOSIS 95 -0.554 -2.323 0 0 0 
KEGG_HYPERTROPHIC_CARDIOMYOP
ATHY_HCM 
59 -0.560 -2.158 0 0 0 
KEGG_DILATED_CARDIOMYOPATHY 64 -0.528 -2.039 0 0.002 0.009 
KEGG_PROGESTERONE_MEDIATED_O
OCYTE_MATURATION 
75 -0.491 -2.011 0 0.002 0.009 
KEGG_WNT_SIGNALING_PATHWAY 116 -0.424 -1.880 0 0.009 0.049 
KEGG_VIRAL_MYOCARDITIS 48 -0.492 -1.863 0 0.010 0.059 
KEGG_HOMOLOGOUS_RECOMBINATI
ON 




54 -0.477 -1.793 0 0.016 0.114 
KEGG_LONG_TERM_POTENTIATION 50 -0.476 -1.786 0.002 0.016 0.124 
KEGG_MISMATCH_REPAIR 22 -0.580 -1.780 0.004 0.016 0.133 
KEGG_REGULATION_OF_ACTIN_CYTO
SKELETON 
156 -0.388 -1.776 0 0.015 0.138 
KEGG_ACUTE_MYELOID_LEUKEMIA 50 -0.468 -1.750 0 0.020 0.187 
KEGG_ECM_RECEPTOR_INTERACTION 64 -0.438 -1.723 0 0.024 0.228 
KEGG_RENAL_CELL_CARCINOMA 64 -0.438 -1.720 0 0.023 0.24 
KEGG_ENDOMETRIAL_CANCER 46 -0.463 -1.709 0.007 0.023 0.25 
KEGG_TIGHT_JUNCTION 91 -0.394 -1.665 0.003 0.032 0.341 
KEGG_CELL_ADHESION_MOLECULES_
CAMS 
69 -0.415 -1.659 0.005 0.033 0.361 
KEGG_PATHOGENIC_ESCHERICHIA_C
OLI_INFECTION 
46 -0.450 -1.655 0.007 0.032 0.371 
KEGG_HEDGEHOG_SIGNALING_PATH
WAY 
33 -0.477 -1.631 0.003 0.038 0.439 
KEGG_MELANOGENESIS 71 -0.400 -1.628 0.003 0.037 0.445 
KEGG_FOCAL_ADHESION 164 -0.358 -1.627 0 0.036 0.447 
KEGG_VASCULAR_SMOOTH_MUSCLE
_CONTRACTION 
80 -0.397 -1.622 0 0.036 0.463 
KEGG_SPLICEOSOME 124 -0.371 -1.619 0 0.036 0.476 
KEGG_BASE_EXCISION_REPAIR 33 -0.469 -1.587 0.013 0.044 0.549 
KEGG_ADHERENS_JUNCTION 66 -0.395 -1.576 0.010 0.047 0.579 
KEGG_P53_SIGNALING_PATHWAY 60 -0.398 -1.567 0.005 0.048 0.597 
 
30
2	
	
 
